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Abstract 
Introduction: Cancer has long been a life-threatening disease to human beings, 
which also adversely affects their quality of life. It is and will continue to be one of 
the top ten causes of deaths globally. According to the Hong Kong Cancer Registry, 
the local crude incidence rate of cancer was 351.5 while the crude mortality rate was 
177.8in 2007. 
Advanced cancer refers to a metastatic cancer or a cancer involving a vital organ that 
cannot be removed. Often it is considered to be incurable and palliative treatments are 
given to shrink the cancer, lengthen the survival time and relieve symptoms, such as 
pain and depression, with the goal of helping patients maintain the best possible 
quality of life. However, some palliative treatments such as chemotherapy and 
radiotherapy are found to be not satisfactory by both clinicans and patients, since they 
can induce many side-effects. This raises the interest of advanced cancer patients in 
traditional Chinese medicine (TCM), which is often considered a kind of 
Complementary and Alternative Medicine. 
Objective: The objective of this study is to compare the health outcomes of Chinese 
herbal medicine in aspects of health-related quality of life (HRQOL) of patients with 
advanced cancer before, during and after treatment. 
Design and Method: It is a single-armed, prospective, pre-post and open-label 
observational study. At the Department of Oncology, Tuen Mun Hospital, 50 patients 
under palliative care were invited to undergo one TCM consultation per week (士2 
days) over a study period of eight weeks. Each participant was treated by the same 
registered Chinese medicine practitioner (RCMP) according to the theories of TCM 
and was prescribed with Chinese herbal medicines. Two quality of life instruments 
were used, EORTC QLQ-C30 and SF-36, to assess HRQOL of patients who were 
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interviewed face-to-face at baseline, on Day 29 and Day 57. Any adverse events (AEs) 
and serious adverse events (SAEs) were also reported to assess the safety of Chinese 
herbal medicine. 
Results: The completion rates were 80% and 70% on Day 29 and Day 57 respectively. 
The attrition rate was 30% and was induced by death, poor general condition and 
withdrawal due to other reasons. The median survival time was 160 days (95% CI, 
151-169 days). After the treatment, global health status, social functioning and 
constipation symptom in QLQ-C30 improved significantly over study (p<0.05). Other 
scales, including role functioning, emotional functioning, fatigue, pain, insomnia, 
appetite loss and financial impact, showed improvement with clinical significance in 
the study (A mean score>5%), while physical functioning and dyspnoea deteriorated 
with clinical significance in the second month (Amean score>5%). No significant 
differences were observed in all scales in SF-36 Q)>0.05). Moreover, the summary 
scales of SF-36 and functioning scales of QLQ-C30 demonstrated moderate to high 
correlations (0.3<r<0.9). No significant difference was observed in body weight and 
laboratory blood tests over study. Thirty-four cases of AEs and SAEs were reported 
but 1 eposide was suspected of having a causal relationship with the Chinese herbal 
medicine used in the study. 
Conclusions: After the two-month TCM treatment, there were overall improvements 
in HRQOL of advanced cancer patients and remissions in some symptoms such as 
constipation and insomnia. This study has revealed that TCM was potentially 
effective for improving the HRQOL of advanced cancer patients under palliative care. 
Moreover, this study has also proved the feasibility of the integration of TCM into 
Western medicine during palliative treatment. Despite the results being not sufficient 
to prove the efficacy of TCM on advanced cancer patients, the clinical and statistical 
importance as well as the trend in favour of the effect of TCM suggested that a 
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Chapter 1 Introduction 
l.lGeneral Introduction 
The incidence rate and mortality rate of cancer have been found increasing over the 
last decade. Some people suffer from this disease even though they lead a healthy 
life-style at their early ages. Many patients are even diagnosed to have advanced 
cancer when they first approach the clinician. However, advanced cancer usually 
means that the cancer cannot be cured. Treatments like chemotherapy, radiotherapy, 
target therapy or other palliative therapies can only help shrink the cancer, relieve 
symptoms, extend the survival time and improve the quality of life (American Cancer 
Society, 2009). Although the treatments can often control symptoms like pain, on the 
other hand they always induce many undesirable side-effects. 
Traditional Chinese medicine (TCM), as a kind of complementary and alternative 
medicine, has been used widely by cancer patients. Many patients approach TCM 
practitioner with the hope to cure their disease. This is particularly popular among 
advanced cancer patients for whom only palliative treatment is applied by their 
clinician. The application of TCM can increase immunity, readjust the disturbed 
physiological state, stabilize pathological condition and prevent aggravation before and 
after conventional treatment is employed. TCM also reduces the functional disturbance 
and the toxic side-effects resulting from conventional treatments. In the advanced 
stages of cancer, if conventional anti-cancer approaches are not applicable, TCM may 
reduce the suffering of patients, improve clinical symptoms and prolong life (Ying & 
De, 1997). According to the theory of Chinese Medicine, the occurrence of advanced 
cancer is mainly due to 'deficiency of anti-pathogenic qi, together with 'presence of 
pathogenic qi\ 'Reinforcing the anti-pathogenic qi and eliminating the pathogenic qV 
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are therefore the principal idea of the treatment. Many previous studies have 
demonstrated the advantageous effects of Chinese herbal medicine on patients with 
cancer. However, scientific investigation of the effectiveness of Chinese herbal 
medicine using the key feature of TCM - 'pattern/syndrome differentiation and 
treatment' is scarce and yet to be explored. The purpose of this study is to assess the 
effects of Chinese herbal medicine on patients with advanced cancer. 
1. 2 Background to the study 
1.2.1 Epidemiology of cancer 
1.2.1.1 Incidence and mortality in the World 
Cancer has been a highly important world health problem, which is by far one of the 
leading causes of death in the world, representing 11.4 million new cases and 7.4 
million deaths (13% ofall deaths) in 2004 (World Health Organization, 2008c, 2009). 
The global age-standardized mortality rate by cause of cancer is 130, following the top 
mortality rate of 301 represented by cardiovascular diseases (World Health 
Organization, 2008d). In the same year, the mortality rate by cancer is 133 in United 
States, 135 in Canada, 147 in United Kingdom and 143 in China (World Health 
Organization, 2008d). According to the Surveillance, Epidemiology, and End Results 
(SEER) Program of the National Cancer Institute fNCI) in 2006, the age-standardized 
incidence rate is 456.20 while the mortality rate is 181.07 in United States fNational 
Cancer Institute). The figures remain high in Canada, with age-standardized incidence 
rate of403.25 and mortality rate of 170.16 per 100,000 in 2005 (Public Health Agency 
of Canada). 
More new cases and deaths occur in high-income countries than in low- and 
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middle-income countries. The number of new cases for cancer in high-income 
countries is 3.95 million while that in low-income countries is 2.26 million in the year 
2004 (World Health Organization, 2008b). This may partly be due to the different age 
distributions between different regions, because most cancers affect older adults. 
Metastases are the major reasori leading to death from cancer. The most common types 
of cancer leading to overall cancer mortality each year globally are lung (1.3 million 
deaths in 2004), followed by stomach (803 000 deaths), colorectal (639 000 deaths), 
liver (610 000 deaths) and breast (519 000 deaths) as shown in Table 1.1 (World Health 
Organization, 2009). 
World Health Organization (WHO) warns that the number of global cancer deaths is 
projected to increase 45% from 2007 to 2030 (from 7.9 million to 11.5 million deaths), 
influenced partly by an increasing and aging global population. New cases of cancer in 
the same period are estimated to rise from 11.3 million in 2007 to 15.5 million in 2030 
(World Health Organization, 2008a). 
Cardiov3SCuUfd'58ases g^¾j^j¾¾^pmmMi¾mM^ m^^y^^^ J^j^ m^p',旧,:•••…:••二 3^5 
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Figure 1. 1 Distribution of deaths by leading causes and gender in the world, 2004 
(Adopted from World Health Organization, 2008c). 
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Table 1. 1 Cancer incidences (thousands) by site and by WHO region, 2004 (Adopted 
from World Health Organization, 2008c). 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ & 
Lung<ancer 1448 27 264 34 401 164 S58 
StonMfJ>canrer 93J 38 89 25 182 78 521 
Cd6nandrectumcam:efs 1080 32 217 23 409 106 293J 
Liv?rrancer 632 65 38 !3 67 64 386 
Cefvixcancer 489 95 95 15 81 180 7B 
Breastcanfff 1100 72 310 54 326 1S4 184 
Pio5tatecancer 605 77 236 13 180 45 S4 
lymphomasandmuniple 479 56 102 » 113 91 79 
myefonia 
Leukaemia 375 20 68 28 86 72 101 
Qthercanms 5187 234 874 2¾ 12M 773 919 
A!!sH8$(exdudingn«t- 11474 716 2 294 470 3 058 1 726 3166 
me!anomaskincan<er) J 
1.2.1.2 Incidence and mortality in Hong Kong 
According to the Hong Kong Cancer Registry, the age-standardized incidence rate of 
cancer was 243.7 per 100,000 while the age-standardized mortality rate was 116.5 per 
100,000 in 2007. Altogether 24,342 new cancer cases and 12,316 deaths from cancer 
were registered in 2007. The corresponding numbers in 1995 were 18,267 and 9,680. 
This represented a striking increase of 33% in new cases and 27% in deaths over the 
past decade (Hospital Authority, 2009a). 
The most common types of cancer to occur in 2007 was lung, accounting for 17.5% of 
all cancer cases, followed by colorectum (16.8%), breast (11.2%) and liver (6.9%) 
(Hospital Authority, 2009a). Among the new cases, over 60% were in people aged 
over 60, which can be explained by the growing and aging population in Hong Kong 
(Hospital Authority, 2009a). 
Cancer is the top cause of death in Hong Kong, followed by heart diseases and then 
pneumonia (Hospital Authority, 2008b). The top cancer leading to overall cancer 
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mortality is lung, accounting for 29.6% of cancer deaths, followed by colorectum 
(13.7%), liver (11.8%) and stomach(5.2%) (Hospital Authority, 2009a). The situation 
of epidemiology in Hong Kong accords with those worldwide and this confirms that 
cancer is a disease that harms people's life critically. 
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Figure 1. 2 Figure 1. 3 Mortality trend of cancer (all sites) in Hong Kong from 
1998-2007(Adopted from Hospital Authority, 2009b). 
1.2.2 Prevalence of Traditional Chinese Medicine 
(TCM) 
TCM is often regarded as a kind of complementary or alternative medicine (CAM) and 
is the major category of CAM used in the United States (Konkimalla & Efferth，2008; 
Xu et al., 2007). CAM is defined by WHO as a broad set of healthcare practices that 
are not part of that country's own tradition and are not integrated into the dominant 
healthcare system. Among the various types of CAM, TCM is one ofthe few that has a 
well-established theory and treatment approaches for diseases dating back over 4000 
years. It is the aggregate ofthe knowledge, skills and practices based on the theories, 
beliefs and experiences indigenous to Chinese culture, used in the maintenance of 
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Chapter 1 Mroduction 5 
health, prevention, diagnosis, improvement or treatment of physical and mental illness 
(World Health Organization, 2000). Besides playing an important role in preventing 
and treating diseases in China, TCM has also been more and more popular in Asian 
countries like Japan, Korean and Singapore, where it is often used as a monotherapy or 
an integrated medicine (Xu et al., 2007). 
Although the integration of TCM into the primary medical sector is still a controversial 
issue in the cumminity, TCM has expanded tremendously outside Asia during the past 
few years. TCM and other CAM are increasingly being incorporated into Western 
medical centers in the United States (M. H. Cohen et al., 2005). In 2007, 
approximately 4 out of 10 adults (38.3%) and 1 in 9 children (11.8%) had used CAM 
in the past 12 months (Barnes et al., 2008). In a recent population based survey carried 
out in Hong Kong, 61.7% of the population has ever consulted a TCM practitioner 
(Chung et al., 2009). It is believed that TCM is gaining popularity with the interest and 
demand among the community as more TCM services are emerging in the public 
health sector. 
1.2.3 Prevalence of Traditional Chinese Medicine 
(TCM) in cancer 
The types of treatment for cancer depend on the stage of the cancer and most of the 
time involve surgery, chemotherapy, radiotherapy, hormone therapy and recently 
targeted therapy. However, many of them are found not satisfactory by the patients and 
doctors, due to the unwanted side-effects and undesirable tumor responses. This 
gradually raises the interest and demand for TCM to treat cancer among the patients 
(Hyodo et al., 2005). A systematic review retrieved 4 studies, including a total of 26 
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surveys from 13 countries, reported the usage of CAM in 7%-64% of adult cancer 
patients with an average prevalence of 31.4% (Ernst & Cassileth, 1998). In a 
nation-wide survey done in Japan, 44.6% of cancer patients have used CAM. Similar 
situation was also noted in Taiwan, where 61% of Taiwanese cancer out-patients were 
reported to have used CAM (Li-chun & L，2004). In Singapore, 56% of cancer patients 
reported CAM usage with the most commonly used CAM being TCM. 54% of the 
respondents informed their oncologists regarding CAM usage while 66.4% of 
oncologists agreed accordingly (Shih et al., 2009). 
1.2.4 Development of TCM in Hong Kong 
Hong Kong, as a part of China and once a colony of the United Kingdom, is 
characterized by its variety and specialty of public medical services. Before the 
handover of Hong Kong in 1997，TCM was not as popular as nowadays and was used 
occasionally by the community. Approaching the handover in the late 80's, society's 
concern for Chinese medicine grew and the government appointed the Preparatory 
Committee on Chinese Medicine to make recommendations on the promotion, 
development and regulation of Chinese medicine in Hong Kong. In 1999, the Chinese 
Medicine Bill was introduced into the Legislative Council and passed in the same year 
(Chinese Medicine Council ofHong Kong, 2001). 
The Chinese Medicine Council of Hong Kong was then established in late 1999, which 
is responsible for implementing the regulatory measures for Chinese medicine 
(Chinese Medicine Council of Hong Kong, 2001). In the meantime, three local 
universities are providing full-time degree courses on TCM aiming to produce 
qualified professionals to support Hong Kong's TCM public health services and its 
development as an international centre for Chinese medicine. 
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At present, about 22% of the medical consultations in Hong Kong are provided by 
TCM practitioners. Fourteen Chinese Medicine out-patients clinics under Hospital 
Authority (HA) have been set up in the public sector (Hospital Authority, 2008a). 
Currently and in the long run, Hong Kong is committing to carrying out various 
evidence-based clinical trials and researches to enhance the competitiveness of the 
Chinese medicine industry. It is also on the way to find its right position in the 
introduction of Chinese medicine into the public healthcare system, by expanding the 
out-patient Chinese medicine services in the public sector, launching the practice of 
Chinese medicine in public hospitals, supporting clinical research, and facilitating the 
development of standards and models of interface between western and Chinese 
medicines. 
In order to help facilitate the development of TCM in Hong Kong as well as worldwide, 
good quality studies in TCM must be carried out promptly. Presenting evidence of the 
effectiveness of TCM is a demanding task to gain the trust and acceptance from the 
local public and across the world. 
1.3 Theoretical rationale of the study 
Conventional treatment to cancer such as surgery, chemotherapy and radiotherapy is 
effective, especially at early stage, but severe side-effects always limit their clinical use 
and underscore the need for unconventional alternatives for less toxicity. Side-effects 
can be very different from therapy to therapy, and from drug to drug. The main 
side-effects of radiotherapy are fatigue and xerostomia. Others include nausea, 
vomiting and diarrhea (American Cancer Society, 2009). For chemotherapy, it is 
common to encounter diarrhea, nausea, vomiting, nephrotoxicity, myelosuppression 
and even cardiac toxicity (Krisztina, 2009; Richardson & Dobish, 2007). These 
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side-effects negatively affect the patients' quality of life (QOL) and even require dose 
limitation or interruption of treatment, thereby reducing the anticipated treatment 
outcome (Kobayashi, 2003). This situation is even more common among advanced 
cancer patients. Accordingly, alternative treatments, especially natural substances, are 
touted for their medicinal aspects and side-effect profiles, Many cancer patients who 
initiate CAM after diagnosis and during or after conventional oncologic treatments 
have expressed good feedback for it is a cost-effective approach (Vapiwala et aL, 
2006). 
The philosophy or principle of TCM involves the diagnosis of the pattern/syndrome 
[|5], through comprehensive analysis of symptoms and signs, which has implications 
for determining the cause, nature and location of the illness and the patient's physical 
condition, and their treatment. This practice is named as pattenVsyndrome 
differentiation and treatment [辨證論治].No matter in which stage of cancer the 
patients are, TCM practitioners treat them according to the holistic condition of yin [陰] 
(negative), yang [陽]positive), qi [氣](human vitality) and blood by means of four 
examinations [四診]:inspection [望診]，listening and smelling examination[^|#], 
inquiry [問診]and palpation [切言多]. 
It is generally stated in TCM that all diseases, including cancer or advanced cancer, are 
caused by disturbance in qi and blood, which are produced by Viscera and Bowels [臟 
腑]，and imbalances between yin and yang aspects of the body. The causes of cancer 
according to TCM theory include drastic emotional changes, improper diet, invasion of 
external pathogens and prolonged diseases, all of which lead to functional disturbance 
of the Viscera and Bowels, and damage to the qi, blood and body fluids. As a result, 
stagnant qi, phlegm, stagnant blood and heat toxins combine to damage the 
IBIMailMHIMMWMBIiBIWPi__iiaBWHBHMBHMWiiaHWWMHMWWiMMWHBHHgBHaBiHgBiHaBBBBWBBWBWM__Mftl imMlii ii_MWMlMWBMMMWMWIBWgaMMBBBMWi_M_IMiMI__lW_WMMWMiMMMMUiaMBMMiMi_MIBa 
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anti-pathogenic qi of the body, consume qi and blood, thus resulting in the formation of 
tumors. There can be different kinds of TCM treatments, such as Chinese herbal 
medicine, acupuncture, cupping and moxibustion, bone-setting and tui-na [推拿] 
(massage), which aim to remedy qi and blood, and balance yin and yang in human 
bodies. Herbs in TCM, for example, can be separated into either yin or yang to restore 
the deficiency or remove the excess yin and yang of a patient. Treatment with Chinese 
herbal medicine is focused on two main aspects, the elimination of pathogens and the 
promotion of the anti-pathogenic qi ofbody. 
Since the overall conditions resulting from the same disease differ from person to 
person, TCM practitioners consider the entire human body to design different treatment 
regimen for different individuals, Consequently, TCM does not only focus on a single 
target or organ but on multiple targets involved or even the whole body in a particular 
disease condition (Konkimalla & Efferth, 2008). There is no pre-determined treatment 
procedure and every patient is handled individually under the theory of TCM. Likewise, 
the same patient is not prescribed with the same Chinese herbal medicine at times, 
which primarily depends on the progress of the disease condition. This holistic and 
patient-tailored approach makes TCM different from allopathic (western) medicine, 
which focuses on the disease and aims at getting rid of it, neglecting the holistic body 
condition. 
The elements of primary healthcare stated in the Declaration of Alma-Ata, 1978 
include being socially acceptable, accessible to community, practical, affordable, and 
appropriate. TCM, as the only public care giver originating from the ancient time in 
China, is thought to be cost-effective, widely accepted and has been put into practice 
up to nowadays. Therefore, for the key to achieving the goal of 'Health for All，，it 
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seems only reasonable to have TCM as one of the components of primary healthcare in 
order to treat diseases including cancer. 
Chinese herbal medicine can regulate and reinforce yin, yang, qi and blood in order to 
help regulate the functions of organs in the human body and promote a better QOL for 
cancer patients. Previous studies including clinical trials, animal models and in vitro 
studies also revealed that Chinese herbal medicine is effective in treating cancer and 
managing conventional-therapy-induced symptoms. However, the use of Chinese 
herbal medicine for specific western medicine (WM) diagnosis is not uncommon, and 
it should be embedded in TCM based on syndrome differentiation, always neglected in 
those studies. Scientific evidence on the efficacy，safety and acceptability of Chinese 
herbal medicine following the pattern or syndrome differentiation and treatment on 
cancer patients is thus a necessity. 
1.4 Significance of the study 
Concluding from the preceding sections, it is obvious that the incidence and prevalence 
of cancer will be growing worldwide in the future. It is also factual that many patients 
are diagnosed to have advanced cancer when they first approach the clinician. 
However, the treatment of advanced cancer is not always satisfactory to clinician as 
well as patients. Complementary and alternative medicine is therefore needed to 
provide a more holistic and affordable therapeutic strategy. Meanwhile, many patients 
approach TCM practitioners for treating cancers all over the world. Yet only limited 
studies on the efficacy of TCM according to its holistic approach to each individual 
advanced cancer patients are documented. 
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It is expected that the use of Chinese herbal medicine can improve or maintain the 
QOL of advanced cancer patients. It is also hoped that the findings of this study can 
provide systematic evidence to demonstrate the effectiveness of Chinese herbal 
medicine for the QOL of advanced cancer patients. 
Further investigations into the correlation between WM doctor and Chinese medicine 
practitioner on the clinical evaluation of patients will also help to reveal the differences 
or similarities from the point of view of a WM doctor or a Chinese medicine 
practitioner. Moreover, by looking at the distribution of the Chinese herbal medicine 
used by Chinese medicine practitioner and the pattern or syndrome differentiation with 
the types of cancer will help to clarify the effects of Chinese herbal medicine and its 
regulatory mechanism on the disease. 
The findings of this study may eventually encourage patients or WM doctors to 
consider incorporating Chinese herbal medicine as a complementary therapy along 
with their palliative treatment or introducing patients to be treated with Chinese herbal 
medicine as an alternative therapy. 
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Chapter 2 Literature Review 
2.1 Introduction 
A comprehensive review of the literatures related to the topic of this thesis was carried 
out to provide a general background for this study. This chapter will summarize the 
literature review starting with the concept of advanced cancer. It describes the 
definitions of advanced cancer and its pathology and common symptoms encountered 
by patients. It also highlights some important mainstream treatments for advanced 
cancer patients. Then it will describe in detail the patterns differentiated by TCM 
diagnosis as well as the corresponding treatments. Empirical evidence about the 
clinical effectiveness of TCM on cancer patients will also be cited. 
This chapter also discusses the concept of health-related quality of life (HRQOL). The 
HRQOL instruments (i.e. EORTC QLQ-C30 and SF-36) commonly used for 
evaluating anti-cancer intervention will be explored. As stated in the following 
paragraphs, HRQOL is becoming more and more important to cancer patients. The 
relationship between HRQOL and advanced cancer will be explained and previous 
clinical studies using both instruments as the primary outcome are specified in this 
review. 
Lastly, previous clinical studies with similar design will be highlighted, and the gaps or 
differences in objectives will be identified. The design of the protocol ofthis study will 
then follow. 
2.2 The concept ofAdvanced Cancer 
There is no universal definition for the term 'advanced cancer’. Usually in different 
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literatures the meaning may be slightly different from each other but the general 
concept can still be identified. Advanced cancer is commonly referred to as a cancer 
that: 1. has spread from its original ^primary) site to other parts in the body (metastatic 
cancer) through blood or lymphatic circulation; or 2. affects a vital organ , but has not 
reached distant sites (American Cancer Society, 2010). In both cases the tumor is 
usually not possible to be removed or cured with treatment. Since there is no cure, the 
aims to handle advanced cancer are to help relieve symptoms, lengthen the survival 
time and shrink the tumor in order to improve patients' comfort (American Cancer 
Society, 2010). 
2.2.1 Pathology of Advanced Cancer 
As stated above, advanced cancer can consist of metastatic cancer or a cancer that 
affects a vital organ. The former occurs when the primary tumor disseminate and grow 
as secondary tumors in the body of the host. This takes time to develop a secondary 
tumor but usually metastasis already occurs before the primary tumor is discovered. 
The latter one simply refers to a primary tumor that grows at or near to vital organs 
where surgery is not feasible (American Cancer Society, 2010). For example, brain 
cancer may be considered advanced because it is not possible to be removed and are 
life-threatening even though it has not spread to other parts ofthe body. 
2.2.1.1 Metastatic Cancer 
Metastatic cancer is established through a series of interrelated steps known as the 
metastatic cascade (McKinnell et al., 2006). These steps are summarized in Table 2.1 
and Figure 2.1. Interruption of any steps in the metastatic cascade can prevent the 
formation of metastatic cancer. However the disease is irreversible once a metastatic 
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cancer is established. 
Table 2. 1 Steps in the metastatic cascade (McKinnell et al.，2006). 
1. Disruption of the basement membrane 
2. Cell detachment 
3. Cell motility 
4. Invasion 
5 • Penetration of the vascular system 
6. Circulating cancer cells 
7. Arrest 
8. Extravasation and proliferation 
ec% ijiDw^ a * Uct^ n 1usiH 'Uawri &-<A Ihioug^ i UaMi Umir^a immis tap4lJiiY 
m «peS«fturn 1 願 皿 ^ p ^ ^ — . _ ^ ^ ^ S ^ B s L • _ — _ 
^^ ^^ ^^ ^ ,, .fc#f l^:(^i^^^^" _^ ^^ ^^ ,^ ^^ ,__ 4 t' \,, j^^^r^'jk^9t ^^§W^^^^^ \ 少^^- _.~^==^^=, \j^^^ -iss^—^~n ^3^Em^ ^^^^=z,. 
W^t,^：广. ^ , < ^ 3 ^ a ^ , 0 ^ ^ ^ ^ m 
/ z -备 ^ ^ 
/ ,. . , :__aW_«^ 3^^ ^^ ^®^ ^ ^ V . mxX 'tH^^h fe4^"Ua!i<am 
C^t"^V < _^>^^^ZZ^ZZZZZZZZT:^ ?^' .-^ —,^ ^—一 '^ ^^m^ n^ <^  lj45^  Umn 3 m 1DCO cc41s <f^i %-r^v*3 
^X^^-^p ^ - j^^^ / /^ 爆 ^T^^ Co kA"r ,^to^ 
W^MM mM 
響禱—着|-穩！ 
mMA ^ ¾ ^ ^m.% 
*ihrr^ 1nbl^ l^ r^ prlratiWr^ ^^ i ^ ™ ^ ' . ^ **I l^AW .;iit*w.iufoflni mr«% i^^ ,l«r 
Figure 2. 1 Process ofmetastatic cascade (Adopted from Alberts, 2002). 
1. Disruption of the basement membrane 
When a primary cancer is formed in an organ, the epithelial cells of the tumor keep diff rentiating to give heterogen ity of cell types and become more malignant. Som  of them acqu re the competenc  to degrade and invad  the bas ment m mbrane andafterw rd h adjacent connective tissue (Bogenr eder 8  Her yn, 2003). The b s entChapter 2 Literature Review
membrane (BM) is breached by the digestion and degradation of its proteins by a 
collection of enzymes called matrix metalloproteinases (MMP) which are produced by 
the tumor cells (Egeblad & Werb, 2002). Disruption of the BM results in a channel for 
the tumor cells to pass into the extracellular matrix (ECM), where MMPs continue to 
degrade the protein in it. 
2. Cell detachment 
Once the BM is disrupted, tumor cells start to detach from the primary tumor. This is 
because tumor cells exhibit a deficiency in cohesion which is essential in the metastatic 
cascade (McKinnell et al., 2006). The cell to cell adhesion characteristic is expressed 
by the molecule called E-cadherin (Frixen et al., 1991). Tumor cells that do not express 
E-cadherin lose this morphology and thus become invasive. Detached tumor cells are 
able to move spontaneously to pass through the ECM and ultimately to capillaries or 
lymph vessels (McKinnell et al., 2006). 
3. Cell migration and motility 
Tumor cells are found to have the competence of motility in vitro (Lucke, 1939) and in 
vivo (Frixen et al., 1991). After they detach from the primary tumor mass, they breach 
the BM and migrate across as individual cells. In the ECM, the motility of tumor cells 
is initiated by an autocrine cytokine known as autocrine motility factor (AMF) and 
more specifically the activation of its receptor (AMF-R). The higher the gene 
expression of AME-R, the higher the cell motility (Takanami & Takeuchi, 2003). 
Besides, there are also other factors contributing to cell motility. One of these factors is 
that a MMP partially digests BM laminin and so opens a formerly hidden site which 
can also induce cancer cell motility (Pirila et al., 2003). Meanwhile, some of the tumor 
cells move to access blood vessels and migrate through the vessel wall through 
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translocation (intravasation). Others interact with the ECM to elicit its migratory 
activity and subsequently break through the walls of capillaries and lymph vessels. 
4. Invasion 
Blood streams are essential to tumor cells. Tumor cells need to access to nearby 
capillaries in the ECM. Similarly, they digest or degrade the wall of the blood or lymph 
vessels and migrate through it. 
5. Penetration of the vascular system 
Tumor cells digest the external wall of the vessel and migrate to the lumen by 
diapedesis (Engell, 1955). Besides, they can also enter newly formed capillaries 
because there are defects or gaps in the new blood vessels (Folkman, 2003a, 2003b). 
At this moment, most of tumor cells entering the blood or lymph circulation are 
destroyed by natural immune system responses. Only the most malignant cells can 
survive (McKinnell et al., 2006). 
6. Circulating cancer cells 
The dissemination of tumor cells to distant organs requires the hematogenous 
circulation of tumor cells. The capillaries provide a way for entrance into the main 
vascular system. But it should be noted that the presence of tumor cells in blood or 
lymph circulation does not necessarily lead to the formation of a metastatic cancer 
(Griffiths et al., 1973; Salsbury, 1975). 
7. Arrest of circulating tumor cells (stasis) 
Circulating tumor cells adhere with each other and to lymphocytes and platelets, 
forming emboli that may stay on the internal surface of capillaries. A thrombus is then 
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formed and so stabilize the embolus which can enhance growth and invasion of tumor 
cells. The stabilized tumor cells can interact with the capillary endothelial cells, 
causing endothelial cell retraction and the BM is then exposed to the inner surface of 
the capillaries. However, some of the tumor cells may die within the thrombus by 
digestion of the emboli and as a result the decrease in invasion. 
8. Extravasation and proliferation 
The stabilized tumor cells move into the intercellular matrix of the connective tissue 
between the retracted endothelial cells and through the breached BM. Proliferation of 
tumor cells and growth of a secondary tumor subsequently occur in the new organ with 
angiogenesis. The whole process repeats and the metastatic tumor will give rise to 
additional metastatic tumor. 
In summary, the establishment of metastatic cancer is a complex series of events. It 
may also involve various genes such as ras and nm23 that are believed to control 
metastasis (McKinnell et al., 2006). Some of them can inactivate tumor suppressors 
while others can enhance metastasis. The location of the body where the tumor cells 
tend to spread is often determined by the location of the primary tumor. Most tumor 
cells that have detached from the primary tumor move and migrate in the blood or 
lymphatic circulation until they get trapped in the next "downstream" blood vessel or 
lymph nodes. For instance, the liver is a common site of metastasis for cancer cells 
starting in the stomach and intestines because blood from the intestines flows into the 
liver. Finally, it is necessary to distinguish a secondary tumor from a primary tumor. 
One can determine by the fact that the metastatic tumor retains histological 
characteristics of its tissue of origin. 
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2.2.2 Sign and Symptoms of Advanced Cancer 
Patients of advanced cancer can have various symptoms depending on the type of 
advanced cancer. Nevertheless, common symptoms can still be found in different 
patients. Table 2.2 lists the common symptoms most frequently encountered by 
patients* 
Table 2. 2 Common signs and symptoms of advanced cancer (American Cancer 
Society, 2010; Cherny et al.，1994; National Cancer Institute, 2005). 
Symptoms Signs 
• Pain • Unexplained weight loss 
• Nausea and vomiting • Pulmonary edema 
• Loss of appetite • Ascites 
• Anorexia/Cachexia 參 Lumps (tumors) on or within body 
• Anxiety • Enlarged liver 







2.2.3 Diagnosis of Advanced Cancer 
Patients often discover cancer only after metastatic cancer is established since there 
may not be any signs and symptoms at early stage. Usually more than one test is used 
to detect advanced cancer, based on clinical and pathologic information before a 
diagnosis is defined. Clinicians usually diagnose advanced cancer by means of the 
following tests: 
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1. Blood tests 
Blood tests commonly include tumor marker test and liver function test. Tumor 
markers are useful for the identification of the types of cancer. For example, prostate 
cancer and colon cancer are assessed by elevated prostate-specific antigen (PSA) and 
carcinoembryonic antigen (CEA) respectively. Abnormal liver function test (LFT) is 
also used as an indicator to detect if the cancer has spread to the liver (American 
Cancer Society, 2010). 
2. Imaging tests 
There are various imaging tests for detecting advanced cancer depending on the 
suspicious location of tumors and economic considerations. 
• Chest X-ray: A chest x-ray can help detect tumors in lungs or pulmonary edema. 
• Computed tomography (CT) scan: The CT scan uses x-rays to show a slice or 
cross-section of body. The images of organs and soft tissues are clearer than 
standard X-rays (American Cancer Society, 2010). 
• Magnetic resonance imaging (MRI) scan: MRI scan uses radio waves and strong 
magnets to produce images similar to CT scans does. It is especially useful for 
looking at the brain and spinal cord. 
• Positron emission tomography (PET) scan: PET scan is advantageous when 
primary cancer is suspected of having spread to other organs (American Cancer 
Society, 2010). 
• Bone scan: This test helps to show whether a cancer has spread to the bones. Bone 
scans can discover the spread of cancer at a much earlier stage than regular x-rays 
can. 
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3. Biopsy 
Biopsy is the only way to confirm the type and nature of the tumor (McKinnell et al.， 
2006). When an imaging test reveals any abnormal image, a biopsy is often carried out 
to ensure that it is cancer by extracting a small piece of tissue and examining its 
histology. 
2.2.4 Current Treatment for Advanced Cancer 
Advanced cancer is recognized to be incurable but its symptoms can often be treated 
(American Cancer Society, 2010). However, in view of the patients and clinicians, 
clinical focus is still on trying the best for curative intent (Shinn et al., 2009), 
especially for newly diagnosed advanced cancer cases. In such circumstances, the goal 
of treatment for advanced cancer is to balance patients' finances and healthcare. When 
an advanced cancer is diagnosed, the possible treatment strategies are palliative care 
with curative intent or prolongation of life or palliative care only (Saraiya et al., 2008). 
According to the NCCN Guidelines, anticancer therapy with curative intent can be 
provided if an advanced cancer is diagnosed with the life expectancy estimated from 
weeks up to years. In the meantime, the management of symptoms caused by 
anticancer therapy as well as palliative care are offered to the patients. Upon 
satisfactory results at reassessments, the current treatments can be continued. If the 
tumors or symptoms cannot be controlled, a change or discontinuance of the anticancer 
therapy is required and palliative care should be intensified fNCCN, 2010). In general, 
some of the treatments used to cure cancer, such as radiation, chemotherapy and 
surgery are also used to relieve symptoms (American Cancer Society, 2010). 
Something can almost always be done to help maintain or improve the QOL at 
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end-of-life period (Cherny et al., 1994; NCCN, 2010; Wanzer et al., 1989). These 
treatments mainly include surgery, radiation therapy, chemotherapy, hormone therapy 
and symptom control medications. 
1. Surgery 
Surgery is not commonly used to treat advanced cancer. If the general condition of the 
patient is apparently fine, surgery may be useful for: 
• relieving symptoms. For example: cancer can sometimes block the intestine and 
cause pain for the patient. A surgery can be carried out to bypass the blockage so 
the bowel can function normally. By relieving the symptoms, surgery can improve 
the QOL and even prolong survival time. 
• stopping pain. Surgery can be done to remove the tumor if it is pressing on a nerve 
or is too close to the spinal cord. This can relieve pain or prevent paralysis. 
2. Radiation therapy 
Radiation therapy makes use of ionizing radiation to kill tumor cells. In advanced 
cancer, palliative radiation is often used to shrink localized tumors to control pain or 
other symptoms. For example, radiation on bone metastasis can reduce cancer pain. 
3. Chemotherapy 
Chemotherapy (chemo) aims to destroy tumor cells by the administration of cytotoxic 
chemicals through veins or by oral dosage. This treatment is usually used as the first 
line treatment for cancer that has metastasized. Most chemotherapeutic drugs work by 
interfering mitosis while some induce cells to undergo apoptosis, effectively targeting 
fast-dividing cells. More than 50 evidence-based chemotherapeutic drugs are currently 
available for cancer treatment. They can mainly be divided into: 
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• Alkylating drugs (e.g. Cyclophosphamide), which destroy tumor cells by directly 
attacking the DNA. 
• Antimetabolites (e.g. 5-fluorouracil), which interfere with the production of DNA 
and control tumor cells from growing and multiplying. 
• Antitumor antibiotics (e.g. Doxorubicin), which interfere with important cell 
functions, including the production ofDNA and cell proteins. 
書 Plant alkaloids (e.g. Vinblastine), which prevent tumor cells from dividing 
normally. 
By shrinking the cancer or destroying the circulating tumor cells, chemotherapy helps 
relieve symptoms and even prolongs the lives of some patients. 
4. Hormone therapy 
Hormone therapy uses drugs to block the actions of certain hormones or reduce their 
production in the body. For example, estrogen which is believed to be related to the 
growth of breast cancer and androgens (e.g. testosterone) which cause prostate cancer 
are restrained by hormone therapy. Tamoxifen is an example of steroid hormone used 
to treat breast cancer which depends on the hormone estrogen for growth. 
5. Symptom control medications/management 
Advanced cancer patients often encounter various symptoms such as cancer pain, 
nausea and vomiting, diarrhea, constipation, insomnia, dyspnoea and psychosocial 
distress regardless of the types of cancer. It is common to use acetaminophen or opioid 
agonists for cancer pain. As for other symptoms, interventions maybe different for the 
same symptom and as assessment for the underlying cause is necessary prior to the 
intervention. 
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2.2.5 Limitation of Current Treatments 
Current treatments are conventional and evidence-based. However, they have limited 
effect in the management of advanced cancer on the account of significant side-effect 
profile which may be unacceptable to patients and have a negative impact on their 
QOL, 
The most frequent side-effects induced by radiation therapy are fatigue and acute 
radiation dermatitis, but currently there Is no general consensus on its prevention or 
treatment of choice (American Cancer Society, 2010; Omidvari et aL, 2007). Radiation 
to the head and neck area can cause impairment of the parotid glands' ability to 
produce saliva (Xu et al., 2007) and thus induce xerostomia, which is usually 
permanent (Chambers et al., 2007). Some patients may also develop teeth destruction 
(Franzel & Gerlach, 2009) and radiation caries (Aguiar et al., 2009). Radiation to the 
stomach area can induce mucosal injury (Sonis, 2010) and cause nausea, vomiting and 
diarrhea. Radiation to the chest area can cause radiation pneumonitis and the 
pneumofibrosis process (Kiazimov, 2009), which may subsequently cause dyspnoea. 
Brain radiation can cause complete alopecia and sometimes problems with thinking or 
memory that may have a late onset. 
Chemotherapy (chemo) aims to destroy tumor cells by the administration of cytotoxic 
chemicals through veins or by oral. This can induce side-effects as a result of affecting 
both the cancer and normal cells and is unacceptable to many patients. The feasibility 
of its administration is limited for many patients due to the remarkable co-morbidity. 
One of the most frequent side-effects is nausea and vomiting (Baker et al., 2005; 
Griffin et al., 1996). Despite the recent advancement in the development of new 
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therapies for prevention, the episodes of nausea and vomiting which follow each cycle 
of chemotherapy are still the most troublesome side-effect experienced by cancer 
patients (Gibson & Keefe, 2006; Girish & Manikandan，2007). Another important and 
dose-limiting side-effect is peripheral neuropathy (Ocean 8c Vahdat, 2004). 
Unfortunately, neither prophylactic strategies nor symptomatic treatments have proven 
useful yet (Kaley & Deangelis，2009). Besides, diarrhea and constipation are also 
common side-effects of chemotherapy, which result from the manifestations of 
alimentary mucositis tract (Gibson & Keefe, 2006). However, such mucositis has still 
not been well defmed and the underlying mechanisms of the condition are yet to be 
established (Stringer et al.，2009). Other side-effects such as fatigue, myelosuppression, 
chemotherapy-induced alopecia are also commonly and frequently encountered 
(Hofman et aL, 2007; Humber et al., 2007; Wang et aL, 2006; Zaboikin et al.，2006). 
Side-effects of hormone therapy depend on the type of hormone therapy used but 
usually include hot flashes, blood clots, and loss of sex drive (American Cancer 
Society, 2010). 
Table 2.3Common side-effects (symptoms) induced by radiotherapy and 
chemotherapy. 
Radiotherapy induced side-effects Chemotherapy induced side-effects 
參 xerostomia 參 nausea and vomiting 
• nausea and vomiting • peripheral neuropathy 
參 diarrhea • diarrhea and constipation 
• pneumonitis and pneumofibrosis • fatigue 
參 alopecia • loss of appetite 
參 acute radiation dermatitis • alopecia 
• fatigue 參 myelosuppression 
參 chest pain 參 increased chance of infection 
• dyspnoea • bleeding or bruising after minor injuries 
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2.3 Diagnosis and Treatment by TCM of Advanced 
Cancer 
2.3.1 (Advanced) Cancer from the TCM perspectives 
In TCM, the origin of cancer or malignant tumor can be traced back to the B.C. 16-11 
century, when the name given to a tumor 'liu,[瘤]was discovered as an Oracle bone 
characters at the capital of Yin at the late Shang Dynasty (R. S. Chen, 2003; Y. K. Chen, 
2009; Yu, 1983). In the Rites ofZhou in the Zhou Dynasty, it was recorded that Chinese 
medicine practitioners were divided into four categories and one of which was called 
'yangyf [瘍醫].There is a consensus that yangyi probably referred to the oncologist 
nowadays (R. S. Chen, 2003). Since then, numerous Chinese classics have documented 
the classification, cause, diagnosis, treatment and prognosis of heterogeneous cancers. 
In these classics, there could be different names for the same type of cancer, and the 
Chinese names could not be specifically matched with any modern cancer name. 
However, these names still refer to a group of cancer types. Table 2.4 shows some 
Chinese terminologies of cancer types. In 1170 A.D., the word 'yan'[癌]first appeared 
in the book 'Wei-Ji-Bao-Shu'[衛濟寶書]written by Dong-Xuann-Ju-Shi [東軒居士]: 
“A tumor is usually hard and looks bumpy just like a rock", where the pronunciation of 
a rock is 'yan' and so the same pronunciation was given to a tumor (R. S. Chen, 2003; 
Y. K. Chen, 2009). However, the diagnosis of cancer by TCM was still often confined 
to observable or touchable tumors, and there was no classic particularly on oncology 
until the establishment of the People's Republic of China. With the knowledge and 
experience in treating cancer from history, and the development of modern science and 
medicine, oncology has become one of the specialties ofTCM. 
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Table 2. 4Chinese terminologies of different cancer types (Adopted from Y. K. Chen, 
2009). 
Chinese terminologies Sites of cancer 
Shirong [失榮],Shiju [石疽],Kongnaosha [控腦砂] Nasopharynx, Hodgkin's 
lymphoma, thyroid 
Jianchun [繭唇]’ Shejun [舌菌] Lip, tongue 
Yege [噎膈],Fanwei [反胃] Stomach，oesophagus 
Fuliang [伏梁]? Jiju [積聚] Stomach, pancreas 
Huangdan [黃疸]，Guzhang [臌脹],Piqi [痞氣]，Liver 
Puzheng [暴症] 
Duru [妒乳],Rushiyong [乳石癰],Ruyan [乳岩] Breast 
Daixia [帶下],Benglou [崩漏],Jiaochang [交腸] Cervix 
Fanhauchuang [反花瘡],Fanhau [翻花] Skin 
Suogangzhi [鎖肛痔],Changtan [腸覃] Colorectum 
2.3.2 Diagnosis by TCM of Advanced Cancer 
In TCM, the causes of cancer include: invasion of external pathogens and six excesses, 
drastic seven emotions, dietary irregularities, overexertion and fatigue, chemical and 
physical factors, inheritance and prolonged illnesses. All of these factors lead to the 
inharmonious status and functional disturbance of the zangfu [臓膽],and damage to 
the qi, blood, body fluids and all the organs in the body. Subsequently, stagnant qi, 
phlegm-retained fluid, static blood and heat toxins are formed and combine to damage 
the anti-pathogenic qi and blood of the body. As a result, abnormal proliferation and 
mutation can be resulted in organs and body fluids, and thus malignant tumors are 
developed (R. S. Chen, 2003; Z. Y. Zhou & Jin). 
The diagnosis of TCM on cancer focuses on the pattern differentiation of the diseases. 
Pathologically, stagnant qi, phlegm-retained fluid, static blood and heat toxins are 
excess, while functional disturbance of the internal organs and the deficiency of the 
anti-pathogenic qi or healthy qi (including yin and yang), blood and body fluids are 
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considered as deficiency (Z. Y. Zhou & Jin). In relation to advanced cancer, tumor has 
already spread to other parts of the body, thus deficiency is often more important than 
excess. 
2.3.3 Treatment by TCM ofAdvanced Cancer 
The treatment approach of advanced cancer is similar to that of any diseases in TCM. 
The difference is the importance of combination of disease identification and pattern 
differentiation for the treatment of cancer (Y. K. Chen, 2009). Targeting on disease 
identification, Chinese herbal medicines, such as Herba Hedyotis Diffusae 
(Baihuasheshecao)[白花虫它舌草]，Herba Scutellariae Barbatae (Banzhilian)[半枝蓮] 
and Fructus Akebiae Quinatae (Bayuezha)[八月丰匕],are used to treat boil [疔瘡], 
swelling [腫]or toxin [毒]according to the old classics or The Pharmacopoeia of the 
People's Republic of China 2005. As for pattern differentiation, the treatment of 
advanced cancer often includes: clearing heat and resolving toxins [清熱角率毒]， 
activating blood circulation and resolving blood stasis [、活血化瘀],dispelling phlegm 
and dispersing nodules [除痰营夂結],dispersing aggregation and breaking accumulation 
[消癥破積],reinforcing healthy qi and tonifying deficiency [扶正補虛](Y. K. Chen, 
2009). Some commonly used Chinese herbal medicines or decoctions are shown in 
Table 2.5. 
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Table 2. 5Commonly used Chinese herbal medicine or decoction (Adopted form 
Ebling，1994; The State Pharmacopoeia Commission of the P. R.China, 2005; Z. Y. 
Zhou & Jin). 
Chinese herbs/decoctions Actions 
Herba Hedyotis Diffusae 白花蛇舌草 Clear heat, resolve toxins, relieve 
(Baihuashcshccao) swelling 
Herba Taraxaci (Pugongying) 蒲公英 Clear heat, resolve toxins, relieve 
swelling, relieve strangury, diuretic 
Radix et Rhizoma Salviae 丹參 Enhance blood circulation, analgesic, 
Miltiorrhizae (Danshen) unblock the meridian, clear the heart 
Radix Astragali (Huangqi) 黃耆 Tonify qi, secure the exterior, diuretic, 
expel toxins, expel pus, promote tissue 
regeneration and wound healing 
Poria (Fuling) 获爷 Diuretic, drain dampness, fortify the 
spleen, quiet the heart qi 
Carapax Trionycis (Biejia) 驚甲 Open the orifices, enhance blood 
circulation, unblock the meridian, 
disperse swelling, analgesic 
Bulbus Fritillariae Thunbergii 浙貝母 Clear heat, disperse nodules, resolve 
(Zhebeimu) phlegm, suppress cough 
Thallus Laminariae Thallus 昆布 Soften hardness and dissipate binds, 
Eckloniae (Kunbu) resolve phlegm, diuretic 
Wu-wei-xiao-du-yin 五味消毒飲 Clear heat, resolve toxins 
Shen-ling-bai-zhu-san 參爷白術营夂 Tonify spleen qi, resolve dampness 
2.4 Current Evidences about the Clinical Effectiveness 
ofTCM on Cancer Patients 
It is notable from the above that TCM has its characteristics and predominance in 
treating cancer patients, probably in the curative, supportive and palliative approach. 
To support its efficacy, numerous clinical researches have been done recently and 
revealed evidences suggesting that TCM is useful in the integration/combination with 
conventional treatments and as an alternative to conventional treatments. Although 
high quality of randomized clinical trials are still urgently needed, recent systematic 
mmmmmmmmKmmmHmmKmmmmsmmMmmmummmmmmmmHmmmmmmmnmmmmmmmMmMmmmmmmmmmKmmmmmmmmmmmmmmmmmmmmKmmmmammmmummmHm 
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reviews still provide some clinical evidences that support the use of TCM formulas and 
herbs on cancer patients. 
Integration/combination with conventional treatments 
The usage of integrative TCM with conventional treatments constitutes the majority of 
the two roles，Some reviews have showed an increased potency of chemotherapy and 
reduced chemotherapy-induced side-effects in combination with TCM. A Cochrane 
review has reported 4 studies using Chinese herbal medicine to treat chemotherapy-
induced side-effects on colorectal cancer patients. The result showed that the episode 
of nausea and vomiting, the incidence of leukopenia have been significantly reduced 
and the production of immuno-competent lymphocytes (CD3 and CD8) has been 
increased (Taixiang et al., 2005). Another meta-analysis of 7 randomized controlled 
trials on breast cancer patients showed that Chinese herbal medicine in combination 
with chemotherapy can alleviate chemotherapy-induced short term side-effects, 
improve bone marrow and QOL (M. Zhang et al.，2007). A review article in China also 
summarized the treatment of nasopharyngeal cancer by radiotherapy combined with 
Chinese herbal medicine. It suggested that the combined therapy increased sensitivity 
to radiation and response rate, relieved radiotherapy-induced side-effects, improved 
immunity, QOL and long term survival rate and reduced recurrence and metastasis 
(Wei, 2001). As a part of integration with conventional treatment, TCM also plays an 
important role in the supportive care after conventional treatment. In a systematic 
review exploring all liver cancer cases treated with TCM in China since 1949，3 studies 
revealed that Chinese herbal medicine might reduce the incidence of liver cancer 
recurrence, metastasis and suppress angiogenesis (W. Y. Wu et al., 2009). A summary 
of the systematic reviews on the use ofTCM for cancer patients is listed in Table 2.6. 
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Alternative to conventional treatments 
In China, TCM is commonly used alone to treat cancer patients, generally in the late or 
advanced stage. In an RCT, 90 colorectal cancer patients were divided into 3 groups: 
TCM group, western group where chemotherapy was applied and integrative group 
with combined therapy by TCM and chemotherapy. The improvement of HRQOL in 
the integrative group was the largest, followed by the TCM group. Their results 
suggested that TCM might improve the HRQOL of patients to a certain extent (L. Z. Li 
et al., 2009). Another RCT accessing the therapeutic effect of Chinese herbal medicine 
on 90 intermediate and advanced non-small cell lung cancer patients revealed that 
TCM might relieve clinical symptoms, improve HRQOL and increase the level of CD4 
(Y. Wu et al., 2008). A review article suggested that TCM was potentially useful in its 
role as an alternative to conventional treatments on elderly patients, advanced cancer 
patients, patients with poor physical status or those who fail DNA screening for 
targeted therapy (W. Wu et aL, 2009). 
For all the reviewed meta-analysis or review articles, single designated decoction with 
or without various ingredients added to/subtracted from it, based upon the 
characteristics of each individual patient, or a single herb, was administrated within a 
study. The Chinese herbal medicines included in the decoction can be referred to Table 
2.6. Amongst the Chinese herbal medicines listed in the cited meta-analysis, 
Astragalus membranaceus (Huangqi)[黃耆]was found to be the most commonly used. 
According to an experimental study, Astragalus membranaceus could exhibit both in 
vitro and in vivo anti-tumor effects, which might be achieved by activating the 
anti-tumor immune mechanism of the host (Cho & Leung, 2007). Other Chinese herbal 
medicines or decoctions that also demonstrated significant anticancer effects in 
experimental studies include: Scutellaria baicalensis [黃等],Scutellaria barbata [半枝 
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蓮](Ruan, Lai, & Zhou, 2006), Radix Tripterygii Wilfordii [雷公藤]，Radix et 
Rhizoma Ginseng [人參]，Rhizoma Curcumae Longae [姜黃]，Coriolus versicolor 
[雲芝],Bie-jia-jian-wan [鱉甲煎九]3 Shen-mai injection [參麥注射液](Hong & Li, 
2009) etc. They achieved the anticancer purpose by inducing apoptosis and 
differentiation, enhancing the immune system, inhibiting angiogenesis and reversing 
multidrug resistance (Ruan et al., 2006). 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.5 The concept of Health-related Quality of Life 
(HRQOL) 
QOL is a broad and complex concept globally related to the subjective feeling of an 
individual and his/her satisfaction in life (Richards & Ramirez, 1997; Sahlberg-Blom et 
al., 2001). It comprises various dimensions of an individual including physical, 
psychological and social well-being, fulfillment of personal expectations and goals, 
economic impact, and also functional capacity to develop daily routines normally. In 
1993，the World Health Organization Quality ofLife (WHOQOL) group defmed QOL 
as as individuals' perceptions of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, standards 
and concerns (World Health Organization, 1993). 
Since QOL covers a wide range of areas of life, it has been adopted by a variety of 
disciplines such as healthcare and political science. However, they define it in various 
ways depending on the viewpoints of the disciplines and the reason for adopting this 
concept (Edlund & Tancredi，1985). With respect to health, QOL is regarded as a part 
of the domain of health and illness, and it is increasingly referred to as 'health-related 
quality of life’ (HRQOL). In such case, QOL has focused on the satisfaction in life of 
an individual that impacts directly upon their health in the dimensions of physical, 
mental and social well-being. In the presence of illness, HRQOL is defmed as the 
impact of the illness or treatment on an individual's physical, psychological, social, 
and somatic functioning and general well-being (Trask et al., 2009). 
2.5.1 The importance ofHRQOL to cancer patients 
Since HRQOL concerns how a person assesses his/her QOL in relation to a medical 
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condition or treatment, it can be regarded as an important outcome indicator for 
treatment response or clinical trials. This is especially helpful in accessing patients 
with cancer. For example, conventional treatments that extend life but impair QOL 
may be less worthy to patients (Trask et al., 2009). As a result, health providers and 
researchers are also interested in the HRQOL by the impact of the treatments (Lee & 
Chi, 2000; Trask et al., 2009). Table 2.7 lists a summary of when HRQOL may be 
assessed in such cases. During the past decades, there has been an increasing 
recognition of the importance of using QOL as an endpoint in randomized clinical 
trials particularly in the oncology field (Lee & Chi, 2000). More than that, such 
recognition is also supported by agencies such as the United States Food and Drug 
Administration (FDA) for the registration of new anticancer drugs (Joly et al., 2007; 
Lee & Chi, 2000; Trask et al., 2009). Besides, the European Organization for Research 
and Treatment of Cancer (EORTC) also recognizes QOL as the important endpoint of 
anticancer therapy and has developed the EOTRC Quality of Life Questionnaire to 
assess this endpoint (QLQ-C30) (Bang et aL, 2005). HRQOL is even important in 
palliative care for advanced cancer patients, which aims at improving a patient's 
subjective well-being, physical and emotional functioning, symptoms and life 
expectancy (Trask et al., 2009). To meet these multiple and varying needs, it is 
believed that an outcome indicator should be holistic, multidisciplinary and 
patient-centered. Hence HRQOL can be defined as the main endpoint for palliative 
cancer patients (Jordhoy et al., 2001). 
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Table 2. 7 Summary of when HRQOL may be assessed in clinic and clinical trials 
(Trask et aL, 2009). 
Reason to include HRQOL In In 
clinic clinical 
trials 
• Understand how existing treatments (standard of care) impact V V 
functioning 
• Understand how novel treatment impacts patient functioning V 
• Identify treatment-related symptoms that need management V V 
參 Provide early indications of a treatments' effectiveness V V 
拳 Assist in determining whether a drug should progress from V 
phase II to phase III 
• Understand relation between HRQOL and overall V 
survival/progression free survival 
• Patient reports of frequent occurrence of symptoms before V V 
adverse events are observed 
參 Patient reports and provider reports of patient symptoms are not V 
highly correlated 
• Differentiate 2 treatments with similar efficacy V V 
• Further complement and augment a products' efficacy and V 
safety data 
2.5.2 HRQOL instruments 
HRQOL is a concept that attempts to combine objective measurements of functional 
capacity across various health domains (health status) with measurements that 
represent an individual's subjective perception of health or sense of well-being. Before 
the past decade, few HRQOL instruments for the assessment of QOL that were reliable, 
valid and concise enough to be of practical use in clinical trials were available. There 
were even fewer instruments that were cancer specific (Aaronson et al., 1993). 
In order to meet the increasing attention for and importance ofHRQOL for researchers, 
care givers and patients, a number of HRQOL instruments emerged and their intent 
was to generate questionnaires for measuring HRQOL, incorporating a range of 
physical, emotional, and social issues. Commonly used HRQOL instruments on cancer 
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patients include: European Organization for Research and Treatment of Cancer 
(EORTC) QLQ-C30; Functional Assessment of Cancer Therapy (FACT); Functional 
Living Index-Cancer (FLIC); Cancer Rehabilitation Evaluation System (CARES); 
Rotterdam Symptom Checklist (RSCL); Medical Outcomes Study Short Form (SF-36) 
(Center for Gerontology and Health Care Research, 2004; Joly et al.，2007; Lee & Chi, 
2000; Trask et al.，2009). Table 2.8 lists some commonly used HRQOL instruments in 
the field of oncology. 
Table 2. 8Some commonly used HRQOL instruments with the number of items in the 
questionnaire and the transformed scales. 
Some common HRQOL instruments No. of items No. of scales 
FLIC 22 5 
CARES 59 5 
EORTC QLQ-C30 30 15 
FACT-G 27 5 
RSCL 39 4 
SF-36 36 8 
2.5.2.1 EORTC QLQ-C30 
The EOTRC Quality of Life Questionnaire Core-30 (QLQ-C30) was developed in 
1993 by the European Organization for Research and Treatment of Cancer (EORTC) 
Quality of Life study group. It is an integral system for assessing the QOL of cancer 
patients participating in international clinical trials (Aaronson et al.，1993). This core 
module is a cancer specific questionnaire valid to be used on patients with various 
types of cancer (Ringdal & Ringdal, 1993). 
A first-generation core questionnaire, the EORTC QLQ-C36, was developed in 1987 
(Aaronson et aL, 1993; Kyriaki et al.，2001). The EORTC QLQ-C30 is a 
second-generation questionnaire. Presently the most updated version is the QLQ-C30 
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Version 3.0 and has been translated and validated into 81 languages worldwide (P. M. 
Fayers et al., 2001). Version 3.0 differs from Version 2.0 in that it has 4-point scales for 
the first 5 items. Moreover, question 4 has been reworded as: “Do you have to stay in 
bed or a chair during the day?" (Kyriaki et al., 2001). 
The EORTC QLQ-C30 consists of30 items that evaluate physical (5 items), emotional 
(4 items), role (2 items), cognitive (2 items), and social (2 items) functioning, as well 
as global health status (2 items). Higher scores on these scales represent better 
functioning. There are also three symptom scales measuring nausea and vomiting (2 
items), fatigue (3 items), and pain (2 items), and 6 single items assessing financial 
impact and various symptoms (dyspnea, appetite loss, sleep disturbance, constipation 
and diarrhea). The scores on the functional scales and the symptoms scales/items are 
linearly transformed such that all scales range from 0 to 100 (Jordhoy et aL, 2001). 
Most translated EORTC QLQ-C30 have been tested and validated in different cultures. 
For the Chinese translation of EORTC QLQ-C30 Version 3, convergent and divergent 
validity were satisfactory, where item-domain correlation ranged from 0.59-0.65 and 
item own subscale correlation higher than item other subscale correlation. Internal 
consistency was demonstrated by Cronbach's a coefficients of ^ 5 0 in all scales. Test 
and retest data indicated by the intraclass correlation coefficients between two tests 
were high (0.46-0.85) (Chie et aL, 2003; Chie et al., 2003; Chie et al.，2004). 
2.5.2.2 SF-36 
The Medical Outcomes Trust 36-item Short-Form Health Survey (SF-36) has been 
developed by Ware et al. since 1986 in the United States (Ware et al., 1993, 2000). It is 
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a generic measure, as opposed to one that targets a specific age, disease, or treatment 
group. Also it is shown to be a valid, reliable, sensitive and responsive instrument for 
measuring the physical and mental health relevant to everyone's functional status and 
well-being. (Lam et al., 1998; Lam et al , 2005; Ware et al., 1993，2000). In addition, 
the SF-36 has been currently translated for use in more than 40 countries and the 
currently updated version is the SF-36 Version 2 (QualityMetric Incorporated). 
The SF-36 is a multipurpose, 36-item survey that measures 8 domains of health: 
physical functioning (10 items), role limitations due to physical health (4 items), bodily 
pain (2 items), general health perceptions (5 items), vitality (4 items), social 
functioning (2 items), role limitations due to emotional problems (3 items), and mental 
health (5 items). It yields scale scores for each of these 8 health domains, and two 
summary measures of physical and mental health: the Physical Component Summary 
(PCS) and Mental Component Summary (MCS). Same as QLQ-C30, the raw scores on 
the SF-36 are linearly transformed such that all scales range from 0 to 100 (Ware et al., 
1993,2000). 
The SF-36 Hong Kong (Chinese) Version 1 has been tested with an adequate 
convergent validity, where item-domain correlations were ^0.4. Discriminant validity 
was indicated by the 100% scaling success rate except the physical functioning scale 
(92.5%). High reliability was shown by the Cronbach's a coefficients of internal 
consistency of ^0 .7 except the social functioning scale (0.65) (Lam et al., 1998). 
2.6 Summary of Literature Review 
As cancer is becoming a more and more common life-threatening disease among the 
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population, it is believed that there will be increasing cases of advanced stages or 
palliative care patients. Regardless of the disease itself or the conventional treatments, 
the physical, physiological and social functioning of an individual are negatively 
affected by various symptoms or side-effects. TCM treatment can regulate qi, blood, 
yin and yang of cancer patients by removing the excess and tonifying the deficiency in 
the body. Many previous studies in the Mainland and overseas have reported desirable 
effects of Chinese herbal medicine on cancer patients. However, there was still a 
limitation on the TCM intervention and the deficient evaluation on the role of TCM for 
cancer patients with palliation. Palliative care aims at improving a patient's subjective 
well-being, and with the support of the use of HRQOL as an outcome of anticancer 
therapy by FDA, HRQOL is thus the main end-point for assessing advanced cancer 
patients. To ensure the feasibility, safety and gross effectiveness of TCM treatment on 
advanced cancer patients, clinical trials with adequately designed method are required 
to determine the impact of TCM. 
2.7 The research questions 
1. What are the effects of Chinese herbal medicine on advanced cancer patients in 
aspects of: 
• health-related quality of life? 
參 safety? 
• hematology? 
• renal and liver function? 
• tumor markers (if applicable)? 
• body weight? 
2. Are there any differences in the overall evaluation on patients between: 
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• Western medicine doctor and Chinese medicine practitioner? 
參 the patients themselves and the clinicians? 
3. What are the distribution of the TCM patterns and Chinese herbal medicine in this 
study? 
4. What is the overall survival of advanced cancer patients taken Chinese herbal 
medicines? 
2.8 Research Hypotheses 
1. There are significant differences in the healthy-related quality of life of cancer 
patients before, during and after the Chinese herbal medicine treatment. 
2. There are no differences in the effect on health-related quality of life, safety, 
hematology, renal and liver function, tumor markers (if applicable) of Chinese 
herbal medicine between different syndromes and different cancer types. 
2.9 The design ofTCM protocol 
The frame of the research protocol was based on the literature reviews, limitations of 
clinical studies and the practicality of this research. According to the literature, TCM 
treatment adopting the pattern differentiation and treatment should be the soul of the 
efficiency. It is the normal exercise in any TCM clinic but limiting studies apply it as 
the intervention. Even in China, the recruited patients often fell into the predefined 
category ofpattern differentiation rather than being treated as an individual. Therefore, 
the intervention of this study was chosen as the individualized and patient-tailored 
approach to TCM treatment. 
Due to the practicality of a time-limited study and competition of patients with other 
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studies, heterogeneous types of advanced cancer patients receiving palliative care were 
recruited in this study. For ethical consideration, it is a common perception that the use 
of an inert placebo control is not possible (Xu et al., 2007). Moreover, it is also 
unethical not to allow patients receive any treatments in a control group even with 
palliative care. Therefore, based on the assumption that the TCM treatment under 
investigation is effective, there was only one treatment group in this study with TCM 
and conventional palliative treatments as the intervention. To determine whether the 
intervention is effective in a single-armed study, a longitudinal study would be more 
appropriate to capture changes in outcome measures at specific points of time (Zhao & 
Kanda, 2000). In order to reduce bias and the number of parameters, patients were 
referred by one oncologist in a hospice clinic and treated by one registered Chinese 
medicine practitioner. 
Since the patients were terminally ill and most of them were probably at the end of 
their lives, substantial attrition caused by death of patients was expected. Therefore, the 
intervention period was not planned to be so long to maintain the best possible 
integrity of sample size. According to previous studies, the rapid progression of this 
disease would permit an examination of the responsiveness of the questionnaire to 
changes in health status within a relatively compressed time frame. In addition, it was 
considered that 1 month was consistent with an intervention period that was likely to 
show a clinically significant effect (Aaronson et aL, 1993; Jordhoy et aL, 2001; 
Jordhoy et al., 1999). It was thus decided that 2 months would be adopted as the 
intervention period in this study. 
Outcome measure adopted the holistic, multidisciplinary and patient-centered 
instrument, which aims to evaluate the change in a patient's subjective well-being. It 
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was postulated that TCM treatment would have a positive impact on the HRQOL of 
advanced cancer patients under palliative care, therefore the HRQOL instruments were 
defined as the main end-points in this study (Jordhoy et al., 2001). In this study, 
EORTC QLQ-C30 was used because heterogeneous cancers were included. This 
cancer-specific questionnaire could indicate the common symptoms and functioning 
encountered by different types of cancer patients. To maintain the comprehensiveness 
of well-being of patients, QLQ-C30 was also accompanied by the SF -36. 
In summary, to compare the health outcomes, and to evaluate the feasibility and safety 
of TCM treatment on advanced cancer patients under palliative care, a longitudinal 
observational study was proposed to collect findings on TCM treatment under routine 
conditions. 
Chapter 2 Literature Review 44 
Chapter 3 Methodology 
3.1 Introduction 
At the moment, the evidence for the utility of TCM in cancer care is promising, but 
prospective clinical trials for evaluation of appropriate stratification and 
individualization according to the TCM diagnostic criteria are still necessary for 
obtaining reliable and generalizable data (Bensoussan et al.，1998). In order to testify 
our early hypothesis, a clinical trial was developed in 2008 and conducted until June 
2010. In this chapter, the protocol of this study will be presented in details. The design 
of study, the selection of subjects, the procedure of the clinical trial，the outcome 
measures, the data collection and analysis will be introduced in paragraphs. 
3.2 Protocol 
The protocol of this study was initiated by Dr. Wong Yeuk Oi, Instructor of the School 
of Chinese Medicine, The Chinese University of Hong Kong, with the collaboration 
between The Pok Oi Hospital Chinese Medicine Polyclinic cum The Chinese 
University of Hong Kong Chinese Medicine Training & Research Centre of Hong 
Kong, Tuen Mun Hospital (TMH) and the School of Chinese Medicine, The Chinese 
University of Hong Kong. 
The protocol ofthe study titled 'Usefulness of Chinese Herbal Medicine in Advanced 
Cancer Outpatients: A Pilot Study on Efficacy, Tolerability and Quality of Life' was 
approved by the New Territories West Cluster Clinical and Research Ethics Committee 
GSfTWC - CREC) on 9 August 2008 with a CREC reference of NTWC/CREC/63 5/08. 
mmmmmmmmmamKmsmsm"^��•_������.1 
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3.2.1 Study Design 
This was an observational clinical study following a non-randomized, uncontrolled, 
open label, single group pre-post and prospective design. It aimed to compare the 
health outcomes of the advanced cancer patients before, during and after Chinese 
herbal medicine. Patients with advanced cancer of any type were first screened by an 
oncologist at the Department of Oncology, TMH. Preliminarily eligible patients were 
then referred to enter this study. Informed consents were obtained prior to the 
enrollment of the patients fulfilling both the inclusion and exclusion criteria. Eligible 
patients were arranged to receive study treatment individually and assessed repeatedly 
throughout the whole observation period. 
3.2.2 Selection ofParticipants 
A convenience sample of advanced cancer patients were recruited from two sources: 
1. referral from Department of Oncology, TMH; and 
2. publishing promotion posters and pamphlets. 
All promotion materials involved are showed in Figures 3.1. Interested patients or 
potentially eligible patients were first screened by oncologists at Department of 
Oncology, TMH. Reviewed inclusion and exclusion criteria were carried out by an 
investigator according to the following inclusion and exclusion criteria. 
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(只供參考之用） 
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Figure 3. 1 Promotion materials for recruitment of subjects. 
3.2.2.1 Inclusion criteria 
Subjects were eligible for inclusion if they fulfilled the following criteria: 
• Provision of written informed consent. 
• Female or male aged 18 or above. 
• Confirmed diagnosis by an oncologist of advanced cancer (histologically or 
radiologically or clinically) of: 
• locally unresectable, or 
• metastasis. 
• Fail conventional anti-cancer treatments (e.g. chemotherapy, radiotherapy, hormone 
therapy, targeted therapy and surgery). 
• Life expectancy of 12 weeks or longer. 
• Being ambulatory. 
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3.2.2.2 Exclusion criteria 
Subjects with one or more of the following criteria were excluded from the study: 
• Unable to communicate in Cantonese or Chinese language, 
• Chemotherapy or other systemic anti-cancer therapy within four weeks before the 
start of study (Day 1). 
• Chinese herbal medicine treatment within four weeks before the start of study (Day 
1). 
• Any unresolved significant toxicity from previous anti-cancer therapy. 
• Grossly abnormal renal or liver function including any one of the following blood 
result within 14 days before screening: 
1. Serum bilirubin > 1.5 x ULRR. 
2. Serum creatinine >1.5 x ULRR. 
3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 x 
ULRR in the absence of liver metastases, or >5 x ULRR in the presence of liver 
metastases. 
4. Alkaline phosphatase (ALP) >2.5 x ULRR in the absence of liver metastases, 
or >5 x ULRR in the presence of liver metastases. 
• Women who are pregnant or breast-feeding. 
• Involvement in any litigation. 
• Simultaneous infection with HIV or Hepatitis C virus. 
• History of significant drug hypersensitivity. 
• Unable to attend follow up or poor compliance to the study protocol. 
An eligibility checklist can be found in Appendix 3. 
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3.2.3 Sample size calculation 
In this study, the results of EORTC QLQ-C30 and SF-36 were defined as the primary 
endpoints and thus the scales of these two questionnaires should be used to estimate 
the sample size. However, there were too many outcome measures such that the 
nominal p-values became distorted. Therefore, the scale 'global health status，in 
QLQ-C30 was selected as being of main primary endpoint in order to calculate the 
sample size, ‘global health status，is one of the relatively few scales of the QLQ-C30 
which is often approximately normally distributed, and so it is appropriate to estimate 
sample size using the normal approximation (Fayers et aL, 1998b). 
According to the "Guidelines for assessing Quality of Life in EORTC clinical trials", 
for a variety of scales including 'Global health status’，changes of between 5% and 
10% (between 5 and 10 points on the 1 to 100 scales) are noticed by patients and are 
regarded by them as "significant changes" (Young et aL, 2002). Therefore, we wished 
to detect an overall difference of the median value (7.5 units), which were expressed in 
terms of an anticipated effect size: 
A= 5 / s, 
where 
8 = anticipated difference in outcome to detect clinical significant change = 7.5 
s = between subject standard deviation of score of Global Health Status of the 
reference sample of stage III/IV cancer patients suggested by EORTC = 23.6 (Fayers et 
al., 1998b) 
Therefore, given a two-tailed test with a statistical power of 80% and a significance 
level of 5%, the formula used to determine the required sample size should be (Machin 
BMBBHBBIHBMWHWiWWWI_ll_l^ lllll_llllllllli__iM_fflfflffl_l_MI__lll_llll_ilU^ I_l_ll^ _ •__millnwiiwiiiniiwniwiiiwin__丨圓11_m_iwi__^ iiii_iw_iiHimnmrnammrnHrnnm 
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et aL, 1997): 
N = (Zi_a/2+Zi.p)VA' + ZVa/2/2, 
where 
Zi_ay'2 = tabulated value = 1.96 
Zi- p = tabulated value = 0.84. 
Therefore, the calculated sample size is: 
(1.96+0.84)2/ 0.31782+ 1.962 / 2 
=79.55 
However, it is foreseeable that it is impractical to achieve this number of recruited 
subjects in limited time. Therefore, we planned to recruit a sample size of50 following 
previous clinical studies with similar designs (Good et al., 2009; Mercadante et aL, 
2009; Simon et al., 2007; Trask et al., 2008). As there might also be a number of early 
deaths and low compliable subjects, we predicted the drop-out rate is about 20%. 
Hence the total number of subjects recruited for the trial should be 50(1+20%) = 60. 
3.2A Setting 
The TCM treatment and most assessments were carried out at The Pok Oi Hospital 
Chinese Medicine Polyclinic cum The Chinese University of Hong Kong Chinese 
Medicine Training & Research Centre of Hong Kong. The collection ofblood samples 
and follow-up with the oncologists took place at the Day Hospice Centre Clinic of 
Tuen Mun Hospital. 
3.2.5 Interventions 
3.2.5.1 Treatment 
All eligible patients were assigned into the treatment group, where they were treated 
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individually by the same registered Chinese medicine Practitioner (RCMP), Prof. 
Yukun CHEN (Figure 3.2). Prof. CHEN has over 30 years of clinical experience in 
treating cancer patients and has been credentialed and privileged by Hong Kong. He 
was responsible for all the TCM consultation according to the routine practice of 
diagnosis and treatment ofTCM, pattern or syndrome differentiation and treatment. He 
decided the best suitable treatment for the patient and the choice of treatment was not 
affected by the design of this observational study. 
' ^ ^ M ^ ^ M m^^^^m 
^S^Mm 
^ P ^ 9 ^ S ^ ^ r T a 
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Figure 3. 2 TCM diagnosis and treatment for one of the patients by RCMP. 
3.2.5.2 Medication and dose/dosage 
Only Chinese herbal medicines were prescribed to the patients. Patient undergoing 
acupuncture or tui-na will be excluded from this study. The prescription for each 
patient was a combination of individual Chinese herbal medicine and the choice, 
number and dose of Chinese herbal medicine were determined solely by the RCMP. 
Each patient was assigned to a follow-up consultation by the same RCMP every week 
^ ^ ^ = ^ ^ = i ^ = ^ ^ = ^ = = = ^ = ^ = ® 5 ^ 1 ^ ^ ^ 
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(±2 days) for an intervention period of totally 8 weeks. One package of Chinese herbal 
medicine was required to be taken orally each study day and the same package of 
remedy was boiled twice a day with at least 4 hours in between. For those who were 
not able to boil the remedy (i.e. living in elderly home), Chinese herbal powder were 
given instead. Besides, every patient was given a 'Patient's Schedule' (Table 3.1) for 
their daily record. A ' V' should be put in the corresponding box when they finished a 
package of Chinese herbs. 
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Table 3. 1 Patient's Schedule. 
中醫藥對晚期癌症的臨床硏究 
中 藥 月 艮 藥 記 ^ ^ 
病人姓名： Subject code: 
Consent date: 
氺請你在服用中藥後即塡上當天之日期* 
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All herbs used in this study were supplied by The Pok Oi Hospital Chinese Medicine 
Polyclinic which was under stringent quality control procedures set up by the Hospital 
Authority (Figure 3.3). Only common non-toxic herbs were allowed to be used in this 
study. Toxic herbs listed in Schedule 1 of The Chinese Medicine Ordinance (Cap. 549 
of the Laws of Hong Kong) were not used. 
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Figure 3. 3 ATCM prescription and package of Chinese herbs/Chinese herbal powder. 
3.2.5.3 Treatment Assignment 
The patients were assigned to visit the TCM clinic for follow-up consultation by the 
RCMP every week (±2 days) for a period of eight weeks. They reported and informed 
the RCMP of any uncomfortable perception and symptom. Afterwards reviewed 
prescriptions by the RCMP were given to the patients. Any untoward events occurring 
at anytime during the study period were also reported to the investigator by phone. All 
patients were evaluated at baseline (Day 1), after 4-week treatment (Day 29土2) and 
after 8-week treatment (Day 57±2) visit. Blood samples were also collected at the 
above three occasions. 
^^^^^^^H^^^^^H^HB^^^^^^^^^^^^^^^^^S^SS^S9^S^^S5S^^S!^ S!^ SS9S!^ ^^S9BSS^^^S^^^BB 
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3.2.5.4 Concurrent Medications 
Since all participants were of the advanced stage and were regarded to be incurable by 
systemic anti-cancer therapy, palliative strategy was adopted by the oncologists. 
Palliative treatment only means palliative medications including analgesics and 
steroids for cancer-related symptoms management. Palliative chemotherapy, radiation 
therapy, targeted therapy, surgery and hormone therapy were excluded in this study. 
Other essential medications included drugs for chronic diseases like cardiovascular 
disease and diabetic mellitus. In order to avoid any interaction between Chinese and 
Western medicine, patients were instructed to take the Chinese herbal medicine at least 
2 hours apart from western medicine. Moreover, any use of concurrent medications 
was reported and recorded in the Case Report Form (CRF). Any treatment for 
anti-cancer purpose was not permitted during the study period. If the patient needed 
systemic anti-cancer therapy, withdrawal from this study was required. 
3.2.6 Procedure and Methods 
3.2.6.1 Informed Consent 
Prior to the inclusion in the study, patients fulfilling both the inclusion and exclusion 
were given the information about the aim, procedures and prospective longitudinal 
nature of the study. Informed consent was then obtained from each participant 
according to the Good Clinical Practices Guidelines. The patients voluntarily signed 
and dated the informed consent form in the presence of a witness. The signed consent 
was photocopied for patient's preservation. They were also informed about their right 
to revoke their consent at any time without an obligation to explain the reason and 
without prejudice to their further treatment. The consent form is shown in Appendix 2. 
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3.2.6.2 Documentation 
A Case Report Form (CRF) was used throughout the whole study to record all 
information about each participant including the consent form, past medical history, 
medications, demographics, assessment and adverse events report. It was completed 
both by the patient and investigator and updated as soon as possible after every visit. 
Moreover, for the purpose of convenience, every participant was assigned a code 
formed by the initial ofhis/her name and a number (e.g. CKL22). 
3.2.6.3 Assessment Procedure 
Patients were assigned to return to the clinic for follow-up visit once every week (±2 
days) and were required to adhere tightly to the assessment scheduled listed below. The 
baseline visit (Day 1) was used as the reference visit for identifying dates of following 
visits (i.e. Visit 2/Day 29 was scheduled 28 days after the baseline visit while Visit 
3/Day 57 was scheduled 56 days after the baseline visit). All the assessments were 
done at most 2 days before or after the scheduled date. 
Screening Period (Day -14 to Day 0) 
Patients applied through the investigator by telephone or patients who were potentially 
eligible were first screened by an oncologist at the Department of Oncology, TMH. 
Meanwhile, they were invited to participate in the study with a referral letter. Blood 
sample was also collected as regular checking. Once the blood result fit the eligibility 
criteria, the patient was invited to a phone interview for reviewed inclusion and 
exclusion criteria. Eligible patients were assigned to start Day 1 within 14 days after 
screening. 
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Baseline VisitAVisit 1 (Day 1) 
The baseline visit was the first day of the study period. Based on individual 
circumstance, the investigator decided either to allow the patient into the study or to 
have the screening procedure repeated. For example, the patient would be rejected to 
the study if he/she required an oxygen concentrator. The following items were done at 
the baseline visit: 
1. Obtained informed consent from patients 
2. Obtained referral letter 
3. Obtained medical history and medication 
4. Performed physical examination 
5. Obtained blood test result 
6. Completed survey questionnaire 
7. Reviewed inclusion and exclusion criteria 
8. Completed QOL questionnaire 
9. RCMP consultation 
10. Dispensed one-week Chinese herbal medicines 
Visit 2 (Day 29) 
1. Performed physical examination 
2. Obtained blood test result 
3. Completed quality of life questionnaire 
4. RCMP consultation 
5. Dispensed one-week Chinese herbal medicines 
6. Collected prescriptions of Chinese herbal medicine from Day 1 to Day 28 
7. Recorded adverse events 
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Visit 3 (Day 57) 
1. Performed physical examination 
2. Obtained blood test result 
3. Completed quality of life questionnaire 
4. Collected prescriptions of Chinese herbal medicine from Day 29 to Day 56 
5. Recorded adverse events 
Treatment period (Day 1 to Day 56) 
The treatment period lasted for 8 weeks (i.e, Day 1 to Day 56). Patient visited the 
RCMP after the inclusion and assessment procedures on Day 1. 
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Potentially eligible 
Subjects recruited from . . . , , 
patients mvited by 
advertisements t . oncologists 
丄 
Preliminarily screened 
by an oncologist at TMH 
Potentially eligible 
patient was referred by 
the Oncologist 
i 
Reviewed screened by 
investigator 
Fulfilled all inclusion and Did not fulfill all inclusion 
exclusion criteria and exclusion criteria 
Consent to enter study Refused to enter study 
i 
complete pre-test questionnaires 
and assessments 
i 
RCMP gives consultation to each 
patientatDay 1, 8, 15,22, 29, 
36, 43，50 with Chinese herbal 
medicine prescribed 
i 
All parameters will be 
re-assessed at Day 29 and 57 
i I 
Data analysis Normal follow-up 
Figure 3. 4 Flow diagram summarizing the procedure of this clinical study. 
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Table 3. 2Study calendar of each participant. 
Screening Baseline Visit Visit ^ 
Period /Visi t l __2 3 






R C M P X X X X X X X X 
consultation 
TCM 
^ 1 X X X X X X X X 
prescriptions 









EORTC x X X 
QLQ-C30 
SF-36 X X X _ 一 
Global Ratings X X X _ 一 
R e c o r d X X X X X X X X 
AE/SAE 
Date ofDeath x 
* Continue according to the same schedule until patient was off treatment/died except 
assessments. After discontinuation of treatment, schedule follow-up until 30/06/2010 
or death. 
!^ m^^^^^tmygHmmamaamBaaHBaaaBinagBMnaagMBmamH jiaiiyMiMiMMgaHgBBHiMgagg—aMaaMttMBMaM^^"<*"^^^ mmmmmm 
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3.2.7 Outcome Measurements 
Outcome measurements in this study include quantitative and qualitative outcomes. 
Primary outcomes were HRQOL assessment using questionnaires: QLQ-C30 and 
SF-36, while secondary outcomes include Global Ratings perceived by patient, RCMP 
and clinician; and safety of Chinese herbal medicine by adverse events (AEs)，serious 
adverse events (SAEs), biochemistry and physical examination. 
3.2.7.1 Survey Questionnaire 
On Day 1 visit before RCMP consultation, each patient was asked to answer a 
structured questionnaire on patient's demographic information: age, sex, cancer 
diagnosis，level of education, employment status, marital status, family income, 
previous treatment and current medications. Patients were taught or assisted by the 
investigator on how to complete study questionnaires. 
3.2.7.2 Quality of life (QOL) instruments 
On Day 1, Day 29 and Day 57 visit before RCMP consultation, patients were also 
invited to complete two HRQOL assessments: SF-36 Hong Kong (Chinese) Standard 
Version 1.1 and EORTC QLQ-C30 Chinese Version 3.0. Both questionnaires have been 
tested for validity and reliability, and used in pervious cancer studies (Apolone et al., 
1998; Grande et al.，2009; Kuenstner et aL, 2002; Mosconi et al., 2002) 
SF-36 
The Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) Hong Kong 
(Chinese) version is a generic questionnaire and is shown to be a valid, reliable, 
sensitive and responsive instrument for measuring the physical and mental health status 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ n H M M M | m | | | m | | m _ _ _ U _ | | | | | | i _ | _ i m _ _ _ _ _ i f f l M M M r nHlim_l___ll_P__wwMMMWMWIIII_l_llllllllllil_l_fflWiWH_IMWMMMMi 
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ofChinese population (Lam et al., 1998; Lam et aL, 2005). It has 36 items measuring 8 
domains including physical functioning (PF), role-physical (RP), bodily pain (BP), 
general health (GH), vitality (VT)，social functioning (SF), role-emotional (RE) and 
mental health (MH). 
EORTC QLQ-C30 
The Chinese version of the European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) consists of 30 
items expressed in six functional scales: physical functioning (PF2); role functioning 
(RF2); emotional functioning (EF); cognitive functioning (CF); social functioning (SF); 
and global quality of life (QL2) and nine symptom scales: fatigue (FA); nausea and 
vomiting ^W); pain (PA); dyspnoea (DY); sleep disturbance (SL); appetite loss (AP); 
constipation (CO); diarrhea (DI); and financial impact (FI). The scores on the 
functional scales are linearly transformed such that all scales range from 0 to 100, with 
a higher score representing a higher level of functioning. The symptoms scale items are 
also linearly transformed such that all scales/items range from 0 to 100. Higher scores 
represent a higher level of sympto_roblems (Aaronson et al., 1993; Chie et al., 2003; 
Chie et al., 2003; Chie et al., 2004; Huang et aL, 2007; Wan et al., 2008; Zhao & 
Kanda, 2004). 
The patients were first explained by the investigator the purpose of the questionnaires. 
They were encouraged to complete the two questionnaires by themselves. If the 
patients were unable to self-administer the questionnaires, such as due to poor vision or 
illiteracy, the investigator would assist the patients by rereading face-to-face the 
questions for them verbatim. The reasons were also documented. If the patients 
requested the investigator to explain what the questions mean, they were suggested to 
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use his/her own interpretation of the question and respond in one of the pre-set 
categories which most closely expressed their feeling and thinking. 
Prior to the administration of both questionnaires, academic license/approval had been 
granted by the EORTC and QualityMetric Incorporated. After being completed by the 
patients, the questionnaires were then reproduced exactly prior to scoring. Scoring of 
the questionnaires was according to the guidelines provided by the two 
above-mentioned organizations. Both questionnaires can be found in Appendix 6 and 
7. 
3.2.7.3 Global Ratings 
Overall evaluation on patient's general health and well-being as perceived by the 
patients, RCMP and clinician were accessed by the Global Ratings. They were used to 
detect any correlation on the overall evaluation on patient between patients, RCMP and 
clinician. Therefore, besides the QOL questionnaires, on Day 1, Day 29 and Day 57 
visit before RCMP consultation, patients were also invited to answer a multiple-choice 
question on his/her overall health and well-being named as the Global Ratings: 
“How would you generally describe the current severity of your disease?" 
1. 乂671^记非常輕微 
2. Mild輕微 
3. Moderate 中度 
4. Severe 嚴重 
5. Very severe非常嚴重 
On the same day ofvisit, the Global Rating were also perceived by the RCMP and the 
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clinician, to rate the severity of the patient's illness after their consultation: 
"How would you generally describe the severity ofhis/her disease?" 
1. V e r y m i k ^ ^ ^ $ f f i t 
2. Mi ld輕微 
3. Moderate 中度 
4. Severe 嚴重 
5. Very severe非常嚴重 
On Day 29 and Day 57 visits, the RCMP and the clinician classified each patient's 
change in global disease status compared to Day 1 visit as follow: 
"How would you classify his/her change in global disease status compared to visit 1?" 
L Much worse 非常差 
2. Worse 差些 
3. Stable 穩定 
4. Better 好些 
5. Much better 非常好 
All the responses should be chosen among the five given alternatives. A sample of 
question set can be found in the Appendix 5. 
3.2.7.4 Physical Examination and Laboratory tests 
Physical examination including body weight was performed at Day 1, 29 and 57 during 
the clinic visit. Besides, laboratory blood test was also performed at the Hematology 
Laboratory, TMH within 14 days before baseline visit, Day 29 and Day 57 visit. The 
following items were obtained in accordance with the schedule of assessments: 
1. Complete Blood Count 
2. Liver and renal function test 
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3. Tumor marker (if applicable) 
3.2.8 Safety Considerations 
3.2.8.1 Adverse Events (AE) 
According to the ICH guidelines, an AE refers to the development of any untoward 
medical occurrence in a patient or a clinical investigation subject administered a 
pharmaceutical product and which does not necessarily have a causal relationship with 
this treatment. An AE can hence be any unfavorable and unintended sign, symptom, or 
disease temporally associated with the use of a medicinal product, whether or not 
considered related to the treatment (ICH, 1995). For the purpose of this study, any 
detrimental changed (including abnormal laboratory results) in a patient's condition 
subsequent to them signing informed consent up to one month after the whole 
treatment (Day 84) were considered as anAE. In this study, anAE did not include: 
1. Pre-existing diseases or signs/symptoms presented on Day 1 ； or 
2. Signs or symptoms associated with the disease unless more severe than 
expected for the patient's condition. 
The patients were advised to report immediately by telephone to the investigator any 
adverse effect and the investigator would decide whether immediate action was 
required. All AEs were recorded in the CRF and assessed if they were related to the 
treatment. 
3.2.8.2 Serious Adverse Event (SAE) 
A SAE is any untoward medical occurrence that at any dose fulfills one or more ofthe 
following criteria: 
1. Death 
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2. Life threatening 
3. Significant or persistent disability/incapacity 
4. Required or prolonged hospitalization 
5. Congenital anomaly/birth defect 
Details of SAE were described clearly by subject outcome, nature of SAE, date of 
start/stop, type of SAE (initial or follow up), frequency (one episode, intermittent or 
continuous), intensity (mild, moderate or severe), seriousness, suspected relationship to 
the study and remedial actions. All SAE were collected from the time of informed 
consent and up to one month after treatment (Day 84). Any SAE were recorded on the 
CRF and reported promptly to the CREC using a Serious Adverse Event (SAE) Report 
Form as soon as possible. A notifying facsimile was received upon a receipt of a SAE. 
The report form concerned can be found inAppendix 8. 
The patients developed any SAE were asked to stop taking the Chinese herbal 
medicine until the end of the SAE. All SAEs were followed until resolution, or until 
the condition stabilized, or until the event was explained. Continuation with the study 
was encouraged as soon as the patient was stable or discharged from hospital. 
3.2.8.3 Causality Assessment 
Whenever a SAE occurred, the investigator reported to the oncologist for collection of 
medical record and blood tests. We looked into any derange of liver and renal function 
test with reference to individual's medical case. Final causal relationship (suspected 
relationship) with TCM was reviewed and judged by the oncologist as definite, 
probable, possible, not related or not assessable. 
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3.2.9 Ethical consideration 
As mentioned earlier, the protocol of this study was approved by the New Territories 
West Cluster Clinical and Research Ethics Committee (NTWC - CREC). It was 
undertaken in accordance with the Guidelines for Good Clinical Practice (GCP) for 
Proprietary Chinese Medicines as well as the World Medical Association Declaration 
of Helsinki, which highly emphasizes the ethical principles for medical research 
involving human subjects. 
Prior to obtaining the informed consent form, thorough and comprehensive explanation 
of the study was made to the patients. The objective of the study, the anticipated 
benefits, possible risk, safety and the human right of subjects were explained to the 
patients. All patients were informed that they had the right to refuse or withdraw from 
the study at any time. They were also assured that any treatment during the treatment 
period would not be affected by the design of this study and all the records of any 
patients were protected confidentially. 
As stated in the Declaration of Helsinki, it is the responsibility of the researcher to 
safeguard the health ofthe patients and minimize any foreseeable risk to the subjects 
(World Medical Association, 2008). Since the Chinese herbs used in the study were 
determined by the RCMP extemporarily, it is impossible to conduct pre-clinical 
scientific tests to the remedy anticipated to be used. Nevertheless, the Chinese herbal 
medicines were prescribed to the patients in the usual manner by the RCMP. Moreover, 
all the herbs used in this study were supplied by The Pok Oi Hospital Chinese 
Medicine Polyclinic and were under stringent quality control procedures set up by the 
Hospital Authority. Only common non-toxic herbs were allowed to be used in this 
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study. Toxic herbs listed in Schedule 1 of The Chinese Medicine Ordinance (Cap. 549 
of the Laws of Hong Kong) were not permitted. 
Upon fully understand with the study, the patients voluntarily signed and dated the 
informed consent form in the presence of a witness. The signed consent was 
photocopied for patient's preservation together with an information sheet as their later 
reference. After inclusion, the CREC and the informed consent form were the major 
measures to safeguard the rights of the subjects. Data collection could then proceed. 
3.2.10 Data Collection 
Together with the CRF, all source data of the patient was maintained by the 
investigator. The source data was archived and obtained immediately after informed 
consent were obtained and updated as soon as possible during the study. They included: 
referral letter, master diagnosis list, consultation summaries of WM and TCM, TCM 
prescriptions, physical examination, blood sample results, concomitant medications, 
serious adverse events (SAE) report form and any other relevant documents. All entries 
on the CRFs were updated in a timely manner and converted into computer softcopy. A 
final complete check was carried out to verify all the inputs on CRF against the source 
data for data processing. 
3.3 Data analysis 
All the data collected will be analyzed by the statistical package SPSS™ 15.0 for 
Window Version. The statistical tests will be two-sided and a p-value of less than 0.05 
is considered significant. 
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1. Socio-demographic characteristics 
-Frequencies will be calculated for descriptive data. 
2. HRQOL 
-The changes in mean scores of each scale in QLQ-C30 and SF-36 in paired 
samples on Dayl and Day29; Day 29 and Day 57 will be analyzed by paired 
t-test or Wilcoxon signed-rank test. 
-The changes in mean scores of each scale in QLQ-C30 and SF-36 on Dayl, 
Day29 and Day57 will be analyzed by Repeated Measures analysis of variance 
(ANOVA). 
-The correlations between the functioning scales in QLQ-C30 and summary scales 
in SF-36 will be tested by Pearson's product-moment correlation coefficient. 
3. Laboratory blood tests and body weight 
-The mean values ofall laboratory blood tests on Dayl, Day29 and Day57 will be 
analyzed for descriptive data. The changes of their means over the treatment 
will also be tested by Repeated Measures ANOVA. 
-The mean body weight from over the treatment will be tested by Repeated 
measures ANOVA. 
4. Global Ratings 
-The relationships of Global Rating between RCMP, clinician (oncologist) and 
patient will be tested by Spearman's Correlations. The inter-rater agreement 
between RCMP and clinician will be analyzed by Cohen's Weighted Kappa. 
5. Adverse events and Serious adverse events 
-Frequencies of any event will be analyzed. 
6. TCM patterns and Chinese herbal medicines 
-The TCM patterns and Chinese herbal medicines will be demonstrated by 
frequencies. 
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7. Survival Rate 
-Overall survival time was analyzed by Kaplan-Meier analysis. 
3.4 Expected Outcomes of Study 
If Chinese herbal medicine is shown to be effective and safe for the treatment of cancer, 
it may provide an alternative choice for doctors and patients, at least, in the palliative 
care session, depending on the cost effectiveness, culture and healthcare professionals' 
views. An adequately powered, controlled study for each cancer diagnosis will be 
worthy to be conducted and required to confirm the efficacy and safety of Chinese 
herbal medicine. 
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Chapter 4 Results 
This chapter will provide the results of the above clinical trial. It will cover the 
socio-demographics of the participants (n=50)，the distribution of the TCM pattern of 
participants and the Chinese herbs in the prescriptions. It will concentrate on the 
comparisons of the main outcomes in terms of the score of QOL questionnaire SF-36 
and QLQ-C30 before, during and after treatment. Finally it will explore whether the 
evaluation on the patients by RCMP is correlated to clinician (oncologist) and the 
safety of Chinese herbal medicines. 
4.1 Study Progress 
This clinical trial started in January 2009 and the follow-up was closed in June 2010. 
The participants were consecutively recruited over almost 1.5 years. Prior to the study 
period, one patient was invited to participate in the study in November 2008. This 
could test out the feasibility ofthe clinical trial and ensure later smooth progress. 
4.2The Participants 
A total of 63 potentially eligible patients were referred by oncologists while 9 patients 
were attracted by the promotion materials. 50 patients were finally recruited and 
consented to the study while others refused to enter the study or they were ineligible 
for the study. The cumulative attrition rates were 20% (n=10) and 30% (n=15) on Day 
29and Day 57 assessment respectively. Figure 4.1 shows the flow ofthe participants 
throughout the study. The reasons for not entering the study and non-adherence are also 
mentioned in the figure. The number of completed assessments varied across three 
visits (Table 4.1). At Day 1 visit, all patients completed all the assessments, while at 
Day 29 visit, 7 patients withdrew and 3 patients passed away. By Day 57，the number 
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of patients who withdrew and passed away increased to 11 and 4 respectively. The 
completion rate was 70% with 35 patients finishing the whole treatment period and all 
the assessments. 
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Referred by oncologist: 63 
Interested patients: 9 
i \ 
Ineligible: 11 
• Poor liver function: 4 
Fulfilled inclusion and exclusion � ” 0 x 1 
• Died before consent: l 
criteria: 61 , ,.? , 
• Poor general condition: 1 
• Not advanced cancer: 5 
I \ 
Informed consent obtained: 50 Refused to enter study: 11 
i 
Assigned to treatment: 50 
I 
Completed baseline assessments: 50 
Dropped out: 10 
• Died: 3 
參 Poor general condition: 3 
I \ 
^ #AE:2 
• Poor efficacy: I 
參 Attended radiotherapy: 1 
Completed Day 29 assessments: 40 
Dropped out: 5 
I \ ^Died: 1 
• Poor general condition: 4 
Completed Day 57 assessments: 35 
Figure 4. 1 Flow of participants throughout the study. 
Table 4. 1 Compliance in terms of completed questionnaires and other outcome 
measures. 
Completed outcome measures 
No. °f Body Laboratory 
patientsat QLQ-C30 SF-36 術 啦 临 ^ 她 
risk 
Baseline 50 50 50 50 50 
Day 29 40 40 40 40 40 
Day57 35 35 35 34 35 
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43Clinical characteristics and Socio-demographics of 
Participants 
The clinical characteristics and socio-demographics of the 50 participants at baseline 
are shown in Table 4.2. 
All participants were Chinese in this study. Overall, 70% (n=35) of the participants 
were male and 30% (n=15) were female. The ratio of male to female of new cancer 
case (primary and advanced included) registered in Hong Kong in 2007 was 1.2:1 
(Hospital Authority, 2009). The high proportion of male patients in this study was due 
to the majority of male patients incidentally referred from TMH. 
The mean and median age of all participants were 63.84 (SD, 12.34) and 65 
respectively while the median of male and female cancer patients were 68 and 62 
respectively in Hong Kong in 2007 (Hospital Authority, 2009). In general, the majority 
of participants in this study were from the lower educated, retired and low family 
income background. 
Since the cancers of the 50 participants were at the advanced stage, they could have 
various primary sites and metastatic sites. Out of the 50 participants, 25 patients had 
colorectal cancer and 13 patients had lung cancer. This distribution is quite similar to 
that in Hong Kong in 2007 where lung cancer ranked at the top and colorectal cancer 
followed (Hospital Authority, 2009). Six patients had advanced cancer that was locally 
unresectable while 44 patients had at least 1 site of metastasis. 
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Most patients (n=40) had received chemotherapy previously and 5 patients had not 
received any anti-cancer treatments (including 1 had received TCM) because they were 
advised by oncologist not to take the risk since they were too old or due to comorbidity. 
A number of patients (n=14) had received TCM treatment and had taken Chinese 
herbal medicines before entering this study but none of them had experienced either 
acupuncture or tui-na. 
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Table 4, 2Clinical and socio-demographic characteristics of partidpants gt b a g e l j n ^ ^ ^ 
• Charactcristic No.ofFatients(n=50) %_ 
Age (years) 




Chinese 50 ^00 
Gender 
Male 35 70 
Female ^5 ^ 
Marital status 
Single 3 6 
Married 38 76 
Divorced 7 14 
Widowed 2 4 
Education 
No education 10 20 
Primary school 22 44 
Secondary school 17 34 
University or above 1 ^ 
Occupation Status 
Full-time 2 4 
Part-time 1 ^ 
Retired 29 58 
Unemployed 10 20 
Others 8 1_6 
Primary site/diagnosis 
Lung 13 2 6 
Colorectum 25 50 
Stomach 2 4 
Pancreas 2 4 
Prostate 2 4 
Non-melanoma skin 1 2 
Breast 1 ^ 
Non-Hodgkin's lymphoma 1 2 
Caecum 1 2 
Nasopharynx 1 ^ 
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Myxoid liposarcoma 1 2 
Bladder 1 2 
Disease status 
Locally unresectable 6 12 
Metastatic 44 88_ 
No. of sites of metastasis 
0 6 12 
1 24 48 
2 9 18 
3 9 18 












4.4Main Outcome - Quality of Life 
HRQOL was the main outcome of this study adopting the two questionnaires 
QLQ-C30 and SF-36. There were 50 registered participants at baseline. The number of 
participants who remained in the study was 40 and 35 on Day 29 (Visit 2) and Day 57 
(Visit 3) respectively. Only patients who completed the first 2 visits and the 3 visits 
with completed questionnaires were taken into account in analyzing HRQOL. For both 
questionnaires, the changes in mean score of each scale were analyzed separately in 
terms ofVisit 1 and Visit 2, Visit 2 and Visit 3，and over 3 visits. 
The change in mean score of each scale in valid paired samples over the 3 visits was 
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analyzed by Repeated Measures ANOVA. To test for homogeneity of covariance, 
Mauchly's Test was carried out prior to the ANOVA. If Mauchly's Test did not show 
significance (p>0.05), homogeneity of covariance was accepted and Sphericity 
Assumed was applied to detect the difference within subjects. If Mauchly's Test 
showed significance, Greenouse-Geisser was applied to detect the difference within 
subjects. Only patients who had completed the whole intervention with completed 
questionnaires were included in this test (n-35). 
The change in mean score of each scale in valid paired samples at Visit 1 and Visit 2; 
and Visit 2 and Yisit3 were analyzed by paired t-test for normally distributed data by 
Normality test (p<0.05), otherwise by Wilcoxon signed-rank test. 
4.4.1 QLQ-C30 
The numbers of completed QLQ-C30 available for data analysis were 50, 40 and 35 
respectively at Visit 1, Visit 2 and Visit 3. The completion rates were 80% and 70% at 
Visit 2 and Visit 3 respectively. 
4.4.1.1 Scoring and Transforming of items into scales 
The scoring procedure was carried out according to the 'EORTC Scoring Manual’. 
Final scale scores were calculated by averaging items within scales and transforming 
the average scores linearly. For all scales, the RawScore is the mean of the component 
items where: 
RawScore 二 (h + I2 + ... + Q/, L = score ofeach item 
Then, for Functional scales: 
Score = {l-(RawScore-l)/range Jxl00 
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and for Symptom scales/items and global health status: 
Score = {(RawScore-l)/range )xl00 
There are totally 6 functional scales including the global health status and 9 symptom 
scales. All of the scales range in score from 0 to 100. A high score for a functional 
scale represents a high/healthy level of functioning whereas a high score for a 
symptom scale or item represents a high level of symptomatology or problems (R M. 
Fayers et al.，2001). 
4.4.1.2 Changes ofIndividual Scale at Different Visits 
Global health status 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Greenhouse-Geisser test showed that p=0.001. There was an obvious improvement in 
global health status in the first month, and then a decline in the second month with 
statistical significance. 
Change over 2 visits: According to the Wilcoxon signed-rank test, p=0.001. There was 
an improvement from Visit 1 to Visit 2 with statistical significance. According to the 
t-test, p=0.157. There was a deterioration from Visit 2 to Visit 3 without statistical 
significance. 
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Table 4. 3Comparison of Global health status at different visits. 
Mean scores (SD) A _ _. 
Scale n — AMean p 
V^ V2 V3 
QL2a 35 54.048(26.458) 68.333(21.466) 63.333(22.884) - 0.001* 
b 40 54.375(25.247) 65.833(21.417) - 11.458 0.001* 
Q L 2 35 - 68.333(21,466) 63.333(22.884) -5.000 0.157 
aComparison of Global health status at VI (Baseline), V2 (Day29) and V3 (Day57) 
withANOVA. 
b Comparison of Global health status at VI (Baseline) and V2 (Day29); V2 (Day29) 
and Y3 (Day57) with Wilcoxon signed-rank test. 
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Figure 4. 2 Graph of Global health status over study. 
Physical functioning 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Greenhouse-Geisser test showed that p=0.232. There was an improvement in physical 
functioning in the first month, and then a decline in the second month, but without 
reaching statistical significance. 
Change over 2 visits: According to the t-test, p=0.333. There was an improvement 
from Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.057. 
！丨""""•"»•咖••"""•"iB^ iMti^Mffl_fl'firr_1 Mlllljgj^ jygli_ll__lill_ll_P>«_丨i_ii__ii_»_Mimtil_MiflMffff^ _M*^ w^™»tfimMffWyi^ gjj 
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There was a deterioration from Visit 2 to Visit 3 without statistical significance. 
Table 4. 4Comparison of Physical functioning at different visits. 
Mean scores (SD) A _ , 
Scale n — AMean p 
V^ V2 V3 
PF2a 35 70.476(22.421) 74.476(18.541) 69.143(23.436) - 0.232 
b 40 67.667(23.415) 70.500(22.990) - 2.833 0.333 
P F 2 35 : 74.476(18.541) 69.143(23.436) -5.333 0.057 
"Comparison of Physical functioning at VI (Baseline), V2 (Day29) and V3 (Day57) 
withANOVA. 
b Comparison ofPhysical functioning at VI (Baseline) and V2 (Day29); V2 (Day29) 
and V3 (Day57) with t-test. 
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Figure 4. 3 Graph ofPhysical functioning over study. 
Role functioning 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.126. There was a noticeable improvement in 
role functioning in the first month, and then a decline in the second month, but without 
reaching statistical significance. 
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Change over 2 visit: According to the t-test, p=0.070. There was an improvement from 
Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.169. There 
was a deterioration from Visit 2 to Visit 3 without statistical significance. 
Table 4. 5 Comparison ofRole functioning at different visits. 
Mean scores (SD) A _ _ 
Scale n — — AMean p 
V^ V2 V3 
RF2a 35 72.381(31.034) 82.857(23.391) 75.714(34.853) - 0.126 
b 40 70.417(31.235) 78.750(26.685) - 8.333 0.070 
肌 35 . 82.857(23.391) 75.714(34.853) -7.143 0.169 
aComparison ofRole functioning at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison ofRole functioning at VI (Baseline) and V2 (Day29); V2 (Day29) and 
V3 (Day57) with t-test. 
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Figure 4. 4 Graph ofRole functioning over study. 
Emotional functioning 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Greenhouse-Geisser test showed that p=0.080. There was an overall improvement in 
emotional functioning across the whole treatment without statistical significance. 
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Change over 2 visits: According to the t-test, p=0.082. There was an improvement 
from Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.707. 
There was also a slight improvement from Visit 2 to Visit 3 without statistical 
significance. 
Table 4. 6 Comparison of Emotional functioning at different visits. 
Mean scores (SD) 
Scale n AMean p 
V^ V2 V3 
EFa 35 82.381(19.572) 87.857(11.844) 88.571(13.420) - 0.080 
b 40 82.292(18.699) 86.875(12.643) - 4.583 0.082 
EF 
35 - 87.857(11.844) 88.571(13.420) 0.714 0.707 
a Comparison of Emotional functioning at VI (Baseline), V2 (Day29) and V3 (Day57) 
withANOVA. 
b Comparison ofEmotional functioning at VI (Baseline) and V2 (Day29); V2 (Day29) 
and V3 (Day57) with t-test. 
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Figure 4. 5 Graph of Emotional functioning over study. 
Cognitive functioning 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
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Sphericity Assumed test showed that p=0.449. There was a decline in cognitive 
functioning in the first month, and then an improvement in the second month, but 
without reaching statistical significance. 
Change over 2 visits: According to the t-test, p=0.186. There was a deterioration from 
Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.244. There 
was an improvement from Visit 2 to Visit 3 without statistical significance. 
Table 4. 7 Comparison of Cognitive functioning at different visits. 
Mean scores (SD) 
Scale n AMean p 
V^ V2 V3 
CFa 35 78.095(16.053) 76.191(18.650) 80.000(19.302) - 0.449 
b 40 77.917(16.184) 74.583(19.607) - -3.333 0.186 
^^ H 
35 - 76.191(18.650) 80.000(19.302) 3.810 0.244 
a Comparison of Cognitive functioning at VI (Baseline), V2 (Day29) and V3 (Day57) 
withANOVA. 
b Comparison of Cognitive functioning at VI (Baseline) and V2 (Day29); V2 (Day29) 
and V3 (Day57) with t-test. 
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Figure 4. 6 Graph of Cognitive functioning over study. 
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Social functioning 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.032. There was a improvement in social 
functioning in the first month, and then a decline in the second month, with statistical 
significance. 
Change over 2 visits: According to the t-test, p=0.05L There was an improvement 
from Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.049. 
There was a deterioration from Visit 2 to Visit 3 with statistical significance. 
Table 4. 8Comparison of Social functioning at different visits, 
Mean scores (SD) 
Scale n AMean p 
VI V2 V3 
SFa 35 68.095(28.403) 80.476(22.682) 70.476(32.611) - 0.032* 
b 40 67.083(28.864) 76.250(25.004) - 9.167 0.051 
F 35 - 80.476(22.682) 70.476(32.611) -10.000 0.049* 
aComparison of Social functioning at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison of Social functioning at VI (Baseline) and V2 (Day29); V2 (Day29) and 
V3 (Day57) with t-test. 
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Figure 4. 7 Graph of Social functioning over study. 
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Symptom scales/items 
Fatigue 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Greenhouse-Geisser test showed that p=0.337. There was an obvious improvement in 
fatigue in the first month, and then a decline in the second month, but without reaching 
statistical significance. 
Change over 2 visits: According to the t-test, p=0.337. There was an improvement 
from Visit 1 to Visit 2 without statistical significance. According to the Wilcoxon 
signed-rank test, p=0.359. There was a deterioration from Visit 1 to Visit 2 without 
statistical significance. 
Table 4. 9Comparison ofFatigue at different visits, 
Mean scores (SD) 
Scale n … AMean p 
VI V2 V3 
¥Aa 35 40.000(25.594) 33.968(25.272) 37.143(24.245) - 0.337 
b 40 42.222(26.533) 38.056(28.231) - -4.167 0.256 
F A 35 - 33.968(25.272) 37.143(24.245) 3.175 0.359 
"Comparison ofFatigue at VI (Baseline), V2 (Day29) and V3 (Day57) withANOVA. 
b Comparison ofFatigue at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 
(Day57) with t-test. 
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Figure 4- 8 Graph of Fatigue over study. 
Nausea and Vomiting 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Greenhouse-Geisser test showed that p=0.821. There was an overall rise in vausea and 
vomiting across the whole treatment, but without statistical significance. 
Change over 2 visits: According to the t-test, p=0.323. There was a deterioration from 
Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.772. There 
was also a deterioration from Visit 2 to Visit 3 without statistical significance. 
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Table 4. 10 Comparison ofNausea and vomiting at different visits. 
� . Mean scores (SD) 
Scale n AMean p 
V^ V2 V3 
NVa 35 12.857(19.422) 13.333(20.926) 14.762(24.176) - 0.821 
b 40 12.083(18.867) 15.000(24.402) - 2.917 0.323 
35 - 13.333(20.926) 14.762(24.176) 1.429 0.772 
a Comparison of Nausea and vomiting at VI (Baseline), V2 (Day29) and V3 (Day57) 
withANOVA. 
u 
Comparison ofNausea and vomiting at VI (Baseline) and V2 (Day29); V2 (Day29) 
and V3 (Day57) with t-test. 
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Figure 4. 9 Graph ofNausea and vomiting over study. 
Pain 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.478. There was an overall improvement in 
pain across the whole treatment, but without statistical significance. 
Change over 2 visits: According to the t-test, p=0.323. There was an improvement 
from Visit 1 to Visit 2 without statistical significance. According to the t-test, p-0.738. 
There was also an improvement from Visit 2 to Visit 3 without statistical significance. 
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Table 4. 11 Comparison of Pain at different visits. 
Mean scores (SD) 
Scale n AMean p 
V^ V2 V3 
PAa 35 34.762(30.618) 30.952(28.337) 29.524(27.441) - 0.478 
b 40 36.250(30.168) 32.500(27.722) - -3.750 0.323 
35 - 30.952(28.337) 29.524(27.441) -1.429 0.738 
aComparison ofPain atVl (Baseline), V2 (Day29) andV3 (Day57) withANOVA. 
b Comparison ofPain at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 (Day57) 
with t-test. 
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Figure 4. 10 Graph of Pain over study. 
Dyspnoea 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.458. There was a decline in dyspnoea in the 
first month, and then an obvious increase in the second month, but without reaching 
statistical significance. 
Change over 2 visits: According to the t-test, p=0.822. There was a slight improvement 
from Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.205. 
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There was a deterioration from Visit 2 to Visit 3 without statistical significance. 
Table 4. 12 Comparison ofDyspnoea at different visits. 
Mean scores (SD) 
Scale n AMean p 
V^ V2 V3 _^ 
DYa 35 21.905(21.302) 19.048(21.822) 24.762(29.531) 一 0.458 
b 40 24.167(25.021) 23.333(28.445) - -0.833 0.822 
35 - 19.048(21.822) 24.762(29.531) 5.714 0.205 
a Comparison of Dyspnoea at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison of Dyspnoea at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 
(Day57) with t-test. 
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Figure 4. 11 Graph of Dyspnoea over study. 
Insomnia 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Greenhouse-Geisser test showed that p=0.164. There was an overall improvement in 
insomnia across the whole treatment, but without statistical significance. 
Change over 2 visits: According to the t-test, p=0.152. There was an improvement 
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from Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.422. 
There was also an improvement from Visit 2 to Visit 3 without statistical significance. 
Table 4. 13 Comparison of Insomnia at different visits. 
Mean scores (SD) 
Scale n AMean p 
V^ V2 V3 _^ 
SLa 35 34.286(35.687) 26.667(34.109) 22.857(32,106) - 0.164 
b 40 34.167(35.796) 26.667(34.756) - -7.500 0.152 
35 : 26.667(34.109) 22.857(32,106) -3.810 0.422 
a Comparison of Insomnia at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
h -Comparison of Insomnia a tVl (Baseline) and V2 (Day29); V2 (Day29) and V3 
(Day57) with t-test. 
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Figure 4. 12 Graph of Insomnia over study. 
Appetite loss 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.629. There was a decrease in appetite loss in 
the first month, and then an increase in the second month, but without reaching 
statistical significance. 
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Change over 2 visits: According to the t-test, p=0.372. There was an improvement 
from Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.579. 
There was a deterioration from Visit 2 to Visit 3 without statistical significance. 
Table 4. 14 Comparison of Appetite loss at different visits. 
Mean scores (SD) 
Scale n AMean p 
V^ V2 V3 ^ 
APa 35 35.238(33.277) 28.571(36.284) 32.381(35.687) - 0.629 
b 40 38.333(35.042) 33.333(37.743) - -5.000 0.372 
35 - 28.571(36.284) 32.381(35.687) 3.810 0.579 
a Comparison of Appetite loss at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison of Appetite loss atVl (Baseline) and V2 (Day29); V2 (Day29) and V3 
(Day57) with t-test. 
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Figure 4. 13 Graph of Appetite loss over study. 
Constipation 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.028. There was an overall decrease in Chapter 4 Results 93 
constipation across the whole treatment with statistical significance. 
Change over 2 visits: According to the t-test, p=0.032. There was an improvement 
from Visit 1 to Visit 2 with statistical significance. According to the t-test, p=0.661. 
There was also a relatively slight improvement from Visit 2 to Visit 3 without 
statistical significance. 
Table 4. 15 Comparison of Constipation at different visits. 
Mean scores (SD) 
Scale n AMean p 
V^ V2 V3 
COa 35 23.810(28.665) 13.333(20.130) 11.429(25.492) - 0.028* 
b 40 24.167(29.223) 14.167(21.200) - -10.000 0.032* 
C ° 35 - 13.333(20.130) 11.429(25.492) -1.905 0.661 
aComparison of Constipation atVl (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison of Constipation at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 
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Figure 4. 14 Graph of Constipation over study. 
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Diarrhoea 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Greenhouse-Geisser test showed that p=0.848. There was an increase in diarrhoea in 
the first month, and then decrease to the baseline level in the second month, without 
reaching statistical significance. 
Change over 2 visits: According to the t-test, p^=0.743. There was a deterioration from 
Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.600. There 
was an improvement from Visit 2 to Visit 3 without statistical significance. 
Table 4. 16 Comparison of Diarrhoea at different visits. 
Mean scores (SD) 
Scale n AMean p 
V^ V2 V3 ^ 
DIa 35 10.476(25.272) 12.381(24.369) 10.476(19.422) - 0.848 
b 40 9.167(23.856) 10.833(23.128) - 1.667 0.743 
P I 35 - 12.381(24.369) 10.476(19.422) -1.905 0.600 
aComparison ofDiarrhoea at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison of Diarrhoea at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 
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Figure 4. 15 Graph of Diarrhoea over study. 
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Financial difficulties 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.538. There was an obvious decrease in 
financial difficulties in the first month, and then an increase in the second month, but 
without reaching statistical significance. 
Change over 2 visits: According to the t-test, p=0.645. There was an improvement 
from Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.860. 
There was a deterioration from Visit 2 to Visit 3 without statistical significance. 
Table 4. 17 Comparison ofFinancial difficulties at different visits. 
Mean scores (SD) 
Scale n AMean p 
V^ V2 V3 
FIa 35 41.905(39.888) 36.191(35.582) 37.143(38.579) - 0.538 
b 40 36.667(39.800) 34.167(34.991) - -2.500 0.645 
F I 35 - 36.191(35.582) 37.143(38.579) 0.952 0.860 
aComparison ofFinancial difficulties at VI (Baseline), V2 (Day29) and V3 (Day57) 
withANOVA. 
b Comparison ofFinancial difficulties atVl (Baseline) and V2 (Day29); V2 (Day29) 
and V3 (Day57) with t-test. 
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Figure 4. 16 Graph ofFinancial difficulties over study. 
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Figure 4. 17 Changes in the functioning scales in QLQ-C30. 
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Figure 4. 18 Changes in the symptom scales in QLQ-C30. 
In order to illustrate the level of symptoms and functioning, Table 4.18 is also provided 
with each QLQ-C30 score from a normative cross-cultural population-based reference 
(P.M. Fayers et al” 2001). The reference values are based on baseline ^)re-treatment) 
QOL data only, although some data were included even when the treatment status of 
the patient was not known. The patients from this population were diagnosed with 
stage 3 and 4 of all types of cancer. The norm values were generally better than the 
baseline values in this study except role functioning and emotional functioning. 
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Table 4. 18 Mean scores of functioninngs and symptoms at each visit with norm 
values. 
Norm value 
VlA V2A V3A All cancer 
(n=50) (n=40) (n=35) Stage 3-4A 
(n=8066) 
QL2 55.00(23.93) 65.83(21.42) 63.33(22.88) 61.5(23.6) 
Functional scales 
PF2 66.13(25.05) 70.50(22.99) 69.14(23.44) 71.2(25.8) 
RF2 71.67(29.98) 78.75(26.68) 75.71(34.85) 70.6(32.8) 
EF 81.00(21.03) 86.88(12.64) 88.57(13.42) 71.5(23.8) 
CF 78.33(16.24) 74.58(19.61) 80.00(19.30) 83.2(21.3) 
SF 67.00(30.02) 76.25(25.00) 70.48(32.61) 75.1(28.9) 
Symptom 
scales/items 
FA 43.33(27.24) 38.06(28.23) 37.14(24.25) 34.7(27.9) 
NV 13.00(20.84) 15.00(24.40) 14.76(24.18) 7.8(17.3) 
PA 40.33(32.31) 32.50(27.72) 29.52(27.44) 29.2(30.8) 
DY 26.00(26.33) 23.33(28.44) 24.76(29.53) 21.7(28.7) 
SL 30.67(34.23) 26.67(34.76) 22.86(32;11) 28.5(31.7) 
AP 40.00(36.27) 33.33(37.74) 32.38(35.69) 20.8(31) 
CO 24.00(30.15) 14.17(21.20) 11.43(25.49) 17.0(28.4) 
DI 10.00(25.42) 10.83(23.13) 10.48(19.42) 8.3(19.5) 
FI 35.33(37.14) 34.17(34.99) 37.14(38.58) 15.4(27.7) 
A Standard deviations of each mean score were presented in brackets. 
4.4.1.3 Clinical significance of Scales 
Since statistical significance concerns whether the observed data can be explained by 
chance fluctuations but does not touch upon clinical significance (Osoba et aL, 1998). 
However, clinical significance is subjective, and is a matter of opinion, the values and 
opinions of individual patients will differ, as will the opinions of the RCMP or 
clinician. Therefore, statistically significant changes in scores over time may not 
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necessarily imply that it also has clinical significance. As suggested by the EORTC, 
the interpretation of results should remain essentially qualitative. Therefore, the 
concept of ‘Minimal Clinically Important Difference' was concluded by the EORTC 
by anchor-based interpretations, where changes ofbetween 5% and 10% are noticed by 
patients and are regarded by them as 'significant changes' (P.M. Fayers et al., 2001). 
To illustrate this, Osoba et al. (Osoba et al., 1998) suggested that when these scale 
scores changed by 5 to 10 points, patients described their condition as 'a little，better 
(or worse). A change of 10 to 20 was described as a ‘moderate，change. A change 
greater than 20 was 'very much，better (or worse). 
Together with the interpretation of individual scores of the scales, Table 4.19, 4.20 and 
Figure 4.19, 4.20 describes the percentage of patients who improve or deteriorate in 
each scale. At Visit 2, the majority of patients demonstrated a ‘moderate，(105/600) or 
‘very much' (190/600) change among the scales. However, the proportion of responses 
representing an 'improve, (176/295) was more than a 'deteriorate' (119/295). Many 
patients also perceived 'no change' (269/600). At Visit 3, the majority of patients 
demonstrated a clinically insignificant (<5) 'improve' (179/525) in all symptom scales. 
However, the responses with clinical significance were more in 'deteriorate' (145/525) 
than in ‘improve，(121/525). 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4. 19 Graphs of responses with improvement/deterioration among scales at 
Visit 2. 
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Figure 4. 19 Graphs of responses with improvement/deterioration among scales at 
Visit 2. 
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4.4.2 SF-36 
The numbers of completed SF-36 available for data analysis were 50, 40 and 35 at 
Visit 1, Visit 2 and Visit 3 respectively. The completion rate was 80% and 70% at Visit 
2 and Visit 3 respectively. 
4.4.2.1 Scoring and Transforming of items into scales 
In this questionnaire, the 36 items were aggregated and transformed with the help of 
SPSS into eight 0-100 scale scores on the assumption that each question carries equal 
weight according to the 'SF-36 manual’ (Ware et al., 1993, 2000). The scoring 
procedure can be summarized in 3 main steps: 
1. Item recording, for 10 items that require recoding; 
2. Computing scale scores by summing across items in the same scale (Actual raw 
scores); and 
3. Transforming raw scales scores into a 0-100 scale: 
Transformed Scale = (Actual raw score — lowest possible raw score)/possible raw 
score range x 100 
For all domains/scales, a higher score indicates a better health state. 
4.4.2.2 Changes of Individual Scale at Different Visits 
Physical functioning 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Greenhouse-Geisser test showed that p=0.349. There was an overall deterioration in 
physical functioning across the whole treatment, but without reaching statistical 
significance. 
Change over 2 visits: According to the t-test, p=0.126. There was a deterioration from 
Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.524. There 
was also a deterioration from Visit 2 to Visit 3 without statistical significance. 
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Table 4. 21 Comparison ofPhysical functioning at different visits. 
c , Mean scores (SD) AA/I-Scale n — — ~ ~ 1 ~ ’ - ^ AMean p 
PF5 35 68.429(25.889) 65.429(24.775) 63.000(26.296) - 0.349 
PFb 40 65.625(26.341) 61.375(26.698) - -4.250 0.126 
35 - 65.429(24.775) 63.000(26.296) -2.429 0.524 
a Comparison of Physical functioning at VI (Baseline), V2 (Day29) and V3 (Day57) 
withANOVA. ^ 
Comparison of Physical functioning at VI (Baseline) and V2 (Day29); V2 (Day29) 
and V3 (Day57) with t-test, 
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Figure 4. 21 Graph ofPhysical functioning over study. 
Role-physical 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.093. There was an overall improvement in 
role-physical across the whole treatment without statistical significance. 
Change over 2 visits: According to the t-test, p=0.016. There was an improvement 
from Visit 1 to Visit 2 with statistical significance. According to the t-test, p=0.853. 
There was also an improvement from Visit 2 to Visit 3 without statistical significance. 
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Table 4. 22 Comparison ofRole-physical at different visits. 
c 1 Mean scores (SD) A ^  n Scale n — — ~ ~ L ~ 1 ^ AMean p 
^ R P 5 35 37.143(42.604) 50.714(42.654) 52.143(43.034) - 0.093 
RPb 40 34.375(41.094) 48.125(42.888) - 13.750 0.016* 
35 - 50.714(42.654) 52.143(43.034) 1.429 0.853 
a Comparison of Role-physical at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison ofRole-physical at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 
(Day57) with t-test. 
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Figure 4. 22 Graph of Role-physical over study. 
Bodily pain 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.943. There was a slight deterioration in 
bodily pains across the whole treatment without statistical significance. 
Change over 2 visits: According to the t-test, p=0.907. There was a deterioration from 
Visit 1 to Visit 2 without statistical significance. According to the t-test, p=0.852. There 
was also a deterioration from Visit 2 to Visit 3 without statistical significance. 
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Table 4. 23 Comparison of Bodily pain at different visits. 
0 , Mean scores (SD) AA/r 
Scale n — ~ ^ 2 ~ v3 AMean p 
BP5 35 59.543(30.069) 58.886(25.580) 58.086(29.330) - 0.943 
BPb 40 57.800(29.323) 57.400(26.130) - -0.400 0.907 
35 - 58.886(25.580) 58.086(29.330) -0.800 0.852 
aComparison ofBodily pain at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison ofBodily pain at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 
(Day57) with t-test. 
moD- ~~i~~ 
65.00*** 
f . w fc_ L 
S !.I_' \ ' Y 1 
SJ ',y^ ftVWSSAM* a n 智 
^ 5 5 . 0 0 -：�
54ft)- '“111'|�|."":'� 
45,00_ 
? {• T 
1 2 3 
VMt 
Exctt'tei: 95% CI 
Figure 4. 23 Graph of Bodily pain over study. 
General health 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.645. There was an overall improvement in 
general health across the whole treatment without statistical significance. 
Change over 2 visits: According to the Wilcoxon signed-rank test, p=0.609. There was 
an improvement from Visit 1 to Visit 2 without statistical significance. According to 
the Wilcoxon signed-rank test, p=0.923. There was also an improvement from Visit 2 
to Visit 3 without statistical significance. 
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Table 4. 24 Comparison of General health at different visits. 
Scale n M e a n s c o r e s ( S D ) _ _ _ A M e a n p 
VJ V2 V3 F 
~ G H 1 35 46.686(24.789) 49.200(25.444) 49.857(24.335) - 0.645 
GHb 40 45.600(24.154) 47.425(24.700) - 1.825 0.609 
35 - 49.200(25.444) 49.857(24.335) 0.657 0.923 
a Comparison of General health at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison of General health at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 
(Day57) with Wilcoxon signed-rank test. 
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Figure 4. 24 Graph of General health over study. 
Vitality 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Greenhouse-Geisser test showed that p=0.464. There was an improvement in vitality in 
the first month, and then a decline to the baseline level in the second month, without 
statistical significance. 
Change over 2 visits: According to the Wilcoxon signed-rank test, p=0.395. There was 
an improvement from Visit 1 to Visit 2 without statistical significance. According to 
the Wilcoxon signed-rank test, p=0.527. There was a deterioration from Visit 2 to Visit 
3 without statistical significance. 
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Table 4. 25 Comparison ofVitality at different visits. 
c , Mean scores (SD) m « « ^ 
S c a l e n VI V2 V3 A M e a n P 
~ V T 5 35 51.857(27.682) 56.571(27.407) 53.286(28.205) - 0.464 
VTb 40 49.625(27.419) 52.750(28.531) - 3.125 0.395 
35 : 56.571(27.407) 53.286(28.205) -3.285 0.527 
aComparison ofVitality atVl (Baseline), V2 (Day29) andV3 (Day57) withANOVA. 
b Comparison ofVitality at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 
(Day57) with t-test. 
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Figure 4. 25 Graph ofVitality over study. 
Social functioning 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.246. There was an obvious improvement in 
social functioning in the first month, and then a decline in the second month, without 
statistical significance. 
Change over 2 visits: According to the t-test, p=0.039. There was an improvement 
from Visit 1 to Visit 2 with statistical significance. According to the t-test, p=0.322. 
There was a deterioration from Visit 2 to Visit 3 without statistical significance. 
Chapter 4 Results 109 
Table 4. 26 Comparison of Social functioning at different visits. 
c , Mean scores (SD) A1VT Scale n — — ~ ~ ^ ~ 1 ^ AMean p 
S F 35 63.214(29.384) 72.500(28.729) 67.143(32.382) - 0.246 
SFb 40 59.375(30.323) 69.063(29.004) - 9.688 0.039* 
35 : 72.500(28.729) 67.143(32.382) -5.357 0.322 
a Comparison of Social functioning at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison of Social functioning at VI (Baseline) and V2 (Day29); V2 (Day29) and 
V3 (Day57) with t-test. 
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Figure 4. 26 Graph of Social functioning over study. 
Role-emotional 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.232. There was an obvious improvement in 
role-emotional in the first month, and then a decline in the second month, without 
statistical significance. 
Change over 2 visits: According to the t-test, p=0.013. There was an improvement 
from Visit 1 to Visit 2 with statistical significance. According to the t-test, p=0.543. 
There was a deterioration from Visit 2 to Visit 3 without statistical significance. 
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Table 4. 27 Comparison ofRole-emotional at different visits. 
c , Mean scores (SD) AA/r Scale n — — ~ ~ ^ ^ ^ AMean p 
" " R E 5 35 53.333(44.428) 64.762(41.178) 60.000(46.301) - 0.232 
REb 40 46.667(45.165) 60.833(42.626) - 14.167 0.013* 
35 : 64.762(41.178) 60.000(46.301) -4.762 0.543 
a Comparison ofRole-emotional atVl (Baseline), V2 (Day29) andV3 (Day57) with 
ANOVA. 
b Comparison ofRole-emotional at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 
(Day57) with t-test. 
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Figure 4. 27 Graph of Role-emotional over study. 
Mental health 
Change over 3 visits: According to the Test of Within-Subjects Effects in ANOVA, 
Sphericity Assumed test showed that p=0.936. There was a slight improvement in 
mental health in the first month, but then it declined in the second month, without 
statistical significance. 
Change over 2 visits: According to the t-test, p=0.947. There was a slight deterioration 
from Visit 1 to Visit 2 without statistical significance. According to the Wilcoxon 
signed-rank test, p=0.649. There was also a deterioration from Visit 2 to Visit 3 without 
statistical significance. 
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Table 4. 28 Comparison of Mental health at different visits. 
Scale n Mean scores (SD) A M e a n " " p ^ 
J " c V^ V2 V3 
~~~Mff 35 75.314(23.990) 75.886(21.508) 74.629(19.280) : 0.936 
MHb 40 73.900(23.759) 73.700(22.644) - -0.200 0.947 
35 - 75.886(21.508) 74.629(19.280) -1.257 0.649 
a Comparison of Mental health at VI (Baseline), V2 (Day29) and V3 (Day57) with 
ANOVA. 
b Comparison ofMental health at VI (Baseline) and V2 (Day29); V2 (Day29) and V3 
(Day57) with t-test. 
$3.TO-
;^ )XO-




^ ^ \ 
I - ‘ 
Visit 
Errorbare:95%CI 
Figure 4. 28 Graph of Mental health over study. 
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Figure 4. 29 Changes in all scales in SF-36. s ^Chapter  Results i l z" 
4.4.2.3 SF-36 Summary Scales 
The profile of the eight scale scores, although informative on individual interpretation, 
may be difficult to interpret as an outcome measure in clinical trials (Ware & Kosinski, 
2007). The physical health summary (PCS) and mental health summary (MCS) scales 
can summarize the eight SF-36 scale scores into two summary scores that give an 
overall assessment of QOL related to physical and mental health, respectively(Lam et 
al.，2005). They are easier to interpret and simpler to analyze statistically in clinical 
trials and longitudinal studies (Ware & Kosinski, 2007). 
Change over 3 visits: In PCS, according to the Test of Within-Subjects Effects in 
ANOVA, Sphericity Assumed test showed that p=0.926, There was an overall 
deterioration in PCS over 2 months, but without reaching statistical significance. In 
MCS, according to the Test of Within-Subjects Effects in ANOVA, 
Greenhouse-Geisser test showed that p=0.111. There was an improvement in MCS in 
the first month, and then it declined in the second month, without statistical 
significance. 
Change over 2 visits: In PCS, according to the Wilcoxon signed-rank test, p=0.566 and 
0.968 respectively for VI to V2, and V2 to V3. There were both slight deteriorations 
from Visit 1 to Visit 2 and from Visit 2 to Visit 3 in PCS without statistical significance. 
In MCS, according to the Wilcoxon signed-rank test, p=0.004. There was also an 
improvement from Visit 1 to Visit 2 in MCS with statistical significance. According to 
the t-test, p=341. There was a deterioration from Visit 2 to Visit 3 in MCS without 
statistical significance. 
Table 4. 29 Comparison of PCS and MCS at VI (Baseline), V2 (Day29) and V3 
(Day57)withANOVA. 
Mean scores (SD) 
Scale n V 1 V 2 V 3 P 
PCS 35 34.0769(15.307) 33.528(14.106) 33.292(14.721)~~0.926 
MCS 35 47.000(14.643) 51.517(12.700) 49.589(13.773) 0.111 
Scores ofPCS and MCS at the 3 visits were analyzed by Repeated Measures 
ANOVA. 
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Table 4. 30 Comparison of PCS and MCS at VI (Baseline) and V2 (Day29); V2 
(Day29)andV3 (Day57). 
o , Mean scores (SD) A AT _ Scale n — — ~ ~ ^ ~ 1 ^ AMean p 
PCS 40 32.955(14.950)~~31.778(14.544) - -1.177~~0.566 
95% CI 28.174,37.737 27.126,36.429 -
MCS 40 45.388(14.516) 50.128(13.234) - 4.740 0.004* 
95% CI 40.745,50.030 45.895,54.361 -
PCS 35 - 33.5283(14.106) 33.2920(14.721) -0.2363 0.968 
95% CI - 28.683, 38.374 28.235, 38.349 
MCS 35 - 51.517(12.700) 49.589(13.773) -1.928 0.341 
95% CI - 47.155, 55.880 44.858，54.321 
All the paired samples were analyzed by Wilcoxon signed-rank test, except MCS for 
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Figure 4. 30 Graph ofPCS over study. 
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Figure 4. 31 Graph ofMCS over study. 
4.4.3 Correlation ofQLQ-C30 and SF-36 
Correlations of the functioning scales in QLQ-C30 and PCS and MCS in SF-36 were 
examined by Pearson's correlation coefficients (Table 4.31-33). High correlations ( r ^ 
0.70) were observed at Visit 2 in PCS with global health status, physical functioning, 
role functioning and MCS with emotional functioning, and at Visit 3 in PCS with 
global health status, physical functioning and role functioning. Other scales in 
QLQ-C30 and SF-36 were ofmoderate correlations (0.3< r <0.7). 
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4.5 Measurement of Physical examination 
4.5.1 Body Weight 
Thirty-four patients were available for comparing the mean body weight over the 3 
visits. Repeated Measures ANOVA were carried out for the analysis. There was a very 
slight decrease in body weight over the whole treatment, but without reaching 
statistical significance (Table 4.33). The overall mean weight loss was 3.98% from 
baseline. 
Table 4. 34 Comparison ofbody weight of patients over 3 visits. 
Visit Mean SD 95% CI 
^ W e i g h t 1 60.74 11.26 56.81,64.66 
2 59.11 11.31 55.16,63.05 
3 58.32 10.55 54.63,62.00 
P 0.159 
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Figure 4. 32 Change of weight over 3 visits. 
Chapter 4 Results 117 
4.6 Measurement of Laboratory Blood tests 
4.6.1 Comparison of CBC，RFT? LFT and LD 
The results of laboratory blood tests at each visit are shown in Table 4.34 in terms of 
the following parameters: complete blood counts (CBC), liver function test (LFT), 
renal function test (RFT) and Lactate Dehydrogenase (LD). The mean values of all the 
parameters at each visit were not deranged from the reference range, except red blood 
cell (RBC) and hemoglobin (Hgb) which were below reference range, Alkaline 
phosphatase (ALP), and LD which exceeded the reference range. For the purpose of 
safety investigation, the mean values of the deranged parameters were compared with 
the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. None of 
the laboratory blood results was classified to the least severity (Grade 1 to Grade 5) of 
the AEs ^National Cancer Institute, 2010). Significant changes over the three visits 
were detected in white blood cell ( W B C ) � = 0 . 0 0 8 ) , TBil OP=0.000), Alanine 
transaminase (ALT) ^)=0.013). 
Table 4. 35 Laboratory blood tests at different visits. 
Visit n Mean SD 95% CI Reference Range pa，b 
CBC~~� — — — 
RBC 1 50 3.83 0.50 3.69,3.97 4.3-5.7 1012/L 0.296 
2 36 3.95 0.51 3.77,4.12 
3 35 3.87 0.52 3.69,4.04 
Hgb 1 50 11.40 1.92 10.85, 11.94 13.4-17.2 g/dL 0.282 
2 36 11.80 1.77 11.20, 12.40 
3 35 11.69 2.09 10.97, 12.41 
WBC 1 50 7.83 5.33 6.32,9.35 3.9-10.7 109/L 0.008* 
2 36 7.19 2.54 6.33,8.05 
3 35 7.74 3.08 6.68，8.80 
PLT 1 50 282.78 126.04 246.96,318.60 152-358 109/L 0.101 
2 36 264.19 118.56 224.08,304.31 
3 35 274.06 114.89 234.59,313.52 
RFT 
Na 1 50 139.86 4.48 138.59, 141.13 136-145 mmoVL 0.328 
2 36 140.81 3.43 139.65, 141.97 
3 35 140.57 3.62 139.33, 141.81 
_K 1 50 4.39 0.52 4.24,4.53 3.5-5.1 mmol/L 0.070 
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2 35 4A6 047 4.30,4.62 —一 
3 35 4.36 0.53 4.18,4.54 
Urea 1 50 5.80 1.79 5.29,6.31 3.5-8.1 mmol/L 0.257 
2 36 5.70 1.71 5.12,6.28 
3 35 5.37 2.01 4.68，6.06 
Crea 1 50 79.70 20.63 73.84,85.56 62-106 umol/L 0.369 
2 36 81.22 20.89 74.15,88.29 
3 35 76.91 19.37 70.26,83.57 
TP 1 50 72.78 6.34 70.98,74.58 60-78 g/L 0.228 
2 36 72.67 6.47 70.48,74.86 
3 35 71.14 7.54 68.55,73.73 
LFT 
Alb 1 50 38.88 5.27 37.38,40.38 35-50 g/L 0.109 
2 36 40.19 4.99 38.51,41.88 
3 35 39.17 5.80 37.18,41.15 
TBil 1 50 6.74 3.74 5.68,7.80 5-20 umol/L 0.000* 
2 36 7.78 3.16 6.71,8.85 
3 35 10.31 6.59 8.05,12.58 
ALP 1 50 127.80 102.26 98.74，156.86 56-119 U/L 0.213 
2 36 118.33 70.06 94.63, 142.04 
3 36 107.58 70.72 83.65, 131.51 
ALT 1 50 25.44 19.54 19.89,30.99 10-57 U/L 0.013* 
2 35 24.94 16.61 19.24,30.65 
3 35 19.11 9.18 15.96,22.27 
AST 1 46 28.59 12.47 24.88,32.29 16-41 U/L 0.336 
2 33 30.15 13,44 25.39,34.92 
3 30 33.00 34.70 20.04,45.96 
LD 1 47 581.28 705.26 374.20,788.35 213-395 U/L 0.109 
2 34 544.91 452.15 387.15,702.68 
3 33 631.03 564.74 430.78,831.28 
aBased on Within - Subjects effects of Repeated measures ANOVA with statistical 
significance ofp<0.05. 
b Sample sizes for analysis were 32 for RBC, Hgb, WBC and PLT; 31 for Na, K, Urea, Crea, 
TP, Alb, TBil，ALP and ALT; 26 for AST and 29 for LD. 
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4.6.2 Tumor Markers 
Tumor markers were not available for all patients since each tumor marker is specific 
and sensitive to various types of cancer, and not every type of cancer has been found 
with its tumor markers QS[ational Cancer Institute, 2006). In this study, measures on 
tumor markers were only applicable on colorectal cancer with 16 valid samples for 
analysis (Table 4.35). 
Table 4. 36 Comparisons of CEA within colorectal cancer patients over 3 visits. 
P ™ a r y Visit Meana SD 95% CI pb Site 
Colorectum 1 409.08 626.53 75.23,742.93 0.181~~ 
2 733.53 1488.02 -59.38, 1526,44 
3 1232.43 2918.72 -322.85,2787.70 
aMean values of carcinoembryonic antigen (CEA) at each visit. 
b Comparison of CEA over 3 visits with Repeated Measures ANOVA. 
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4.7Adverse Events and Serious Adverse Events 
A summary of adverse events (AEs) and serious adverse events (SAEs) was shown in 
Table 4.36. There were totally 34 cases of AEs and SAEs recorded in this study. The 
most frequent AEs were death (n=8), nausea and vomiting (n=4) and dyspnoea (n=5), 
most of which were moderate in severity and happened as one episode or intermittent 
in frequency. 
Seventeen of the AEs were reported as SAEs. Eleven of them involved hospitalization 
and 6 involved death. Only two patients resumed the study after being discharged from 
hospital upon confirmation that the SAE was not related to the TCM medication. 
Others were withdrawn from the study because the duration of hospitalization was too 
long (usually more than one week). Four death cases were recorded during study while 
another 4 were recorded after the patients withdrew from or completed the study. 
According to the records in SAE Report Form, all the SAEs were reported to the 
NTWC-CREC as moderate in intensity except death which was defined as severe 
intensity in CTCAE. 
Among all the AEs and SAEs, one episode (diarrhoea) was considered to have possible 
causal relationship with the TCM medication. This is because the episode had not 
happened before the patients entered this study and were resolved spontaneously after 
the intervention was suspended. Other AEs and SAEs were considered to have no 
causal relationship with the intervention afler reviewing the Chinese and Western 
consultation notes together with the laboratory blood results. They were resolved 
without any change of intervention. 
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Table 4. 37 Frequencies of AEs and SAEs on Day29, Day57 and Day85. 
Day 
Adverse Events 29 57 85 Total 
(n-5Q) (n-40) (n=35) 
Diarrhea 1 1 
Constipation 2 2 
Abdominal pain 1 1 
Nose bleeding 1 1 
Edema 1 1 2 
Dyspnoea 3 1 1 5 
Stroke 1 1 
Increase pain 1 1 2 
Increase bone pain 1 1 
Influenza 1 1 
Ascites 1 1 2 
Hypercalcaemia 1 1 
Nausea and ^ ^ 
vomiting 
Insomnia 1 1 
Death 3 2 4 9 
Total 2A 8 5 34 
'n' was presented as the number of patients under observation. 
Patients were followed up until 28 days after the end of study or withdrawal from 
study. 
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4.8 Global Ratings 
4.8.1 Global Rating 1 - Severity ofDisease 
Global Rating 1 was a single-item scale measuring the severity of disease on the 
patients as perceived by the respondents. It was responded by the patients themselves, 
the RCMP and the clinician at Visit 1. The question and response choices are presented 
as follows: 






Spearman rank correlation was used to determine the relationship between the scores 
of Global Rating 1 among patients, RCMP and clinician. Fifty patients were valid for 
the analysis. According to Table 4.37, none of the Spearman's rho had been 
demonstrated with statistical significance. There was no relationship between the 
scores of Global Rating 1 given by patients, RCMP and clinician. 
Table 4. 38 Correlation of score of Global Rating 1 among patients, RCMP and 
clinician. 
Patients Clinician RCMP 
Spearman's~~ Patients Correlation Coefficient 1.000 -0.074 -0.061^ 
rho Sig. (2-tailed) . 0.611 0.672 
N 50 50 50 
Clinician Correlation Coefficient -0.074 1.000 0.036 
Sig. (2-tailed) 0.611 . 0.807 
N 50 50 50 
RCMP Correlation Coefficient -0.061 0.036 1.000 
Sig. (2-tailed) 0.672 0.807 . 
N 50 50 50 
The mean scores and frequencies of Global Rating 1 as perceived by patients, RCMP 
and clinician are shown in Table 4.38 and Figure 4.29. In general, the score given by 
the patients showed quite a normal distribution. The RCMP tended to perceive a more 
severe score with respect to that perceived by the clinician. 
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Table 4. 39 Mean score with SD ofGlobal Rating 1 perceivedby patients, RCMP and 
clinician. 
Patients Clinician RCMP 
n 50 50 50 
Mean score 3.12 2.12 4.62 
SD 0.96 0.33 0.49 
95% CI 2.85,3.39 2.03,2.21 4.48，4.76 
50 y — 
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Figure 4. 33 Frequency of Global Rating 1 perceived by patients, RCMP and 
clinician. 
4.8.2 Global Rating 2 - Global Disease Status 
Global Rating 2 was a single-item scale measuring the change in global disease status 
in each patient. It was responded by the RCMP and clinician at Visit 2 and Visit 3 • The 
question and response choices ofGlobal Rating 2 are presented as follows: 
How would you classify his/her (your) change in global disease status compared to 
visit 1? 
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4.8.2.1 Change in Global Disease Status 
Changes in categorical data at Visit 2 and Visit 3 by RCMP and clinician were 
analyzed by Wilcoxon Signed Ranks Test. Table 4.39 shows that there was no 
statistical significance with the changes of response of Global Rating 2 in Visit 2 and 
Visit 3 by RCMP and clinician. However, it is noted that the mean scores of Global 
Rating 2 responded by RCMP is generally higher than those responded by clinician. 
Table 4. 40 Changes in response of Global Rating 2 by RCMP and clinician. 
Visit p 
2 3 
Mean score Mean score 
^ D ) ^ ^ D ) ^ 
RCMP 3.78(0.48) 40 3.57(0.66) 35 0.100~ 
Clinician 2.92(0,42) 39 2.97(0.30) 35 L0Q0 
4.8.2.2 Agreement between RCMP and clinician 
An inter-rater agreement analysis using the Cohen's Weighted Kappa statistic for 
ordered categories was performed to determine the consistency of responses of Global 
Rating 2 among RCMP and clinician on the sample patients (J. Cohen, 1960; Fleiss et 
al., 2003). There were 39 and 35 valid samples at Visit 2 and Visit 3 respectively to 
carry out the analysis with MedCalc® Version 11.3.3.0. Table 4.40 and Table 4.41 list 
the inter-rater agreement matrixes of Global Rating 2 between RCMP and clinician at 
Visit 2 and Visit 3. According to the results, K�二 0.06, 95% CI (-0.0409, 0.161) at Visit 
2; and K = 0.104, 95% CI (-0.0980，0.306) at Visit 3. Both K were less than 0.2, 
indicating a very low level of agreement between RCMP and clinician (Altman, 1991). 
Table 4. 41 The inter-rater agreement matrix of Global Rating 2 between RCMP and 
clinician at Visit 2. 
^ RCMp 
1 2 3 4 5 Total 
1 0 0 0 0 0 0~ 
2 0 0 2 3 0 5 (12.8%) 
3 0 0 8 23 1 32(82.1%) 
Clinician 4 0 0 0 2 0 2(5.1%) 
5 0 0 0 0 0 0 
Total 0 0 1 0 2 8 1 39 i Q i a i J (25.6%) (71.8%) (2.6%) 
Quadratic weights were used for the 5 categories at 1, 0.937, 0.750, 0.437 and 0. 
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Table 4. 42 The inter-rater agreement matrix of Global Rating 2 between RCMP and 
clinician at Visit 3. . 
RCMP 
1 2 3 4 5 Total 
1 0 0 0 0 0 0~ 
2 0 1 0 1 0 2 (5.7%) 
3 0 2 9 21 0 32(91.4%) 
Clinician 4 0 0 0 1 0 1 (2.9%) 
5 0 0 0 0 0 0 
T + 1 o 3 9 23 0 35 l Q t a i (8.6%) (25.7%) (65.7%) 
Quadratic weights were used for the 5 categories at 1，0.937，0.750，0.437 and 0. 
4.8.2.3 Patients' perception after treatment 
Global Rating 2 was also responded by the patients themselves at Visit 3. Thirty-five 
patients were valid for conducting the analysis. The results were quite normally 
distributed. The majority of patients felt their disease were stable or even better after 
the treatment (Table 4.42, Figure 4.30). 
Table 4. 43 Response by patients in global disease status compared to Visit 1. 
Response choices (n=35) 
1 2 3 4 5 
Much worse Worse Stable Better Muchbetter 
Frequency 1 5 15 12 2 
Percentage 2 9 14 3 42.9 34.3 5.7 
(%) ' " 
16 r 
1 4 ] _ J " 7 " 3 " " " 一 ― 
|^^^^^^^= 
1 ^ ^ E E l z z E t z r — : t = : — B = : 
j Muchwoise Worse I Stable Better Muchbetter 
i 
^ 1 
1 2 3 4 5 
I ！ 1 
Responsechoices 
Figure 4. 34 Response by patients in global disease status compared to Visit 1. 
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Chapter 4 Results 
4.9Distribution of TCM patterns and Chinese herbal 
medicines 
In this study, the TCM patterns (n=61) were determined solely by the RCMP and all 
the TCM patterns were open-ended. There were 25 different TCM patterns identified 
from the result. The distribution of TCM patterns is shown in Table 4.43 and 
categorized by different type ofcancer. The major TCM pattern observed was Retained 
dampness-toxin [濕毒蘊糸吉](n=18), which was diagnosed mainly in colorectal cancer 
patients (83.33%). It was followed by Binding of phlegm and static blood [痰瘀互糸吉] 
(n=9)，which was mainly diagnosed in lung cancer patients (88.89%). 
The common Chinese herbal medicines used in this study were also explored. The 
cumulative frequency of every herb and every decoction throughout the whole 
treatment were 4397 and 327 respectively. All the herbs can be categorized according 
to their main effects and actions. In this study, the herbs were grouped into three main 
categories according to The State Pharmacopoeia Commission of the P.R. China: 
heat-clearing and detoxicating medicinal [清熱角军毒類]，tonifying and replenishing 
medicinal [補益类頁]and other medicinal, which is neither the former nor latter. In each 
category, only the top ten Chinese herbal medicines were listed with their 
corresponding frequencies (Table 4.44). The most commonly used Chinese herbal 
medicines in this study were Herba Hedyotidis Diffusae [白花蛇舌草](300/4397) 
under heat-clearing and detoxicating medicinal，and Poria [获爷](251/4397) under 
tonifying and replenishing medicinal (Figure 4.31). 
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4.10 Survival Rate 
All eligible patients were followed up since they had entered the study until the end of 
observation regardless of their continuation with the TCM treatment after completion 
of the study. Survival time was analyzed by Kaplan-Meier analysis on an 
intention-to-treat basis. Fifty patients were included in the survival data. By the date of 
30 June, 2010, 15 patients were censored. The median survival time was 160 days 
(95% CI, 151days to 169days) (Figure 4.32). 
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Figure 4. 36 Overall survival for patients. 
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4.11 Conclusion 
Fifty advanced cancer patients were recruited in this observational study and 35 
patients had completed the whole study. Among all the participants, 25 had colorectal 
cancer while 15 had lung cancer. Their ages ranged from 40 to 88 with a median age of 
65. Most of the participants were male, retired，low-income and low-educated. 
After the two-month intervention period in a pre-post observational study, the HRQOL 
of patients resulted from the QLQ-C30 has demonstrated an overall improvement in 
the aspects of Global health status, Social functioning and Constipation with statistical 
significance. Clinical improvements throughout the two months were also observed in 
Emotional functioning, pain and insomnia, but without reaching statistical significance. 
Some scales (i.e. Role functioning, Social functioning, Fatigue, Appetite loss and 
Financial difficulties) demonstrated an obvious improvement in the first month, and 
then declined in the second month. Moreover, clinically significant deterioration in 
Physical functioning, Nausea and vomiting, and Dyspnoea were also observed over the 
intervention. As for the SF-36 results, the HRQOL has demonstrated an overall 
improvement in Role-physical and General health, but without reaching statistical 
significance. Other scales including Vitality, Social functioning, Role-emotional and 
Mental health demonstrated an improvement in the first month, and then declined in 
the second month. In addition, an overall deterioration in Physical functioning and a 
slight drop in Bodily pain were observed throughout the whole treatment. Moderate to 
high correlations (r > 0.3) were observed in the PCS and MCS with the functioning 
scales including global health status in QLQ-C30. 
Apart from the results of HRQOL, there was no significant difference found in the 
changes of weight and CEA level before, during and after treatment. According to the 
laboratory blood results, significant increase in WBC and TBil, and a significant 
decrease in ALT were observed. RBC and Hgb were deranged from the reference range. 
Thirty-three cases of AEs and SAEs were recorded during study. There were 34 cases 
of AEs and SAEs from the baseline until one month after completion or withdrawal of 
study. One case of the AEs was suspected to have possible causal relationship with the 
TCM medication. The median survival time was 160 days. 
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There were no significant relationships between the scores of Global Rating 1 given by 
patients, RCMP and clinician. There was also no significant relationship in the Global 
Rating 2 by RCMP and clinician at Visit 2 and Visit 3. As reflected by the Global 
Rating 2 responded by patients at Visit 3, 42.9% and 34.3% of the patients felt that 
their disease was stable and better respectively compared to Visit 1. 
In this study, the most common TCM patterns diagnosed by the RCMP were Retained 
dampness-toxin [濕毒蘊結],followed by phlegm and static blood [痰瘀互結].The 
most commonly used Chinese herbal medicines were Herba Hedyotidis Diffusae [白花�
蛇舌草]and Poria [茯苓〗，�
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Chapter 5 Discussion 
5.1 Conclusion on findings 
Advanced cancer is an important disease around the world and by far it is defined as an 
incurable disease which always leads to death ultimately. Not only the disease itself, 
but the side-effects induced by current treatments also always adversely affect the 
HRQOL of patients. It is very common but also a fear for patients to face the huge 
discomforts during the palliative period or even toward the end oftheir lives. Therefore, 
alternative treatments are always necessary to provide curative and palliative approach 
to advanced cancer patients in order to improve or maintain their HRQOL. TCM is one 
of the CAMs that has a well-established theory and treatment approaches for diseases 
dating back over 4000 years. It has developed an aggregate of knowledge and 
experience on various diseases including cancer. More than that, scientific evidences 
have also demonstrated the effectiveness of Chinese herbal medicine on cancer patients, 
by means of improving HRQOL, tumor response, survival rate, relieving symptoms 
and stimulating immunity. However, the individualized and holistic characteristic of 
TCM was rarely reported as intervention in previous clinical trials. TCM treatment 
following the pattern differentiation is thus a worthy study topic for exploring the 
effectiveness on advanced cancer patients. 
This pre-post observational study has successfully demonstrated the changes of 
HRQOL of advanced cancer patients treated with TCM. In the course of the study, they 
were also treated with conventional palliative care at a day hospice centre of a regional 
hospital. The results support the previous hypothesis that the HRQOL of advanced 
cancer patients under palliative care is elevated during and after a short-term TCM 
treatment. The key findings in this study can be concluded in the followings: 
HRQOL 
• Global health status ¢=0.001), social functioning ¢)=0.032) and constipation 
symptom ¢)=0.028) improved with statistical significance over study. 
• Global health status, role functioning, emotional functioning, social functioning, 
fatigue, pain, insomnia, appetite loss, constipation and financial impact improved 
with clinical significance during or over study (Amean score >5%). 
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• Physical functioning and dyspnoea deteriorated with clinical significance in the 
second month ( A mean score >5%). 
• No significant differences (clinical and statistical) were observed in cognitive 
functioning, nausea and vomiting and diarrhea ^)>0.05 and A mean score<5%). 
• No significant differences were observed in all scales in SF-36 ^)>0.05). 
• Most scales in QLQ-C30 and SF-36 improved in the first month and then declined 
in the second month. 
• Summary scales of SF-36 and functioning scales of QLQ-C30 were of moderate 
to high correlation (0.3<r<0.9). 
Physical and laboratory blood tests 
• WBC ^ 0 . 0 0 8 ) and TBil ^)=0.000) were observed with a significant increase, 
while ALT ^)=0.013) was observed with a significant decrease. However, they 
were of no clinical significance. 
• RBC and Hgb were observed with a mean value below the reference range in all 
visits. 
• No significant difference was observed in other parameters included in CBC, LFT 
and RFT over study ^)>0.05). 
• No significant difference was observed in the CEA level over study ^p>0.05). 
• No significant difference was observed in the body weight over study ^)>0.05). 
Adverse Events and Serious Adverse Events 
• The total frequency of AEs and SAEs in all follow-up was 34. One of the AEs was 
suspected to have a causal relationship with TCM. 
Global ratings 
• No significant relationship was observed between the scores of Global Rating 1 
given by patients, RCMP and clinician ^)>0.05). 
• No significant changes were observed in the responses of Global Rating 2 in Visit 
2 and Visit 3 by RCMP and clinician ^>0.05). 
• The inter-rater agreement between the responses of Global Rating 2 given by 
RCMP and clinician on the sample patients were poor (K = 0.06 and 0.104). 
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Distribution of TCM patterns and Chinese herbal medicines 
• Sixty-one TCM patterns were observed and were organized into 25 different TCM 
patterns. 
• Major TCM pattern observed was Retained dampness-toxin (n=18), which was 
diagnosed mainly in colorectal cancer patients (83.33%). It was followed by 
Binding of phlegm and static blood (n=9), which was mainly diagnosed in lung 
cancer patients (88.89%). 
• The cumulative frequencies of every herb and decoction were 4397 and 327 
respectively throughout the whole treatment. 
參 The most commonly used Chinese herbal medicines were Herba Hedyotidis 
Diffusae (300/4397) under the heat-clearing and detoxicating medicinal, and Poria 
(251/4397) under the tonifying and replenishing medicinal category. 
Overall survival 
• The median survival time was 160 days (95% CI, 151days to 169days). 
To conclude, although the results were not sufficient to prove the efficacy of TCM on 
advanced cancer patients, the clinical and statistical importance as well as the trend in 
favour of the effect of TCM suggested that a larger-scale clinical study is warranted to 
extend and provide more accurate and unbiased findings. 
5.2 Baseline profile of participants 
The results of this study bring with it an obvious set of socio-demographic 
characteristics of advanced cancer patients. Such characteristics are found comparable 
to the cancer registry in Hong Kong and worldwide, supporting the epidemiology 
among cancer patients. The occurrence of primary site in this study was mainly found 
in colorectum (50%) and lung (26%). Although there may be competitions for subjects 
with other concurrent studies, this can still reflect the general incidence of major 
cancer types in Hong Kong where the top two in 2007 were also lung cancer (17.5%) 
and colorectal cancer (16.8%). Other leading cancer sites were (11.2%), liver (6.9%), 
prostate (5.0%), stomach (4.1%), nasopharynx (3.8%) and non-melanoma skin (3.1%). 
Not all incidence cases belonged to the advanced stage, but we can still estimate the 
occurrence of advanced cancer from the figures of leading cause of cancer deaths. 
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Lung (29.6%) and colorectal (13.7%) cancer remain the leading cause of cancer deaths, 
and the following percentage of cancer deaths were caused by liver (11.8%), stomach 
(5.2%), breast (4.3%) and pancreas (3.5%) cancer (Hospital Authority, 2009a). It is 
noted that none of the participants were diagnosed with advanced liver cancer because 
the majority of such patients had poor general conditions with highly deranged LFT 
which violated the inclusive criteria of this study. 
In this study, the occurrence of advanced cancer in men was much more than in 
women, where the ratio of male to female participants was 2.3:1. In Hong Kong, the 
incidence and mortality of cancer were also observed predominantly in men over 
women (M:F, 1.2:1 for incidence and 1.61:1 for mortality) (Hospital Authority, 2009a). 
The higher occurrence in men may be accounted for by genetic or lifestyle factors such 
as smoking and alcohol fNguyen et al., 2009; Stojsic et al., 2010). 
The median age of participants was 65. However, there was a considerable variation 
according to gender. According to Hong Kong Cancer Registry, the median age at 
diagnosis was 68 years for men and 62 years for women, and death was 71 years for 
men and 74 years for women (Hospital Authority, 2009b). The figures were similar and 
it is concluded that cancer generally affects older people and advanced cancers are 
often found among these people. The low income and retired status are also the major 
characteristics of the participants in this study. 
In Hong Kong, evidenced-based medicine is always the core treatment strategy in 
clinical practice. Therefore, almost all the patients in this study had received 
chemotherapy, radiotherapy or surgery as their first-line treatments (Martoni et al., 
2007; Prevost et al.，2005; Timmerman et al., 2009). Clinically, most patients have 
received surgery before recurrent cancer or metastatic cancer is developed. In this 
study, prior treatments were given to patients for palliative purpose with curative intent. 
However, palliative care subsequently predominated as the patients failed those 
first-line treatments. A few patients (n=5) had never received any anti-cancer 
treatments because they were too old to receive such side-effect inducing treatments or 
they suffered from other major diseases such as transient ischemic attack and recurrent 
stroke. 
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Quite a significant proportion of participants (28%) had consulted TCM before being 
invited for this study. It is understood that alternative treatments are being more and 
more popular among advanced cancer patients who hope to cure their diseases and 
extend their survival time. Apart from our participants, some patients were ineligible 
for this study because they had TCM within one month before referral. In conclusion, 
this reflects that TCM is gaining popularity among advanced cancer patients and even 
patients on conventional treatments. 
5.3 Feasibility of TCM on advanced cancer patients 
TCM is generally well accepted by advanced cancer patients receiving palliative care. 
Such feasibility had been proved by the acceptable recruitment and compliance of 
participants but somehow some barriers were encountered in this study. 
The acceptance of TCM by patients with advanced cancer in this study was in keeping 
with current prevalence in Hong Kong and in other countries (Shih et al., 2009; Ernst 
& Cassileth, 1998; Li-chun & L, 2004). The patients consult Chinese medicine 
practitioners not only prior to or afler conventional anti-cancer treatments for health 
promotion and minor ailments, but also during treatments (Ferro et al.，2007). Apart 
from that, patients also used Chinese herbal medicine on a regular daily basis in the 
forms of traditional soups and teas. As stated in the literature reviews, TCM has its 
value and should be demanded by cancer patients in both alternative and 
supplementary way. However, further studies are encouraged to support the 
implementation of referral system at WM session to RCMPs on the integrative therapy 
of TCM and WM for appropriate treatments for different cancer patients in Hong 
Kong. 
5.3.1 Recruitment of Participants 
Fifty patients were finally recruited in this study due to the limited duration of a 
postgraduate study. The recruitment of participants was very challenging. In view of 
the slow (3-4 patients per month) and unstable recruitment in the first three months, 
some measures had been introduced. Some promotion materials were created: a poster 
was posted at the offices of every District Councilor in the New Territories West 
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Cluster. Besides; and a pamphlet were distributed at Pok Oi Hospital and some elderly 
homes in the same cluster (Figure 3.1). Besides, invitation for collaboration with other 
hospital clusters was also made but was refused due to subject competition. 
The recruitment rate did not improve afterwards. In fact, the patients attracted by the 
promotion materials were scarce (n=9). Moreover, most of them were not eligible for 
the study because their diseases were not in the advanced stage (n=5) or they were 
currently on chemotherapy (n^2). Only two of the patients were finally recruited 
through the posters. The small number of patients attracted may reveal that it is now 
more convenient and easier for patients to access TCM treatments. More importantly, 
patients no longer wait until they get to the advanced stage to approach TCM. This 
may show the importance of TCM for patients. They are more likely to approach TCM 
at an earlier stage or even after newly diagnosed. The small number of eligible patients 
attracted by the promotion materials could be explained by the fact that our target 
patients were followed up at the day hospice centre, TMH. Eligible patients in the 
cluster were approached and referred directly at the centre. 
The referral and recruited number of subjects was fewer than expected. This could be 
explained by the fact that many patients had consulted TCM before they learnt about 
the study. Therefore, the oncologist did not refer them for further screening as it may 
give rise to ethical issue if the patients were asked to stop their TCM treatment for a 
washing period of one month. Other than this reason, the general condition of most 
patients was too poor to enter the study. One of the concerns was that they may need 
intermittent hospitalization which would limit their exposure to the intervention. 
5.3.2 Compliance of participants to the study schedule 
The compliance of participants in this study was poor, as demonstrated by the high 
drop-out rate (30%) and low adherence to the study schedule. The drop-outs were 
accounted for by death during the study (n=4) and withdrawal (n=ll) of participants, 
which were in turn due to the poor general conditions and disease progression of 
participants. The most common complaints by patients concerning their poor general 
conditions were fatigue and dysponea. Some patients did not consume the decoction 
daily or only attended follow-up when telephone calls were made to remind them. 
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However, it was noted that the compliance of participants to the hospice centre at TMH 
was much higher compared to that at TCM clinic. The patients still attended follow-up 
at the hospice centre rather than TCM clinic after they had withdrawn from or 
completed this study. Nevertheless, the proportions of participants who remained under 
observation in this study (80% and 70%) was comparable to those in previous studies 
accessing patients with similar baseline characteristics treated with palliative care, 
representing 58.9% - 85.5% in the first month and 34.9% - 66.3% in the second month 
(Jordhoy et al., 2001; Stromgren et aL, 2005). 
It can be seen that the importance of WM as assigned by patients is higher than that of 
TCM. This is probably because they consider TCM as complementary or 
supplementary, at least for treating advanced cancer. Not treating TCM as an essential 
medication, the patients were found to have poor compliance with consuming the 
decoctions. Besides, patients may also think that TCM does not bring obvious or even 
any subjective improvement on their health, thus choosing to withdraw from the study. 
When they consider the balance between the efficacy and the preparation time of 
Chinese herbal medicine which require boiling, they may consider TCM less efficient 
if they found little or no improvement compared with lots of boiling time. Another 
potential reason may be attributed to the lack of objective indicators on the 
effectiveness of TCM. The methods of diagnosis and evaluation in TCM were confined 
to the four examinations, which only provide subjective information from the 
perception of a RCMP. Given that there is no objective outcome indicators for the 
treatment efficacy, patients may feel ignorant of what is happening during the progress 
with TCM. As a result, the poor compliance in this study may result as an 
underestimate of effectiveness. 
The main reason contributing to the high drop-out rate was the hospitalization of 
patients and attrition. Apart from the patients who required prolonged hospitalization 
which did not enable them to resume study, all patients were encouraged to visit the 
RCMP as soon as possible after they were discharged. However, during hospitalization 
the patients were not allowed to take Chinese herbal medicines, which may also induce 
underestimation on the effect of TCM. Besides, compliance is also known to fall 
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considerably as death approaches, meaning that the change of HRQOL may only 
reflect a diminishing and varying study sample (Elmqvist et al., 2009; Jordhoy et al., 
2001). 
Due to the low compliance, serious attrition and slow recruitment in this study, it is 
suggested that a multi-centred clinical trial would be possible to access and recruit 
more suitable participants. During the study period, frequent reminders to the patients 
are encouraged to ensure good adherence to the study schedule as well as daily TCM 
intake. Community recruitment may not be necessary in the case of advanced cancer 
patients, as symptomatic patients are normally referred to the day hospice centre clinic 
at public hospitals in each cluster in Hong Kong. Referral from the hospital directly 
provides the recruitment with the majority of eligible patients, except patients who are 
visiting private oncologists. Last but not least, it is also important to establish good 
communication and cooperation with the nurse at the palliative care section, to get hold 
of the best way to contact patients. 
5.4 Health-related Quality of Life 
This is a prospective study comparing the health outcomes mainly on the HRQOL of 
advanced cancer patients by the intervention of TCM treatment. Patient selection was 
based on previous failure of conventional anti-cancer therapy, or ineligibility to receive 
conventional treatments, suggestive of the inability to achieve curative intent of the 
disease. Thus, patients in this study were receiving palliative care with symptoms 
control. Unlike previously published studies, which adopted Chinese herbal medicine 
for specific WM diagnosis (Gan et al., 2010; McCulloch et al., 2006; Taixiang et al., 
2005), the current TCM treatment utilized the features of individualization and holistic 
approach to diagnose and treat each patient. 
To the author's best knowledge, this study would be the first clinical trial with an 
intervention based on syndrome differentiation of TCM treatment on heterogeneous 
types of advanced cancer patients with palliative care. Although it was not a 
randomized control trial with a large sample size, it straightly followed a well-designed 
observational study structure and attempted to generate the most convincing results to 
the readers. In order to increase the validity of findings in this study, several technical 
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attempts had been done. 
First of all, face-to-face interview with each patient was carried out by the same 
investigator. Originally, QLQ-C30 and SF-36 were designed as self-administered 
questionnaires (Aaronson et aL, 1993; Ware et al., 1993，2000). Yet the majority of 
respondents in this study were found to be illiterate, or with visual problems or poor 
general condition. This could induce different interpretations as resulting from different 
ways of administration. Second, the patients were interviewed before they consulted 
the RCMP, so that the interaction between the patients and the RCMP would not 
influence the patients' responses to the questionnaires. Besides, the RCMP and 
clinician did not know the results of HRQOL. They had no access to the completed 
questionnaires, which might also induce potential bias to the outcomes. Third, in order 
to minimize the parameters in the intervention, the patients were treated consistently by 
the same RCMP over the study period. This avoided any underestimate or overestimate 
as a result of patients changing from one RCMP to another. Fourth, a washing period 
of one month prior to the baseline of this study was introduced. This could minimize 
either the positive or negative effects of previous conventional treatments on the 
patients, so that the outcome could reflect the unadulterated effects of TCM. Lastly, the 
patients were followed up with telephone calls prior to every scheduled TCM 
consultation and reminded to take Chinese herbal medicine daily. This could ensure the 
best possible compliance in order to avoid underestimate ofthe effectiveness ofTCM. 
Based on the fact that the majority of patients with advanced cancer will eventually die 
from their disease, a good death is the pursuit for all of these patients. HRQOL thus 
becomes an important issue to be considered (Chie et al., 2003). Since TCM is a 
medicine believed to alter an individual's subjective perception on his/her general 
health condition, it can demonstrate mainly a general performance-related efficacy on 
that individual. Accordingly, it needs an outcome to evaluate the changes in health and 
well-being, rather than simple objective parameters such as tumor response (Paterson 
et al., 2009; L. Y. Wong & Leung, 2008). HRQOL is probably the best outcome 
measure on advanced cancer patients treated with TCM. 
According to the results of the present study, the patients' overall HRQOL shows a 
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general improvement after the TCM treatment. This is generally in accordance with the 
findings in pervious TCM systematic reviews and clinical trials, which have evaluated 
the impact on HRQOL of advanced cancer patients with similar TCM treatments. 
However, the interventions in those international studies were different from this study, 
in which the combination of TCM and conventional therapy was compared with 
conventional therapy alone. Also, they adopted a designated TCM formula or a single 
herb in the combination group (Gan et al., 2010; M. Zhang et al., 2007). In the 
Mainland, some RCTs and observational studies were found to use TCM alone as the 
treatment group, yet they used one designated TCM formula or assigning patients into 
several designated TCM patterns (R. S. Chen et al., 2006; Tian et al., 2010; W. Y. Wu 
et al., 2009). 
Since there was no control group in this study, it may be worth exploring the 
comparison of the HRQOL of heterogeneous advanced cancer patients receiving 
palliative chemotherapy, palliative care program, conventional palliative care and in 
the last three months of their lives in existing studies (Bang et al., 2005; Elmqvist et al.， 
2009; Jordhoy et al., 2001; Stromgren et al., 2005). The patients in this study are more 
comparable with those receiving palliative chemotherapy, with similar baseline 
characteristics and scale scores. In the other study, the median age was 58, ranging 
from 28-78 from a Korean population. However, their life expectancy was more than 6 
months in order to be eligible for chemotherapy. As shown in Figure 5.1, the trends of 
functioning and symptom scales in this study were well in keeping with those in the 
palliative chemotherapy study. This suggests that TCM may be an alternative to 
palliative chemotherapy, for patients with life expectancy of at least 3 months. When 
compared with other studies, the baseline scale scores in this study were better, because 
patients with poor general condition were excluded upon screening. Nevertheless, it 
can be noted that the general trends in each scale were also quite in keeping with those 
under palliative care program and conventional palliative care, except nausea and 
vomiting. The changes in HRQOL during the last 3 months of life of patients were 
shown to demonstrate the functioning impairments and symptom occurrence when 
approaching death. 
The norm values supplied by the EORTC (P. M. Fayers et al., 2001)，are however not 
comparable to the results of this study, as the norm values were based on pre-treatment 
^^j^^^^^^^^gggggggggjgggHgMHBBBHMBBWBWagMHWii-MHa^MriMMWWMaWga-iMMMWWWMM--gW 
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data, which included patients newly diagnosed with stage III/IV cancers. The norm 
values were generally better than the baseline values in this study, except role and 
emotional functioning because the general condition of patients presenting the norm 
values must be better than those in this study. However, it was observed that the 
functioning and symptom scale scores after treatment were approaching the norm 
values except nausea and vomiting. The symptoms insomnia and constipation were 
even better than the norm values. This may suggest that TCM potentially improves 
patients' HRQOL and symptoms to a level as early as before conventional treatments, 
but is still not able to reveal any alternative role of TCM for those treatments. 
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Figure 5. 1 Changes in the mean scores of various scales for patients with different 
treatments. 
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The findings of this study summarize the longitudinal changes in the health outcomes 
of patients receiving TCM treatment with palliative care. The HRQOL of advanced 
cancer patients before, during and after TCM treatment were compared over a period 
of two months. Statistical significance concerns whether the observed data can be 
explained by chance fluctuations, but does not touch upon changes in HRQOL with 
clinical significance (Osoba et al., 1998). However, as clinical significance m 
subjective, and is a matter of opinion, the values and opinions of individual patients 
would differ. Therefore, in this discussion the interpretation of results remains 
qualitative as well as quantitative. 
QLQ-C30 in this study reveals significant improvements in Global health status, Social 
functioning and Constipation throughout the study Q)<0.05). Regardless of any 
statistical significance, there was a general improvement in all functionings except 
physical functioning, which declined below the baseline level after improvement in the 
first month. The declining physical functioning was consistent with the results of other 
studies, in which patients were receiving palliative care prior to death (Axelsson & 
Sjoden, 1998; Morris et al.，1986). Other functionings also detected a decline after 
improvement in the first month but still the decline had not outweighed the initial 
improvement (Figure 4.17). This might be explained by the overall effect of TCM 
treatment on patients' health, but patients might have a subjective perception of a better 
health outcome in addition to some hope when they attempted a new treatment strategy 
after previous failed treatments. The drop in the functioning scales in the second month 
may be due to the limitation in general well-being resulting from disease progression, 
as reflected by the corresponding increase in the score in symptoms including fatigue, 
appetite loss, nausea and vomiting, dyspnoea and financial difficulties (Figure 4.18). 
Nevertheless, the deterioration in functionings in the second month did not touch on 
the baseline levels, as reflected by the subjective perception by patients on the 
continuous improvement in pain, insomnia and constipation. Among the functioning 
scales, cognitive functioning was observed with a drop in the first month and then rose 
beyond baseline level. This may show that TCM affects with a delay on the patients' 
cognitive functioning, which refers to patients' concentration and memory of things. 
Nausea and vomiting were showing a constant deterioration throughout the treatment, 
as the patients reported that the bitter taste of decoction worsened the symptom. 
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The findings in SF-36 were in keeping with those in QLQ-C30, with general 
improvement in all functioning scales except physical functioning (Figure 4.29). 
However, it is noted that bodily pain recorded a continuous deterioration over the 2 
months. The increasing severity ( | A score — 1.4) was not in accordance with the 
decreasing severity observed in QLQ-C30 ( | A score |= 5.3). The contradiction was not 
well established due to the large 95% CI of the mean scale score at each visit but a 
small effect size ( A - 0.002). Nevertheless, the different designs of the two 
questionnaires, where there is one more question concerning how much the pain 
interfere with patients' normal work in SF-36, may generate inconsistency about the 
pain severity between these two questionnaires. The patients might assign more 
importance to the influence of pain on their normal work, compared to the subjective 
feeling of the pain alone (i.e. the patients may have better resistance to pain, but feel 
more frustrated by the restriction imposed on work). 
SF-36 is known to be the ‘golden standard' when testing the validity of QLQ-C30 as 
well as other newly developed QOL instruments (Chie et al., 2003; Chie et al., 2004; 
Clifton et al., 2007). However, it has been used in only few studies evaluating the 
HRQOL of cancer patients (Mosconi et al., 2002). Other studies explain that SF-36 
addresses no symptoms other than pain and fatigue, while the QLQ-C30 also includes 
sleep, financial difficulties, nausea and vomiting, dysponea, appetite loss, constipation, 
and diarrhea. QLQ-C30 is thus a valid alternative to the SF-36 when a broader 
assessment of symptoms is desired (Apolone et aL, 1998; Fredheim et al., 2007). 
Although the correlation between the functioning scales in QLQ-C30 and summary 
scales in SF-36 was also moderate to high (0.3< r <0.9) in this study, it was noted that 
SF-36 is more comprehensive for detecting physical, mental and pain issues. It may 
still help to reflect some problems not indicated by QLQ-C30，suggesting that it would 
be an aid to QLQ-C30. Nevertheless, this is just a preliminary problem that arises, an 
controlled trial with larger sample size is required to investigate this issue. 
In light of the fact that the HRQOL of advanced cancer patients with palliative care is 
gradually deteriorating over time before death, this study may preliminarily show that 
TCM significantly improved the global health status, social functioning and 
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constipation symptom of patients after treatment. It might also exert a positive 
short-term effect on other functionings and symptoms, but did not help in physical 
functioning, nausea and vomiting, and dyspnoea. However, causal relationships 
between TCM and the improvement of HRQOL of advanced cancer patients could not 
be strictly supported by this study, due to the observational approach and small sample 
size. This suggests the need for further studies adopting a randomization control 
procedure, to better evaluate the true and unbiased association. 
5.5 Safety ofTCM 
Safety in this study was demonstrated by AEs and SAEs as well as body weight and 
laboratory blood tests. Since there was no control group in this study and due to the 
complexity and poor general condition of the disease, the safety of TCM on advanced 
cancer patients cannot be strictly observed. Therefore, the AEs and SAEs were 
reviewed individually with reference to LFT, RFT, CBC and consultation notes in 
order to predict any causal relationship with TCM. One of the AEs were found to have 
possible relationship with TCM, as the symptoms arose after the TCM intake and 
provided that the episodes had not occurred before. According to the NCI CTCAE, the 
AEs and SAEs in this study were not severer than Grade 3 except death (Grade 5). 
Together with the results in all SAE Report Form, this would suggest adequate safety 
ofTCM in this study. 
It was expected that a considerable weight loss would be observed over time. However, 
the decrease in mean body weight (mean difference =2.42) was not significant. 
Moreover, such weight loss does not constitute an issue of safety, for which the 
threshold loss was 5% from baseline, as defined in CTCAE. Moreover, the mean value 
of LFT and RFT of patients also did not violate the defmed range as mentioned in the 
eligibility criteria (See section 3.2.2.2). Besides, a substandard RBC and Hgb with 
respect to the reference range and a significant increase of WBC (P<0.05) were noted. 
The results may be statistically significant, but they are not clinically significant, as it 
is very common that malignancy will reduce Hgb and raise WBC. Also the deranged 
RBC and Hgb were not categorized to any grading of AEs in CTCAE. Finally, 
significantly elevated TBil (P<0.05), and dropped ALT (P<0.05) were detected in this 
study. Nevertheless, the values were still within normal range. Hence it could well be 
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due to normal variation without any clinical significance. Such results were not 
mentioned in existing studies. Since there was no control group in this study, it could 
not be concluded that TCM has any effect on the above blood parameters. 
More importantly, the design of this study can only provide evidence of safety 
information on specific decoctions on patients. In this study, some toxic Chinese herbal 
medicines such as Scorpio were used. However, their toxicity can be reduced as a 
result of combination with other herbs within the decoction. Therefore, it is believed to 
be safe to use toxic Chinese herbal medicines under appropriate combination [酉己伍]of 
herbs, which is in turn a matter of experience of a RCMP. Yet the Chinese herbal 
medicine in this study was safe, thanks to the experienced RCMP. However, the design 
of this study cannot represent all the RCMPs to be capable of providing equivalent 
results. Therefore, in order to provide evidence to verify the safety effect of TCM, a 
larger-scale randomized controlled trial with more RCMP involved in the intervention 
may be required. 
5.6 Chinese medicine practitioner vs Western medicine 
doctor 
The inter-rater agreement between Chinese medicine practitioner and Western 
medicine doctor on advanced cancer patients has been successfully investigated, a 
topic that has not been mentioned in existing studies. As demonstrated by Global 
Rating 1 and Global Rating 2, the relationship between the evaluations of patients by 
the RCMP and clinician were very weak. This suggested that the evaluation of patients' 
disease status by RCMP was different from that by the clinician in this study. The 
RCMP generally graded the disease as 'severe' at baseline and then graded a 'better' 
status during and after treatment. On the other hand, the clinician generally graded a 
relatively 'mild，at baseline and then a 'stable' during and after treatment. The change 
from ‘severe’ to ‘better’ in disease status over treatment in view of the RCMP was in 
keeping with the findings of HRQOL. This confirmed the earlier statement that TCM 
focuses on the general health condition and well-being of an individual, which refer to 
the HRQOL of patients (Paterson et al., 2009; L. Y. Wong & Leung, 2008). The 
viewpoint of RCMP is based on the holistic approach of TCM which is different from 
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that of a WM doctor , who focuses only on targeted organs (Efferth et al.，2008). 
Although many western doctors understand that TCM is safe and effective, they are 
uncertain about how or why it works (Harmsworth & Lewith, 2001; Ho, 2001; W. C. 
Wong et al., 2006) as they do not understand the theory underlying TCM. It is 
important for Chinese medicine practitioners and Western medicine doctors to be 
aware of the different philosophy underlying each of the two medical systems (Ho, 
2001; W. C. Wong et al., 2006). That will lead to a better Chinese medicine 
practitioner-Western medicine doctor relationship and possibly a better efficacy for 
patients. 
After all, in order to avoid the potential bias noted in this study, it is suggested that the 
Global Ratings should be responded by another RCMP and clinician who are not 
involved in the treatment of patients as well as to be blinded from the HRQOL results. 
Further RCTs are warranted to investigate the viewpoints from Chinese medicine 
practitioner and Western medicine doctor, 
5.7 TCM pattern differentiation and treatment 
Following the pattern differentiation and treatment of TCM, there were 25 different 
TCM patterns identified in this study. Whether or not the TCM patterns diagnosed by 
the RCMP correspond with the types of cancer was not supported by this study, due to 
the small sample size as well as the qualitative and open-ended nature of the treatment. 
Most patients were diagnosed with Retained dampness-toxin [濕毒蕴結](n=18), 
which was mainly found in colorectal cancer patients (83.33% of the pattern). That was 
followed by Binding of phlegm and static blood [痰瘀互結](n=9); and Binding of 
phlegm and qi [痰氣互結](n=5), which were both diagnosed for lung cancer patients 
(88.89% and 80% of the patterns respectively). This may suggest that the diagnosis of 
colorectal cancer patients were mainly caused by the pathogens of dampness and toxin, 
while that of lung cancer patients were mainly caused by the pathogens of phlegm, 
static blood and qi. Due to the small sample size in all subgroups, it is not possible to 
generate a full picture of the distribution of TCM patterns for all types of cancer. 
Nevertheless, the very preliminary results on the diagnosis of pattern differentiation 
were in accordance with the general principle of TCM oncology (R. S. Chen, 2003; Y. 
K. Chen, 2009; Yu, 1983) and previous clinical studies in the Mainland (He et al., 
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2010; Y. L. Lu，2010). 
Regarding colorectal cancer, Tang et al (Tang et al., 2007) reported that it is mainly 
caused by lower energizer dampness-heat [濕熱下注];blood stasis due to qi 
stagnation[^i^^lif] ; spleen-kidney yang deficiency[WW^im]; liver-kidney yin 
deficiency [肝腎陰虧];and dual deficiency ofqi and blood [氣血雙虧].Zhang (E. X. 
Zhang, 2006) stated that the TCM pattern could be divided into: lower energizer 
dampness-heat [濕熱下、注];large intestinal stasis-toxin [大腸瘀毒];and spleen-kidney 
deficiency [脾賢虐亏虛].Both Tang et al and Zhang stressed that patients with 
advanced colorectal cancer were generally characterized by deficiency ofthe healthy qi 
and thus the healthy qi should be reinforced and the pathogenic factors eliminated. 
As regards lung cancer, Lin et al (L.Z. Lin et al, 2006) studied 294 patients with 
advanced non small cell lung cancer fNSCLC) who were randomly assigned into three 
groups: TCM group treated with TCM only; western group treated with chemotherapy; 
and integrative group treated with combined therapy of TCM and chemotherapy. They 
reported that the TCM pattern differentiations were divided into: lung depressed with 
phlegm and static blood [肺鬱痰瘀];spleen deficiency with phlegm-dampness [脾虛�
痰濕];yin deficiency with phlegm-heat [陰虛痰熱];and dual deficiency of qi and yin 
[氣陰兩虛]„ Li et al. (Li & Hua, 2009) investigated the characteristics of syndrome 
distribution in 283 cases of advanced NSCLC of preliminary diagnosis. They reported 
that there were 25 types of syndromes which mainly composed of dual deficiency of qi 
and yin [氣陰兩虛];deficiency of qi [氣虛];qi deficiency with blood stasis [氣虛血�
瘀];and obstruction of phlegm dampness and static blood [痰濕瘀阻]. 
In previous clinical trials, groups with predefined TCM patterns were set up and 
patients were assigned into these groups, with prescription of a designated decoction 
without modification over time. In this study we discovered that there could be a wide 
scope of TCM patterns in one specific type of cancer. For example, there were 14 
different patterns among all colorectal cancer patients. Therefore, in order to adhere to 
the individuation approach of TCM, the way of pattern differentiation should remain 
unconfined in further clinical studies. It is suggested that a population-based RCT is 
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required to evaluate the impact of individuation of TCM on specific type of cancer, 
hence to further investigate the prevalence of TCM patterns in association with the 
impact of TCM. This will improve clinical efficiency in terms of convenience and 
evidence-based approach. 
In this study, the commonly used Chinese herbal medicines on advanced cancer 
patients were also explored. The cumulative frequency of every herb and every 
decoction throughout the whole treatment were 4397 and 327 respectively. All the 
herbs can be categorized according to their main effects and actions. In this study, the 
herbs were theoretically grouped into three main categories: heat-clearing and 
detoxicating medicinal [清熱角军毒类頁],tonifying and replenishing medicinal [補益類] 
and other medicinal. Among the heat-clearing and detoxicating, and tonifying and 
replenishing medicinal categories respectively, Herba Hedyotidis Diffusae (n=300) and 
Poria (n=251) were the most often used. The high frequency of these two herbs 
suggested that they were included in almost every decoction in every consultation. 
According to the Traditional Chinese Pharmacy, Herba Hedyotidis Diffusae can clear 
heat and remove toxin [清熱角军毒]and drain dampness and relieve strangury [禾[_1濕通�
淋].Previous studies summarized that extracts from Herba Hedyotidis Diffusae can 
reinforce immunity, induce apoptosis, and inhibit occurrence of leukemia and 
chemomorphosis (D. D. Liu et aL, 2009; Z. Liu et al., 2010; Shi et al., 2008). In the 
State Pharmacopoeia Commission of the P.R. China, Poria can induce diuresis to drain 
dampness [禾[�7乂滲濕],fortify the spleen and quiet the heart [健脾寧心、].Extracts from 
Poria also demonstrated a series of cytotoxic and growth-inhibitory effects on tumor 
cells (Gapter et al., 2005; Ukiya et al., 2002; M. Zhang et al., 2006; L. Zhou et al., 
2008). 
The frequent use of Herba Hedyotidis Diffusae and Poria also suggested that the 
treatment of advanced cancer patients in this study is based on two main principles of 
the combination of herbs: l.disease identification and pattern differentiation, 2. 
reinforcement of the healthy qi and elimination of the pathogenic factors. Wu (W. Y. 
Wu, 2010) has summarized his clinical experience as well as published RCTs. He 
demonstrated the importance of disease identification together with pattern 
differentiation, in which the accuracy of pattern differentiation is the key to the success 
Chapter 5 Discussion 153 
oftreatment (W. Wu et al., 2009). Besides, Liu and Lu (Liu, 2008; M. Lu, 2009) also 
stated that in cancer patients the excessiveness of the pathogenic qi is due to the 
deficiency of the healthy qi. Therefore reinforcement of the healthy qi and elimination 
of the pathogenic factors is also particularly important for the disease (Y. K. Chen, 
2009). 
5.8 Implication of study 
5.8.1 Clinical implication 
When cure is not possible, the goal of treatment changes from curative intent to 
prolongation of life and palliation of symptoms (Park, 2008). Palliative care is thus 
emphasized for improving advanced cancer patients' HRQOL when approaching death 
(Jordhoy et al., 2001). Although conventional anti-cancer therapies such as 
chemotherapy are the prioritized treatments, the unacceptable side-effects always limit 
their availability to patients. 
In this study, the HRQOL of heterogeneous advanced cancers patients under palliative 
care was found to be elevated over a short-term TCM treatment. Their global health 
status, social functioning and constipation symptom were improved significantly. Yet, 
physical functioning, nausea and vomiting and dysponea were all symptoms that 
require further attention. Provided that the HRQOL is declining when approaching 
death (Elmqvist et al.，2009; Jordhoy et al., 2001)，it is already a benefit to at least 
maintain the HRQOL for as long as possible. In such case, TCM seems to be more 
advantageous than other forms of conventional palliative care. In addition to the mild 
adverse events demonstrated by the occurrence of AEs and laboratory blood tests in 
this study, it was well accepted by the patients, as reflected by the majority of patients 
perceiving a stable or better disease status after treatment. With the positive findings of 
this study, further studies designed with rigorous design and large sample size are 
warranted, to provide better evidence ofTCM treatment. 
5.8.2 Policy implication 
It is an encouraging result that the cooperation between Chinese medicine practitioner 
and Western medicine doctor was successfully demonstrated through this study. Some 
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Western medicine doctors are uncertain about the quality, efficacy and safety of 
Chinese herbal medicines (Chan, 2005), so that they may discourage patients from 
TCM treatments. In the Mainland, TCM is widely used in conjunction with Western 
medicine and is considered to be safe (K. J. Chen & Lu, 2006; Department of Health, 
2008; Harmsworth 8c Lewith, 2001). In Hong Kong, however, the practice of 
integrated TCM and WM is currently confined to acupuncture services in hospitals. As 
Chinese herbal medicine is increasing its popularity in the community, the Department 
of Health has been developing the Hong Kong Chinese Materia Medica Standards on 
60 commonly used Chinese herbal medicines to safeguard public health (Department 
of Health, 2008). It appears that TCM will be an important part of 'integrated medical 
care，and accordingly, it is necessary to allow information flow between WM doctors 
and TCM practitioners, and also a well-constructed patient-referral system. The results 
in this study indicate that integrated TCM and WM cater for the patients' social needs. 
For further development, adequate RCTs with the assistance of government policies 
and financial support are urgently needed in Hong Kong. 
Last but not least, this study also demonstrated a different viewpoint between the 
RCMP and clinician, indicating their different backgrounds of knowledge. It would be 
beneficial to the public and healthcare providers if the healthcare providers, including 
doctors, acquire a good knowledge ofboth WM and TCM (Ho, 2001). 
5.9 Limitations of the study 
Any study of evidence-based medicine requires rigorous design and scientific 
methodology to generate the most accurate and unbiased results. However, the rigor of 
this clinical trial was hindered by a number of issues, mainly due to the ethical and 
practical concerns. Therefore, attentions should be paid to the limitations associated 
with the interpretation of findings. 
The major limitation was related to the design of this study. Due to ethical 
consideration and uncertainty about the practicality and feasibility of the study at the 
protocol-preparing stage, it was designed as an observational study without neither a 
positive nor negative control group. Therefore, no conclusion can be drawn about the 
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health outcomes of advanced cancer patients from those not receiving TCM or even 
palliative treatment. Not only that the outcomes could not show any effect over a 
control group, but the potential confounding factors, for example palliative care, were 
also not identified. Therefore, consideration must be given to the internal validity when 
determining the effect ofTCM, which was partially attributed to the confounders. 
This study examined a sample from advanced cancer patients who had failed in 
previous conventional therapies or were not eligible for such therapies. Their impaired 
general health conditions were expected to result in serious attrition including death. 
Although the attrition rate was comparable to previous studies (Elmqvist et al., 2009; 
Jordhoy et al., 2001), the validity of the findings was diminished due to the relatively 
small sample size valid for data analysis. 
In addition to the serious attrition, which results in a lack of integrity of sample, the 
patient selection was also not adequate to represent the study population, resulting in a 
loss of external validity. First of all, a sample of convenience was used in this study. 
Despite the current sample demonstrating quite a comparable social-demographic and 
clinical characteristics with those in the HA cancer registry, selection bias was still 
introduced and the patients by referral might be more ready to have a positive 
subjective expectation on TCM. Second, because of practical reason, the sample was 
composed of heterogeneous types of cancer patients. This would induce confounding 
effect due to the variety of baseline characteristics. Finally, also due to practical reason 
as well as ethical consideration, the patients were currently under palliative care. 
However, palliative care was not supposed to generalize the therapeutic effect of TCM 
in this study. 
Poor adherence to the proposed schedule by participants also resulted in a loss of 
validity of the findings. Apart from those requiring hospitalization, patients were not 
monitored to ensure they had taken the decoctions twice every day, which consumed 
much time. Whether they had really complied with the instruction depended only on 
their trustworthiness. In the absence of any strategy to ensure the best compliance, one 
may consider that such intervention was a practice of the real-life situation. 
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In order to avoid substantial attrition due to death, a study period as short as two month 
was utilized in this study. This could not demonstrate the HRQOL change with a 
long-term effect. In this study, the trend of HRQOL scales, which generally improved 
and then declined, were not clearly established. Adjustment in the study period with 
reference to the overall survival of this study in future studies with a similar design 
would guarantee more consistency and accuracy. 
The intervention in this study only involved one RCMP, who was qualified with 
education background and clinical experience. However, it is not representative enough 
to support the efficacy of all TCM oncologists, as TCM treatment may vary between 
RCMPs who are influenced by their clinical experience and style. A larger 
multi-centered study with more than one RCMP involved in the intervention is 
warranted. 
5.10 Recommendations for further studies 
To the author's best knowledge, this is the first clinical trial of the key feature of TCM 
(i.e. pattern diffentiation and treatment) on advanced cancer patients with palliative 
care. It provided pioneering information about the comparison of health outcomes 
including HRQOL of patients before, during and after treatment. The positive findings 
on its feasibility, practicality and potential efficacy suggested that a larger-scale RCT 
be carried out to establish a conclusion with a strong causal relationship. A number of 
recommendations could be given on the aspects of design, patient selection, 
intervention and outcome measures that warrant further investigations. 
First of all, a controlled trial comparing TCM combined with palliative care with 
palliative care alone should be possible to be executed in further studies, provided that 
it is a multi-centered study. Mok et al. (Mok et al.，2007) carried out the first 
double-blind placebo-controlled RCT to explore the individualized treatment of TCM 
in reducing chemotherapy-induced toxicity. They screened 322 patients but 39.2% of 
them could not accept the placebo-controlled design while 22.3% had already been 
taking Chinese herbal medicines before study. Therefore, a multicenter study would be 
the most probable to improve the accrual rate to accomplish a controlled study. A larger 
sample size is also guaranteed in a multicenter study. 
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The current study focused on the effect of TCM on a group of heterogeneous cancer 
patients. In order to explore any association between the treatment effect and the types 
of cancer, a number of set cancer types, such as colorectal and lung cancer, would be 
appropriate to ensure the recruitment and outcomes in one study. Besides, the general 
conditions of patients recruited in this study were relatively good. Those who were 
bedbound or required an oxygen concentrator were excluded. Consideration may be 
taken to station a RCMP and stock Chinese herbal medicine at each of the multiple 
centers. This would improve recruitment rate. 
As suggested in the above, consultations by only one RCMP might not be 
representative of the effect of treatment. Involving more than one TCM oncologist in 
the intervention is recommended for further studies. This would provide a more 
generalized but real-life results. Apart from that, in view of the uncertain trends of 
HRQOL within two months, a longer observational period of no more than 160 days 
may be appropriate to ensure at least 50% of the patients at risk for a more meaningful 
tendency. 
Finally, as reflected in this study, SF-36 may be more comprehensive while QLQ-C30 
is more responsive. Further studies would retain the two questionnaires as the HRQOL 
outcome for investigation which focuses on the HRQOL change over treatment. 
Moreover, it is recommended to conduct the surveys in a random chance in order, that 
is to complete SF-36 prior to QLQ-C30 and vice versa by random. 
5.11 Overall Conclusion 
Advanced cancer has consistently been found to be highly prevalent in terms of 
morbidity and mortality. It also negatively affects the HRQOL of patients, especially 
for patients approaching their deaths. This observational study presented an 
encouraging idea of the role of TCM in improving the HRQOL of advanced cancer 
patients under palliative care. Despite the uncontrolled design of the study, the health 
outcomes were positive and some scales in HRQOL were even impressive. In light of 
the fact that the HRQOL will be deteriorating until death, the intervention of TCM may 
be more beneficial than futile. Together with the feasibility and practicality of this 
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study, the framework of this study may form the basis of continuous quality 
improvement by identifying areas where the methodology can be improved. Further 
investigations are urgently needed with appropriate adjustments to warrant greater 
efficacy. 
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Appendix 2 Consent form. 
SubjectNumber參加者編碼 
School of Chinese Medicine, The Chinese University of Hong Kong ； 
Pok Oi Hospital Chinese Medicine Polyclinic # Tuen Mun Hospital 
Consent Form 
Usefulness of Chinese Herbal Medicme in Cancer Outpatients: A pilot Study on 
Efficacy, Tolerability and Quality ofLife \ 
tovestigators: Dr. Yeukoi WONG, Dr. Singhung LO, Prof. Yukun CHEN, Prof. Zhiying 
LIANG, Ms Ka Yee Wong, Mr. Willy Min. CHAN, Prof. Chmitao CHE | 
. I， , hereby consent to participate in this study which is the , 
Usefulness of Chinese Herbal Medicine in Cancer Outpatients: A pilot Study on Efficacy, 
Tolerability and Quality ofLife. I acknowledge that the purpose and methods of the study 
have been Mly explained to me. I have read the patient information sheet and understand 










Patient Signature Patient Name 
病人簽署 病人姓名 ！ 
Witness Signature Witness Name 
見證人簽署 見證人姓名 
Investigator Signature Investigator Name 
硏究人員簽署 研究人員姓名 
. Date “ ‘  
日期 
By Dr. Yeuk-Oi WONG 4 
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Appendix 3 Inclusion and exclusion criteria check list. 
S u b j e c t N u m b e r 參加者編碼 
Appendix Standard screening script 
School of Chinese Medicine, The Chinese University ofHong Kong 
Pok Oi Hospital Chinese Medicine Polyclinic • Tuen Mun Hospital 
UsefulBess of Chinese Herbal Medicine in Cancer Outpatients: A pilot Study on 
Efficacy, Tolerability and Quality ofLife 
Screening Script for Patient Recrui tment 
Inclusion Criteria (A subject will be eligible for inclusion if A L L the following items applied) 
Yes No 
1. Patients coosult the Pok Oi Hospital Chinese Medicine Polyclinic cum 
The Chinese University ofHong Kong Chinese Medicine Training & 
Research Centre. 
2. Provision of informed consent 
3. Age o f l 8 or older 
4. Confirmed diagnosis of advanced cancer OiistologicalIy or 
radioIogically) by an Oncologist 
5 • B eijig ambulatory 
6. Life expectancy of 12 weeks or longer 






Exclusion Criteria (Any ofthe following is regarded as a criterion for the exclusion from the 
study) 
Yes No 
1. Unable to communicate in Cantonese or Chinese language. 
2. Chemotherapy or other systemic anti-cancer therapy within four 
weeks before the start of study day 1. 
3. Chinese herbal medicine treatment within four weeks before the 
start of study day 1. 
4. Any unresolved significant toxicity from previous anti-cancer 
therapy. 
5. Serum bilirubin > 1.5 x ULRR. 
6. Serum creatinine > 1.5 x ULRR. 
7. Alanine aminotransferase (ALT) or aspartate aminotransferase 
(AST) >2.5 x ULRR in the absence of liver metastases^  or >5 x 
ULRR in the presence of liver metastases 
8. Alkaline phosphatase (ALP) >2.5 x ULRR in the absence of liver 
metastases, or >5 x ULRR in the presence of liver metastases. 
9. Women who are pregnant or breast-feeding. 
10. Involvement in litigation 
11. Simultaneous mfection with HIV or Hepatitis C virus. 
12. History of significantly drug hypersenivity 
13. Utiable to attend follow up. 
ANY lYES' answer 
I Cannot enter study 
Recruiting Interviewer 
Name: — Date: . 
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Appendix 4 Survey Questionnaire. 
SubjectNumber參加者編碼 
1.請問你的教育程度是：�
(1)�口 無 上 學�
(2) • 小 學�
(3) O中學（包括預科）�










⑵ 口 學 生�




(2) • 主 婦�
(3) • 學 生�
(4) •若失業，請問以前的職業是：�
5.請問你目前工作狀况是：�
(1) • 全 職�
(2) • 兼 職�
(3) • 退 休�
(4) • 失 業�
(5) • 其 他�
6.請問你的家庭總收入大約是：�
(1) • S HK$ 9,999 
(2) • HK$ 10,000-19,999 
(3) • HK$ 20,000-29, 999 
(4) • HK$ 30,000-39,999 
ByDr.Yeuk-Oi WONG « 
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SubjectNumber參加者編碼 
(5) • HK$ 40,000 -59,999 
(6) • ^ HK$ 60,000 
7 .請問你首次被診斷患有腫瘤在甚麼時間：—月前/ _ _年 _ _月 _—日�
8.請問你患哪種腫瘤�：�
9.請問你曾用何種方法治療腫瘤：（可以選擇多項）�
⑴ • 手 術�
(2) • 電 療�
(3) • 化 療�
(4) • 放 療�
(5) •� 中藥�
(6) • 針 灸�
(7) • 推 拿�












藥名 ：� 劑量：� 服法：�
藥名 ：� 劑量：� 服法：�
硏究人員簽名：� 日期:�
By Dr. Yeuk-Oi WONG 9 
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Appendix 5 Global ratings 
SubjectNumber參加者編碼 





1. How would you generally describe your health, concerning your disease? 
請描述您的健康狀況:�
Completely free from symptoms�完全無症狀� ①�
~ | Almost free from symptoms�幾乎無症狀� ②�
Symptoms sometimes�有時有^£^ � 
—\ Symptoms often經常有症狀‘� ④�
~ ] Symptoms always ffiSWffift^ � 
2. How would you generaUy describe the severity of your disease? 
請描述您的病情程度是'• 
]� 非常輕微verymUd � 
]� 輕微mild � 
j� 中度moderate � 
嚴重 severe ® 




Appendix Clinician initial assessment form ： 
School of Chinese Medicine, The Chinese University ofHong Kong 
Pok Oi Hospital Chinese Medicine PolycUnic • Tuen Mun Hospital 
Usefulness of Chinese Herbal Medicine in Cancer Outpatients: A pilot Study on 
Efficacy, Tolerability and Quality ofLife 
Clinicians' Global Rating 
1. How would you generally describe the severity of his (her) disease? 
very mild � 
口 mild � 
moderate � 
I I severe � 
very severe � 
請訪問員根據病人病例塡寫以下各項 :�
病人姓名� _�















Chinese Medicine Practitioner'Global Ratim� 中翳師評估（初診)�
1. How would you generally describe the severity of his (her) disease? 
請問你認爲病人症狀的嚴重程度是：�
] 非常輕微 ¥ 6 7瓜皿 ① 
]� 輕微mild � 
中度moderate � 
嚴重severe � 












^^ggHggaMgBiaBMHgaaBaWM_Mm_IB___W_^_IHIfl___^_^__lli__Mli__nWI_BaBaBBawgHWMWMBMWaMBMIII_l___l___nHmm^nMMaB^aM -g--BIM____IMil l_MWHMMHMiWfflW 
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很 好 -� 2�
好 … - … - … 3 




比一年前好多了 -----——---……- 1 
比一年前好一些-� ------� 2�
和一年前差不多 …… 3 
比一年前差一些� 4�








b.中等3鍍的活動，比如—子，使用吸彳 9 O 
塵 器 清 潔 地 面 - 玩 腦 _ 丁 对 _ 丄�
^提起或攜帶蔬菜，食品或雜貨� 1� 2� 3�
d .上幾層樓梯 I� 2� ^�
e .上一層樓梯 I� 飞� ^�
f .彎腰，跪下，或俯身 I� 2� ^�
g.步行十條街以上（一公里) I� 飞� ^�
h.步行幾條街（幾百米) I� 飞� ^� 一�
i .步行一條街（一百米) I� 飞� ^�




















*無方礙� -� -� 1�
有很少妨礙� -� - - - - - 2�
有一難礙 - - 3 
有較棚礙 - … … - …… 4 
有極大妨礙… … - 5 
7.在過去一個星期裏，您的身體有沒有疼痛？如果有的話，疼痛到什麼程度？�
(只圈出一個答案）�
€ 1 沒 有 一 - … - … … - … … - - 1 
很輕微 -----……-……� 2』�
輕微� ㈣…… - - - - - - 3 
_ 一 ® - - 4 
細� -� - - - - - - 5�





有很少影響——----- — 2 
m-mm 3 
有較大影響� - - - - - - 4�






如 此 時 間 時 間� 沒有�
a.您覺得充滿活力？ 1 2 ^ 4 ^ 6 
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b.您覺得精神非常緊張？ R |2� 丨3� |4� 丨5� |6� 一�
c.您覺得情緒低落，以致於沒有; “ “ ~ 7 ~ ~ 7 
任何事能使您高興起來？� 丄�
d.您感到心平氣和？� ““1� 2� 3� 4� 5� 6�
e.您感到精力充足？� 1� 2� 3� 4� ^� 6�
f.您覺得心情不好，悶悶不樂？�1� 2� ^� 4� ^� 6�
g.您感到筋疲力盡？ 1� 2� 3� 4� 5� 6�
h.您是個快樂的人？� 1� 2� ^� 4� ^� 6�




常常有妨礙-——- ……-------…… 1 
大部分時間有妨礙-……-----� ----一……—— 2 
有 時 有 妨 礙 - - — — - - - - - - - - 3 
偶爾有妨礙� - -………… 4 




a.您好像比別人更容易生病 I� 2� ^� 4� ^�
b.您好像所有您認識的人一樣健7 2� ^ 4� ^�
康�
c.您覺得自己的身體狀況會變壞1� 2� 3� 4� 5�
d.您的健康極好� “ I� 2� ^� 4� ^�
硏究人員簽名：� 曰期:�
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出生日期：� ^� 月� 曰�
今天日期：� 年 _ _ _ 月 _ ^ 曰�
~� 沒有有點相當非常�
1 •您從事一些費力的活動有困難嗎，�
比如說提很重的購物袋或手提箱？� 1 .� 2� 3� 4�
2•長距離行走對您來說有困難嗎？ ‘ 1 2 3 4 
3•戶外短距離行走對您來說有困難嗎？� 1� 2� 3� 4�
4，您白天需要呆在床上或椅子上嗎？ 1 2 3 4 
5.您在吃飯、穿衣、洗澡或上廁所時需要他人幫忙嗎？� 1� 2� 3� 4�
在過去的一星期內：� 沒有有點相當非常�
•� 6.您在工作和曰常活動中是否受到限制？� 1� 2� 3� 4�
7-您在從事您的愛好或休閒活動時是否受到限制？� 1� 2� 3� 4�
8.您有氣促嗎？� 1� 2� 3� 4�
9-您有疼痛嗎？� 1� 2� 3� 4�
10.您需要休息嗎？ 1 2 3 4 
11.您睡眠有困難嗎？ 1 2 3 4 
12.您覺得虛弱嗎？� 1� 2� 3� 4�
13，您食欲不振（沒有胃口）嗎？� 1� 2� 3� 4�
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SubjectNumber參加者編碼 
1 4 -您覺得噁心嗎？ 1 2 3 4 
15 •您有暇吐嗎？ 1 2 3 4 
1 6 .您有便秘嗎？ 1 2 3 4 
在過去的一星期內：� 沒 有 有 點 相 當 非 常�
1 7 ,您有腹瀉嗎？ . 1 2 3 4 
1 8 _您覺得累嗎？ 1 2 3 4 
1 9.疼痛影響您的日常活動嗎？ 1 2 3 4 
20�.您集中精力做事有困難嗎，如讀報紙或看電視？ 1 2 3 4 
21 •您覺得緊張嗎？ 1 2 3 4 
22-您覺得憂慮嗎？ 1 2 3 4 
23*您覺得脾氣急躁嗎？ 1 2 3 4 
24，您覺得壓抑(情緒低落）嗎？� 1� 2� 3� 4�
25 •您慼到|己憶、困難嗎？ 1 2 3 4 
26’您的身體狀況或治療影響您的家庭生活嗎？ 1 2 3 4 
27’您的身體狀況或治療影響您的社交活動嗎？ 1 2 3 4 
28‘您的身體狀況或治療使您陷入經濟困難嗎？� 1� 2� 3� 4�
對下列問題’請在1� -7之間選出一個最適合您的數字並畫圈。�
29� .您如彳可評價在過去一星期內您總的健康情況？�
1 2 3 4 5 6 7 
非常差� 非常好�
30 •您如何評價在過去一星期內您總的生命質量？�
1 2 3 4 5 6 7 
非常差� 非常好�
訪問員姓名：� 訪問員簽名：� 曰期:�
Copyright 1995 EORTC Study Group on QuaUty ofLife. AH rights reserved Version 3.0 
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Appendix 8 Serious Adverse Event (SAE) Report Form. 
NTW Cluster Clinical & Research Ethics Committee Title: SAE Report Form 
Effective Date: 1 November 2005 Document No: NTWC CREC001F8a 
Revision No; 05 (local in NTWC) Page 175 of2 
Serious Adverse Event (SAE) Report Form 一 Local in NTWC Study Sites 
(Download updated form from NTWC intra-net [http://ntwc.home/ccrec/] for use & submit supporting 
documents if applicable) 
For NTWC C&REC Office Use: 
Date received: (dd/mm/yy) 
Ref. No.: 
1. Basic Information 
Study title 
Ref. No. | | Protoco[jno.� 丨 — 
Study start date |� 丨 Anticipated end date | 
Maximum number of subjects/samples/records 60 
planned (local) 
2. Study Site(s) Involved 
Name of study site: |Tuen Mun Hospital 
3. Subject Outcome at Time of Report 
| Complete recovery� 丨� 丨 Recovery with sequelae� 丨� 丨 Events not yet resolved 
| [Unknown l [Death; cause: 
4. Serious Adverse Events 
Subject reference: Code l |lnitials� 丨 |Age [ [Sex� 丨�
Relevant medical 
history & current 
treatments: 
Nature of SAE: 
(Describe temporal 
relationship with 




NTW Cluster Clinical & Research Ethics Committee Title: SAE Report Form 
Effective Date: 1 November 2005 Document No: NTWC CREC001F8a 
Revision No: 05 (local in NTWC) Page 2of 2 
SAE start date� 丨 | SAE stop date | |/not resolved* 
Type of SAE� 丨 [initial� 丨 |follow up 
Frequency [ [One episode | llntermittent |Continuous 
Intensity |� 丨 Mild | | Moderate� 丨 |Severe� 丨� 丨 Not applicable 
Seriousness� 丨 | Death l |Life threatening 
l l Significant disability/incapacity� 丨 | Required hospitalisation 
l | Persistent disabity/Incapacity� 丨 | Prolonged hospitalisation 
l l Congenital anomaly/birth defect� 丨 | None of the above 
l l Other medically important condition 
5. Suspected relationship to Study 
| Definite� 丨 |Probable� 丨 |Possible | | Not related� 丨� 丨 Not assessable 
6. Remedial actions 
On the affected|X [None | |Adjusted dosage 
subject: I 1 
Interrupted temporarily | | Discontinued/ terminated study 
For all subjects/ Nil 
study design: 
Report by |Name Signature Date 
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